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Introduction 3
1 Introduction 
1.1 Principles of the innate immune system 
Pathogens infect the human body through a variety of routes. They can enter via the 
mucosal surfaces or the external epithelial surfaces during physical contact or in the 
case of wounds, punctures or bites. If a pathogen has successfully overcome these 
protective surfaces the human body launches a rapid innate response in order to 
prevent pathogen proliferation until the primary adaptive response consisting of T 
and B cells provides antigen-specific protection after 4 to 7 days. These innate 
mechanisms can act very fast within minutes or a few hours because there is no 
requirement for clonal expansion. In most cases pathogens are already eliminated at 
this stage and no clinical symptoms are evident. The innate arm of our immune 
system is the evolutionarily ancient and more universal among organisms. 
Invertebrates for example rely only on innate immunity. 
 
Innate immunity was first described by the Russian pathologist Elie Metchnikoff by 
studying macrophages in sea stars [1], but soon immunological research focused 
mainly on the investigation of mechanisms underlying adaptive immune processes. 
The discoveries of the dendritic cells, of pathogen-specific receptors like Toll-like 
receptors and advances in NK cell biology triggered a broad interest in the field of 
innate immunity. It is now increasingly clear that the two arms of the immune system, 
the innate and the adaptive arm, are highly connected and it seems that nearly every 
aspect of the adaptive immune response is controlled by the innate immune system 
[2-4]. 
The two key features of the mammalian innate immune system are first the ability to 
recognize pathogen and/or tissue damage and second to signal the danger to the 
components of adaptive immune system both in a very rapid manner [5]. The innate 
immune system includes neutrophils, granulocytes, monocytes, macrophages, 
dendritic cells (DCs) and natural killer (NK) cells as the cellular components whereas 
the complement system and the interferons are the non-cellular components. The 
relative recent characterization of specialized lymphocyte subsets like the γδ T cells, 
NKT cells or CD4+CD25+ regulatory T cells to name a few underlines the close 
relationship of both arms of the immune system. 
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1.1.1  Immunobiology of NK cells 
1.1.1.1 NK cell recognition and the “missing-self hypothesis” 
 
Natural killer (NK) cells are large granular lymphocytes and account for 5-25% of the 
peripheral blood lymphocytes depending on the donor. They belong to the innate 
immunity because their receptors are encoded by germline genes that do not undergo 
somatic recombination. Functionally, however, NK cells are in many aspects more 
closely related to T cells than to any other leukocyte of the innate immune system, 
because they possess the same killing mechanism as cytotoxic T lymphocytes (CTL) 
and secrete IFNγ like CTL and TH1 helper T cells [6]. NK cells express an impressing 
array of activating and inhibitory receptors. All signals received by this receptors are 
integrated and the final outcome decides whether the cell is activated or not by the 
respective target cell. Originally when the term “natural killer” was coined as early as 
1975 when it was thought that NK cell recognition did not involve the MHC [7-9] and 
that NK cells are able to kill efficiently cells lacking MHC [10]. However Klas Kärre, 
in his doctoral thesis introduced the now classic "missing self-recognition" concept in 
1984 [11], which means that NK cells are inhibited by self-MHC class I molecules 
and eliminate cells which fail to express self-MHC molecules. There were still many 
open questions, for example, why some MHC class I- positive tumor cells still can be 
lyzed by NK cells?  
1989 Trinchieri postulated activating structures present on target cells [12], which 
could account for the conflicting results. In the late 1990s the new concept of 
“induced-self” was introduced by Diefenbach and Raulet, which was based on 
observations of Bauer, Spies and colleagues, which stated that NK cells eliminate 
cells expressing stimulatory ligands for activating receptors [13-18]. One of the key 
receptors mediating the recognition of induced-self is the NKC-encoded NKG2D 
molecule [14] which will be discussed in more detail in 1.1.1.3. An modified 
“missing-self hypothesis” would state, that NK cells kill targets that fail to express 
MHC class I molecules, but express ligands for activating receptors. 
 
Importantly, without an activating signal the NK cell does not respond to a target cell 
even when the target fails to express inhibitory ligands. The inhibitory receptors 
weaken the signals from activating receptors rather terminating them totally, which 
implies that a strong activating signal overcomes the inhibitory signal and the target 
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will by lyzed [6]. Signal interpretation is more similar to an analog scale rather than a 
binary switch, an analogy which is symbolized by Figure 1.1. 
 
NK cell recognition
Balance between activating and inhibitory receptors
human 
NK cell
+
activating 
receptors
NCR
NKG2D
DNAM-1
CD96
2B4
NKp80
-
inhibitory 
receptors
NKG2A/CD94
KIR
ILT2  
Figure 1.1 NK cell recognition as a balance between activating and inhibitory receptors. All 
signals received by activating and inhibitory receptors are integrated and the final outcome 
decides whether the NK cell is activated or not by the target cell, whereby the signal 
interpretation is more similar to an analog scale rather than a binary switch. Abbr.: NCR, natural 
cytotoxicity receptors; KIR, killer cell immunoglobulin-like receptors; DNAM-1, DNAX 
accessory molecule 1 (CD226); ILT2; inhibitory receptors Ig-like transcript 2. 
 
1.1.1.2 Inhibitory receptors 
 
NK cells express activating and inhibitory receptors, which can be subdivided into 
three classes. The first class is the killer cell immunoglobulin-like receptors (KIR), 
which belong to the immunoglobulin superfamily (IgSF), the second class is the C-
type lectin-like receptors (CTLR) and finally the so called natural cytotoxicity 
receptors (NCR). Most CTLR are encoded within the natural killer gene complex 
(NKC), which is discussed in detail in 1.1.7. However, all classes contain inhibitory 
and activating receptors. 
Inhibitory receptors encompass members of the KIR family in humans, the Ly49 
family in mice, and the CD94/NKG2A heterodimers in mouse and humans [19-21]. 
KIRs are expressed on NK cells and a subset of memory T cells [22-25], and are 
encoded in the leukocyte receptor complex (LRC) region on chromosome 19q [26]. 
KIRs are specific for allelic variants of HLA-A, -B and -C molecules, for example, 
KIR2DL1 binds HLA-C group 2 members (e.g. HLA-Cw2, -Cw4, -Cw6). The KIRs 
are thought to play an important role in a process called “NK licensing” which will be 
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described in 1.1.1.5. In mice, monitoring of allelic loss of MHC class I expression is 
fulfilled by receptors of the Ly49 family, which are discussed in 1.1.7.3. 
All inhibitory NK receptors contain one (Ly49) or two (KIR2DL and KIR3DL) ITIMs 
(immunoreceptor tyrosin-based inhibitory motifs; I/VxxYxxL) in their cytoplasmic 
domains [19]. For details regarding signaling of inhibitory receptors see Figure 1.2. 
 
ITAM
NKG2D
homodimer
NKD
MICA
KIR2DS KIR2DL
KIR2DL1
KIR2DL2
KIR2DL3
monomers
NKD
DAP10 DAP12
HLA-Cw3
activating receptors inhibitory receptors
CTLR
C-Typ lectin-like-
receptors
KIR
Killer cell immunglobulin
like- receptors
ITIM ITIM
NKG2A
CD94
heterodimer
CTLR
C-Typ lectin-like
receptors
KIR
PI3K Syk/ZAP70 SHP-1
MHC class I HLA-E
YINM
Killer cell immunglobulin
like- receptors  
 
Figure 1.2 Activating and inhibitory receptors on NK cells. Both KIRs (killer cell 
immunoglobulin-like receptors) and CTLR (C-type lectin-like receptors) comprise activating and 
inhibitory receptors. The activating receptors do not contain ITAM themselves, but associate 
with adaptor molecules like DAP10 or DAP12 which contain an ITAM (DAP12) or YINM 
(DAP10) necessary for signal transduction. In humans, ligation of NKG2D leads to the 
phosphorylation of the YxxM-motif and activates the phosphatidylinositol-3-kinase (PI3K) 
pathway. In mouse there is a differential use of DAP10 and DAP12 [15]. DAP12 signals via the 
tyrosine kinases Syk and ZAP70, which are recruited via their SH2 domains. The ITIMs of the 
inhibitory receptors are tyrosine-phosphorylated upon receptor ligation by src-kinases and in 
turn recruit and activate SH2-domain-containing-protein tyrosine phosphatase 1 and 2 (SHP-1 
and -2). Subsequently, SHP-1 and SHP-2 dephosphorylate and thus inactivate signal transducers 
of activating signaling pathways [6]. The cartoons of the crystal structures were created using 
ProteinExplorer [27] (www.proteinexplorer.org). The PDB code of the NKG2D-MICA-complex 
is 1HYR [28] and for KIR2DL-HLA-Cw3 1EFX [29]. For the KIR2DS/MHC class I and 
NKG2A/CD94/HLA-E complexes the crystal structures of KIR2DL/HLA-Cw3 and 
NKG2D/MICA were used respectively due to the lack of crystallographic data. 
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1.1.1.3 Activating NK receptors 
 
In humans, a number of activating NK receptors including NKp30, NKp44, NKp46, 
NKp80 and NKG2D have been characterized, but, apart from NKG2D, the 
unidentified nature of the corresponding cellular ligands strongly curbs further 
advance in the understanding of their role in NK-mediated immunoregulation and 
immunosurveillance [6,30]. Since NKG2D-ligands are inducibly expressed on 
infected cells or upon genotoxic stress and are associated with malignant 
transformation, the hypothesis was put forward that NKG2D may serve as an 
immune detector of harmful cells promoting their elimination [6,14,31,32]. NKG2D 
is expressed by virtually all human NK cells, γδ T cells and CD8+ T cells and, together 
with the adaptor protein DAP10, assembles into an activating immunoreceptor 
complex [6,14]. Upon ligation of its MHC class I-related, stress-inducible ligands 
encoded by the MIC and ULBP genes, NKG2D stimulates NK cytotoxicity and 
cytokine secretion [14,18]. 
 
The natural cytotoxicity receptors (NCR) NKp46, NKp44 and NKp30 were found by 
a screen for monoclonal antibodies (mAbs), which are capable of mediating 
redirected lysis of a Fc receptor expressing tumor cell line [30]. The NCRs were 
named after the molecular weight. NKp46 and NKp30 are present on all NK cells 
regardless of the activation status, therefore representing the only available truly NK-
specific markers. NKp44 is only expressed by activated NK cells [33]. Cross-linking 
of NKp46 and NK30 induces Ca2+ influx, cytotoxicity and cytokine production 
[34,35]. NKp46 in encoded within the leukocyte receptor complex (LCR) on human 
chromosome 6. NKp46 has also been cloned in mice [36] and it was recently reported 
that mouse NKp46 is also the only marker which is truly NK specific. The cellular 
ligands of the NCRs are yet not known. NKp46-Fc fusion proteins bind to tumor cells 
as well as influenza virus–infected cells and it was also shown that NK cells are 
activated by recognition of haemagglutinins on virus-infected cells via NKp46 [37]. 
Using an NKp46 knock-out mouse Gazit et al. could show that NKp46 protects from 
lethal influenza virus infection, however the involvement of NKp46 in tumor 
immunity still remains unclear [38,39]. The role of NKp30 in the NK/DC crosstalk 
will be discussed in 1.1.6. Regarding NKp44 it was published that NKp44-Fc fusion 
proteins bind to HIV-infected CD4+ T cells [40] indicating also an involvement in the 
immunity against viruses. 
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Figure 1.3 Activating receptors on human NK cells. CD16, NKp46, NKp30, NKp44, DNAM-1 
and 2B4 are type I glycoproteins belonging to the Ig-SF containing either one or more Ig-like C2 
type (C2) or a V-set domain (V). NKG2D and NKp80 are dimeric type II glycoproteins belonging 
to the C-type lectin-like receptor superfamily. Both the NCRs and NKG2D contain in their 
transmembrane region positively charged amino acids, which interact with signal-transducing 
adaptors, which contain negatively charged residues. The CD3ζ chain (ζ) and FcεRIγ chain (γ) 
are able to form disulfide-linked homodimers or heterodimers and contain ITAMs, which are 
phosphorylated by tyrosine kinases of the Src family followed by the recruitment of Syk and 
ZAP70 tyrosine kinases [30]. In contrast 2B4, DNAM-1 and NKp80 do not contain charged 
residues in the transmembrane region and are characterized by tyrosine-based motifs in their 
cytoplasmic tails [30,41,42]. 2B4 associates with SAP adaptor and SHP-1/SHP-2 tyrosin 
phosphatases, whereas NKp80 contains a tyrosin motif in its cytoplasmic domain, which could 
bind Syk analog to Dectin-1 [43]. The tyrosin motif of DNAM-1 is a possible binding site for 
Grb2, which activates the Ras pathway [41]. Data was compiled from [30,41,44]. 
 
1.1.1.4 Viral modulation of NK cell immunity 
 
Viruses have coevolved together with their respective hosts and, hence, developed 
many mechanisms to avoid recognition by the hosts’ immune system or to ensure 
detection of viral invaders, respectively. Together with cytotoxic T cells the major 
combatants against virus-infected cells are NK cells [12]. Amongst various viral 
pathogens, human and mouse cytomegalovirus (HCMV and MCMV) are the model 
pathogens regarding their overabundance of immunoevasive mechanisms that allow 
a life-long persistence in the host. Cytomegalovirus impairs T cell recognition by the 
down-modulation of MHC class I surface expression through various mechanisms. 
HCMV-encoded US6 blocks the transporter of antigenic peptides TAP, also HCMV-
encoded US3 retains MHC class I heavy chains in the ER. In addition the two HCMV-
encoded immunoevasins, US2 and US11, induce the dislocation of class I MHC 
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heavy chains in distinct pathways from the ER membrane and target them for 
proteasomal degradation in the cytosol [45,46]. Via the binding of US11 onto the 
channel-like protein Derlin-1 HCMV hijacks with Derlin-1 the cellular garbage-
disposal machinery and disposes MHC class I molecules from the ER cytosol straight 
into the proteasome [47]. The strongly reduced MHC class I surface expression leads 
to a reduced engagement of inhibitory KIRs facilitating NK-mediated lysis. NK cells 
also indirectly monitor the expression of classical MHC class I molecules via HLA-E 
and Qa-1b in human and mouse, respectively. Since cell surface expression of HLA-E 
and Qa-1b is dependent on class I signal peptides, their surface expression indicates 
an intact MHC class I loading process in the ER. HLA-E and Qa-1b is bound by the 
heterodimeric inhibitory CD94/NKG2A receptors expressed by a major subset of NK 
cells and a minor subset of memory T cells in humans and rodents [48-50]. Failure to 
express HLA-E and Qa-1b on the cell surface leads to a reduced inhibitory signal to 
the NK cell.  
However, HCMV evolved also several NK evasion mechanisms. On the one hand, 
HCMV exploits the NK recognition of MHC class I by expressing an MHC class I 
replica, the UL18 glycoprotein, which strongly binds the pan-HLA-class I-specific 
NK inhibitory receptor ILT2 (inhibitory receptors Ig-like transcript 2) [51]. 
Additionally a peptide derived from the HCMV UL40 glycoprotein mimics signal 
peptides from HLA-class I molecules, and ensures HLA-E surface expression and 
ligation of inhibitory CD94/NKG2A receptors [52,53]. 
 
1.1.1.5 NK licensing 
Certain combinations of MHC class I alleles and KIR variants expressed by NK cells 
have been associated with the resistance to infections, the susceptibility to 
autoimmune diseases and even complications of pregnancy, as well as the outcome 
after a hematopoietic stem-cell transplantation [54]. The KIRs expressed by NK cells 
ensures that NK cells do not attack “self”. The genes for the MHC proteins and the 
KIR are inherited independently from one another and are highly polymorphic. One 
open question was how is it possible that receptors that are highly polymorphic 
recognize also highly polymorphic ligands? It was known already in the early 1990s, 
that in β2-microglobulin knock-out mice (β2m–/–) (with an MHC class I-deficient 
phenotype) NK cells are not attacking “self” but rather NK cells from such β2m–/– 
mice failed to kill β2m–/– blasts, while they retained the ability to kill the prototype NK 
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cell target lymphoma YAC-1, however at reduced levels [55]. 
Recently, it was proposed that the acquisition of full NK functionality requires a 
process termed “licensing” during NK maturation on a clonal level [56]. 
Paradoxically, the ITIM-bearing inhibitory KIRs specific for self MHC class I 
molecules are crucially involved in this positive activation during NK development. 
The majority of individual NK cells express only one or rarely two such “self-
restricted” KIRs [57]. Very recently it was reported, that in humans around 13% of 
the peripheral NK cells are even KIRnegNKG2Aneg, which will be discussed later [58]. 
The “licensing model” states now that only such NK cells are licensed whose KIRs are 
engaged by the corresponding self-MHC molecules. NK cells, which are not licensed 
do not exhibit NK effector functions [56]. This model explains observations made in 
the past like the impaired NK killing capacity by NK cells from β2m–/– mice as 
discussed above. Licensing could also be important in the problem why donor NK 
cells given to leukemia patients during bone marrow transplantation as treatment do 
not always have an anti-tumor effect. Leukemia patients can be treated by 
transplantation of bone marrow or hematopoietic stem cells. The patient's bone 
marrow and leukemia cells residing in the marrow are destroyed by irradiation and 
are replaced with marrow or stem cells from a donor (allogeneic transplantation). 
However, there is the risk of graft-versus-host (GvH) disease, which can be favorable 
for the patient by eradicating residual leukemia cells, called the graft-versus-leukemia 
or GvL effect. T cells are crucial mediators of these reactions. A different approach 
was used by the so called haploidentical (i.e. partly HLA-mismatched) hematopoietic 
cell transplantation pioneered by the Velardi group and others [59-61]. 
Haploidentical means that only one MHC-haplotype is matched with that of the 
recipient, which would be the case with either parent of the patient and with 
statistically 50% of the siblings of the patient. In certain donor-recipient 
combinations NK cells in the graft are not inhibited by HLA molecules of the host and 
are therefore alloreactive in the GvH direction. This leads especially in the case of 
acute myeloid leukemia (AML) to a greatly reduced probability of leukemia relapses 
and a reduced graft rejection (graft versus host, GvH), since the NK cells also 
eliminate host APCs, which are thought to be responsible for GvH effects [61]. Due to 
the absence of the appropriate recipient HLA ligands for the donor KIRs it is possible 
that the licensing is impaired, which influences the functional capacity of 
transplanted NK cells. It was shown that the licensing effect was less prominent in 
pre-activated NK cells [56], which means that licensing can be bypassed under 
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certain conditions. This could explain that certain transplantation protocols used in 
hematopoietic cell transplantation have more success than others [54,58]. 
As mentioned above recent studies in humans showed also that NK cells must 
encounter self MHC class I to become a fully functional NK effector [58]. Anfossi et 
al. described in humans a KIRnegNKG2Aneg subset accounting for ~13% of the 
peripheral NK cells. These cells are hyporesponsive to MHC class I-negative targets 
as well as to stimuli via NKp46-expressing targets or even CD16 cross-linking in cell-
free stimulation assays. In contrast, bypassing surface receptors using 
PMA/ionomycin leads to a normal response by these cells. A very large fraction of 
KIR+NKG2A+ cells, however, did also not respond to classical NK stimuli indicating 
that there are other factors contributing to NK cell reactivity [58]. 
 
1.1.1.6 The CD56dim and CD56bright NK subsets in humans 
 
It has been previously recognized that there are two functionally distinct NK cell 
subsets in humans: CD56dim and CD56bright NK cells. These NK cell populations differ 
in their localization properties: the CD56bright NK cells are more abundant in 
lymphoid organs than the CD56dim NK cells, and the latter being the most prominent 
subset in blood accounting for up to 90% [62]. The CD56dim NK cell population was 
also reported as being more prone to cytotoxicity, whereas the CD56bright NK cells 
tend to produce more cytokines such as IFNγ [63]. This distinction was recently 
modified stating that the CD56dim NK cells are more “target cell responsive”, which 
means they show higher CD107a and IFNγ expression upon stimulation with a MHC 
class I-deficient target. In contrast the CD56bright secrete more IFNγ in response to 
NK-stimulating cytokines like IL-12 and IL-15 being therefore more “cytokine 
responsive” [58]. 
 
1.1.1.7 Unconventional T cells subsets: T cells and NKT cells 
 
Both subsets are T cells by definition as they express a TCR. However both T cell 
subsets are considered as components of the innate arm of the immune system, since 
both T cell subsets use a restricted TCR repertoire. 
In contrast to "classical" αβ T cells, which account for the majority of T cells and 
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recognize short peptides bound to MHC molecules, the less frequent γδ T cells display 
a very restricted TCR repertoire. γδ T cells recognize a variety of possible antigens 
mostly self-molecules like CD1 or self-molecules associated with cellular stress like 
MICA, MICB or F1-ATP synthase in humans or T10/T22 in mice [64,65]. T22 
recognition is dominated by a certain TCR-δ CDR3 motif, which is mainly germ-line 
encoded and could allow for a rapid and significant response without an initial need 
for clonal expansion [66]. γδ T cells express scavenger receptors like WC1, TLRs 
(Toll-like receptors) and NK receptors [65,67]. They exhibit functions similar to αβ T 
cells and NK cells such as cytokine production and cytolysis [68]. γδ T cells can kill 
Listeria monocytogenes-infected macrophages [69]. Triggering of NKG2D alone 
activates γδ T cells to secrete TNFα and to release cytotoxic granules [70]. Recently, it 
was demonstrated that γδ T cells like DCs can function as professional APCs [71]. In 
contrast to DCs γδ T cells need to be activated. After activation γδ T cells express the 
lymph node homing receptor CCR7 and express increased MHC class II as well as 
CD80/86 levels [71]. γδ T cells are mostly located within the intestinal epithelial layer 
[64,72]. γδ T cells have been found at relatively high proportion among tumor-
infiltrating lymphocytes (TILs) of various origins [73] and several mouse models 
indicate that they likely play a role in tumor immunosurveillance [74-76]. The only 
well-characterized tumor ligands for human γδ T cells are the NKG2D ligands MICA 
and MICB. Since γδ T cells also express NKG2D, activation may occur via both, TCR 
and NKG2D binding. There are many reports that γδ T cells interact very closely with 
myeloid cells [65]. Half of the lung resident γδ T cells were shown to be in direct 
contact with DCs in the mouse [77] and in the skin a bi-directional activating 
crosstalk between DCs and γδ T cells was demonstrated in humans, which was cell-
cell contact-dependent [78]. 
 
Classical or invariant NKT (iNKT) cells are defined as CD1d-dependent and express 
the invariant Vα14-Jα18 (mice), Vα24-Jα18 TCR (humans). Technically iNKT cells 
can be identified by staining with an α-galactosylceramide (α-GalCer) loaded CD1d 
tetramers [79]. iNKT cells include two subsets, either CD4neg or CD4+. The CD4neg 
subset selectively produces the TH1 cytokines IFNγ and TNFα, and expresses 
NKG2D. In contrast, CD4+ CD1d-restricted iNKT cells potently produce both TH1 
and TH2 cytokines [79]. All invariant NKT cells recognize α-GalCer, a marine-
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sponge-derived glycosphingolipid [80]. Yet α-GalCer is not a likely physiological 
antigen of iNKT cells, since it is very rare in microorganisms and absent in 
mammalian cells [81]. Additionally, bacterially derived glycosylceramides can 
activate all iNKTs [82]. Recently, iGb3 (a glycosphingolipid) was identified as an 
important endogenous, lysosomal ligand for iNKT cells, which is required for iNKT 
development in the thymus and is also able to activate iNKT cells albeit weaker than 
α-GalCer [83]. iGb3 plays critical role in the activation of NKT cells during infections 
with Gram-negative bacteria that contain LPS in their cell wall. CD1d-mediated iGb3 
presentation by DCs and TLR-mediated IL12 secretion also by DCs leads to iNKT 
activation, which in turn secrete IFNγ. In the case of LPS-negative bacteria, it was 
shown that iNKT are solely activated via CD1d-expessing DCs via above mentioned 
glycosylceramides [81,82]. 
 
1.1.2 Monocytes and macrophages 
Cells of the monocyte lineage have important functions in the innate arm of the 
immunity since they phagocytose foreign material or cell debris, present antigen to T 
cells and produce important cytokines initiating the immune response like TNF, IL-6, 
IL1β or IL-8. In addition there are also inflammatory mediators like prostaglandins or 
leukotrienes, which are secreted by macrophages in response to pathogens. In order 
to detect pathogens the monocytic cells possess a wide variety of cell surface receptors 
like the Toll-like receptor (TLR) family or pattern recognition receptors, which will be 
discussed in detail in 1.1.4. 
 
1.1.2.1 Hematopoietic differentiation of myeloid cells 
 
Circulating monocytes in the blood differentiate from a common myeloid progenitor, 
which they share with granulocytes (see Figure 1.4 for details). They circulate for up to 
3 days [84] before they are recruited into tissues upon different stimuli and 
differentiate into tissue macrophages, a process, which was shown already as early as 
1939 by Ebert and Florey [85]. 
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Figure 1.4 Hematopoietic differentiation of mouse myeloid cells. In the bone marrow stem 
cells differentiate into myeloid and lymphoid progenitor cells. The myeloid progenitors 
subsequentially give rise to granulocyte-monocyte progenitors, which differentiate into 
granulocytes and monocytes. For more details see main text. Del Hoyo et al. [86] decribe a 
common precursor population, which can give rise to all DCs including plasmacytoid DCs. This 
pathway is indicated with an “?”. This illustration was drawn after [87]. 
 
Blood monocytes can also differentiate into myeloid dendritic cells in the tissue, but it 
seems that at least mouse monocytes are not the only source for DCs since a common 
precursor population for DCs was also described [86]. In the human system DCs can 
be generated in vitro by cultivating monocytes in the presence of IL-4 and GM-CSF 
for 7 days [88]. In humans, however, the in vivo development and differentiation 
pathway from monocytes to DCs is only poorly understood. 
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1.1.2.2 Monocyte heterogeneity 
 
The main surface marker for monocytes is CD14, which is part of the 
lipopolysaccharide (LPS) receptor. Although there is quite some morphologically 
heterogeneity among monocytes regarding size or granularity, only with the 
discovery of differential expressed surface markers one could define different 
monocytes subsets.  
 
Table 1.1 Markers of circulating monocytes subsets in human and mice. The minor 
CD14+CD16+CD64+ population was omitted since it is not well-characterized yet. Adapted from 
[89]. ND, not determined. NC, antigen is not conserved. 
 
Markers 
human 
CD14hiCD16neg 
human 
CD14+CD16+ 
mouse 
Ly6C+CD62L+ 
“inflammatory” 
mouse 
Ly6CnegCD62Lneg 
“resident” 
Chemokine receptors 
CCR2 +  +  
CCR5  + ND ND 
CCR7 +  ND ND 
CX3CR1 + ++ + ++ 
other markers 
CD11c ++ +++  + 
CD14 +++ + ND ND 
CD32 +++ + ++ + 
CD62L ++  +  
Ly6C NC NC +  
MHC class II + ++   
7/4 ND ND +  
 
In humans, there are altogether three different subsets known so far: the 
CD14hiCD16neg cells, which are regarded the classical monocytes, the 
CD14+CD16+CD64neg subset [90] and finally the minor CD14+CD16+CD64+ 
population [91]. Compared to the classical subset the CD14+CD16+ cells express 
more MHC class II, more CX3CR1 (CX3C-chemokine receptor) and they are CC-
chemokine receptor 5 (CCR5) positive in contrast to the classical, which are 
CCR2+CCR5neg [89]. Another important difference among the surface receptor 
expression is CD62L (or L-selectin), which is expressed only on the classical 
monocytes. A summary of important markers in human and mouse monocytes is 
shown in Table 1.1. 
With the observation that there are mouse counterparts to the human monocyte 
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subsets it seems appropriate to draw conclusions from in vivo studies in mice 
regarding the relevance in humans. With the help of adoptively transferred GFP-
expressing monocytes it could be shown that the CCR2+ subset is short-lived and is 
quickly recruited to the site of experimentally induced inflammation and upregulates 
CD11c and MHC class II.  
In contrast the CCR2neg monocytes persist longer in the blood and it could be shown 
that some cells could be detected in the spleen expressing a DC-like phenotype [92]. 
There is evidence, however, that also CCR2+ monocytes can differentiate into DCs 
[92]. Using an in vitro transendothelial-migration model Randolph et al. [93] could 
show that the human CD14+CD16+ subset preferentially differentiates into DCs. In 
vitro both monocyte subsets in human and in mice differentiate into DCs upon 
cultivation in IL-4 and GM-CSF [88,92,94]. It is not clear yet, at what point in the 
development the two subsets separate. There is evidence in mice that after the 
complete depletion of monocytes the CCR2+ monocytes are the first to recover in the 
circulation [95]. Together with the description of a population with an intermediate 
Ly6C expression one could discuss following development model as depicted in 
Figure 1.5. 
 
In healthy donors ~ 10% of the monocytes belong to the CD14+CD16+ subset. 
Regarding functionality of the CD14+CD16+ monocytes it was shown that this subset 
is a major source for TNFα producing threefold more of TNFα upon LPS stimulation 
and up to tenfold more TNFα after Pam3Cys-stimulation compared to 
CD14hiCD16neg cells [96]. The expression level of TLR2 (the receptor for Pam3Cys) 
was twofold higher in the CD14+CD16+ subset again compared to CD16neg cells [96]. 
Details regarding TLR ligands will be discussed in detail in 1.1.4. In patients with 
severe infections this subset is strongly expanded [97,98]. 
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Figure 1.5 Developmental model of mouse and human monocytes subsets. Ly6C+ monocytes 
are released into the blood (A) and without an inflammatory stimuli they develop into Ly6Cneg 
CX3CR1
+ resident monocytes (B, C). Upon inflammatory stimuli like CCL2 binding to its 
receptor CCR2 most of the Ly6C+ and the Ly6Cmid monocytes are recruited into the tissue and 
develop into macrophages (D). Some monocytes are migrating to the draining lymph node and 
differentiate to DC. A process, which was shown to be dependent on CCR7/CCR8 expression 
(E). The Ly6CnegCX3CR1+ resident monocytes finally replenish the tissue-resident macrophages 
like the aleveolar macrophages, osteoclasts or tissue-resident DC (G, F). The solid arrows 
indicate that the pathways are supported by in vivo mouse data, whereas the dashed arrows 
indicate a more hypothetical status. This model was drawn after [89]. 
 
1.1.2.3 Specialized tissue macrophages 
 
The very heterogeneous nature of tissue macrophages is a consequence of their 
specialization of function in very different parts of the body. The professional antigen-
presenting Langerhans cells, for example, are found in the epidermis of the skin. The 
osteoclasts are responsible for remodeling bone, whereas the alveolar macrophages 
are responsible for the clearance of environmental particles, viruses and other 
microorganisms in the lung. The Kupffer cells in the hepatic sinusoids of the liver 
remove debris and dying cells of the blood similar to splenic macrophages in the white 
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pulp, which are by themselves again very heterogeneous. Finally there are many 
subsets of macrophages in the central nervous system (CNS) like the microglia or the 
perivascular macrophages in the small blood vessel near the brain [89]. 
Under steady-state conditions this tissue macrophages undergo local proliferation to 
replenish their resident populations whereas under stress conditions circulating 
monocytes are recruited into the tissue. This could be shown for the Langerhans cells 
[99] in the epidermis or for the alveolar macrophages in the lung [100,101] and for 
most of the other tissue macrophages like the Kupffer cells [102]. Generally there are 
three modes of macrophage activation: the classical via an IFNγ priming signal and a 
subsequent LPS exposure as a second signal, which leads to a strong TNFα 
production, higher antimicrobial activity and to an activation of cellular immunity by 
upregulating MHC class II and CD86 expression. The innate activation is the second 
mode of activation only via TLR ligands like LPS or peptidoglycans, which again 
leads to secretion of pro-inflammatory cytokines and increased production of reactive 
oxygen species (ROS). The third kind of activation is the so called alternative 
activation via IL-4 and IL-13, which results in higher activity in tissue repair, 
increased cell growth and reduced inflammatory function. IL-10 and TGFβ are 
strongly deactivating for macrophages, which results in MHC class II downregulation 
and anti-inflammatory cytokine production [89,103]. 
 
1.1.3 Dendritic cells 
The first description of dendritic cells (DCs) stems from Paul Langerhans [104] in the 
human skin, but he erroneously thought that this cells are nerve cells. Nearly a 
century later Steinman and Cohn discovered DCs in the mouse spleen and termed 
them “dendritic cells” [105]. Dendritic cells are professional antigen-presenting cells 
and have the exceptional ability to induce primary immune responses. DCs sample 
the environment and transfer this information to the cells of the adaptive immune 
system and are therefore crucial linkers of the innate and the adaptive arm of the 
immune system. Mature DCs are the most effective APCs for T cell priming [106] 
whereby without costimulatory signals an interaction between an immature DC and a 
T cell can induce tolerance [107]. So DCs determine not only whether an adaptive 
immune response is mounted, but also what type of immune response is induced. 
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1.1.3.1 Mouse and human dendritic cell subsets 
 
Mouse DC subsets are much better defined than the human one. In mice there are 
three different subsets [108,109]; two are considered conventional DCs, which 
express high levels of CD11c and differentially express CD8α. The CD8αneg are found 
in the marginal zones of the spleen, whereas the CD8α+ express also high levels of 
CD205 and are found in the T cell zones of the spleen. The CD8α+ are able to cross-
present exogenous antigen to CD8+ T cells [110]. The third category are the 
plasmacytoid DCs (pDCs), which are also called natural interferon-producing cells 
since they produce large amounts of type I interferons in response to viral infections 
[111]. It took nearly fifty years from the first description to clearly define that the cell 
subset described already 1958 by Lennert et al. [112] are the interferon-producing 
cells described by Trinchieri 1978 [113]. Lennert et al. reported cells in the T cell zone 
of lymphoid tissue displaying a plasma cell like morphology, but lacking B cell and 
plasma cell markers yet expressing some monocyte markers and therefore termed 
them plasmacytoid monocytes. The question whether the pDCs are of lymphoid or 
myeloid origin is still an ongoing matter of debate [111]. As discussed in 1.1.2.1 a 
common precursor population for DCs was described [86], which could give rise to 
all DC subsets. There are also several hints that pDCs are of lymphoid origin, but it 
seems that there is a certain plasticity in the development of pDCs [114] and DCs in 
general. 
Human DCs are all bone marrow-derived leukocytes and are distinct from follicular 
DCs, which are no leukocytes [115]. It is possible to generate, under cytokine-driven 
conditions, ex vivo, four different type of human DCs: the Langerhans cells (LC), the 
dermal DCs (interstitial DCs, IDC), the plasmacytoid DCs (pDCs) and the monocyte-
derived DCs (moDCs), which are the best-characterized type of human DCs [116]. 
Human DCs don’t express CD8α but there are several markers, which differentiate 
human DCs: CD11c, CD123 and the four monoclonal antibodies BDCA-1 through 
BDCA-4 (blood dendritic cell antigen 1-4) generated by Dzionek et al., which define 
clearly three distinct populations of DCs present in the blood, which account together 
of ~ 1% of the PBMC [117]. The so called myeloid DC subset 1 (MDC-1) cells are 
efficient APCs and secrete large amounts of IL-12 in response to bacteria and 
represents 0.6% of all PBMCs. In contrast the pDCs account for 0.37% of the PBMCs 
and secrete large amounts of type I IFN in response to viruses, which strongly 
activates NK cells, but only little IL-12 and they are only poor APCs. The smallest 
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population of blood DCs are the myeloid DC subset 2 (MDC-2) and constitute only 
0.03% of the PBMC of a healthy donor. The role of this subset remains to be 
established. It is important to note that after maturation in culture the expression 
profile of BDCA-2, BDCA-3 and BDCA-4 on the three blood DC subsets is 
indistinguishable [117]. The differentiation markers expressed by the different 
human DCs subsets is displayed in detail in Table 1.2.  
 
Table 1.2 Markers of DC subsets in humans. The nomenclature MDC-1 and MDC-2 stands for 
myeloid DC subset 1 or 2 respectively. The expression levels of the different markers of the pDCs, 
and the MDC-1/2 subset was determined ex vivo. The expression levels of the in vitro IL-4/GM-
CSF monocyte-derived DCs are shown of immature DCs only. Due to the lack of TLR-specific 
antibodies most data regarding TLR expression in literature was acquired using RT-PCR, which 
resulted in conflicting results (indicated in the table by +/-). Data complied from [108,116-118]. 
ND, not determined/found in the literature. 
 
DC subset human pDC 
human 
MDC-1 
human 
MDC-2 
in vitro monocyte-
derived DCs 
CD1a    + 
CD1c/BDCA-1  +  + 
CD4 ++ + + ND 
CD11b  +/   + 
CD11c  ++ + + 
CD14  +/    
CD16     
CD56  subset +/  subset +/  ND 
CD80    + 
CD83    + 
CD86 + +++ ++ ++ 
CD123 ++ + + ++ 
CD208 
(DC-LAMP) 
 ND ND  
BDCA-2 +    
BDCA-3   +  
BDCA-4 +   + 
TLR1 + ++ ND + 
TLR2 +/  ++ ND ++ 
TLR3  ++ ND + 
TLR4   ND +/  
TLR5 +/  + ND + 
TLR6 + ++ ND + 
TLR7 + + ND +/  
TLR8  ++ ND + 
TLR9 ++  ND  
TLR10 +/  + ND + 
 
Only after developing of these cytokine-driven methods for the generation of larger 
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quantities of human DCs large scale studies were made possible during the 1990s. 
Still, the question of the in vivo relevance of all this data generated with these in vitro 
generated DCs is not answered completely. With the availability of appropriate 
reagents, however, it is now it is possible to directly purify human blood DCs and 
evaluate the cells ex vivo. 
 
1.1.3.2 Antigen capture and maturation of DCs 
 
 
Inducing
factors DC precursors
Properties
immature DC
mature DC
Cytokine Release
Antigen Capture
Antigen Presentation
 
Figure 1.6 Maturation of dendritic cells. The environmental stimuli necessary for each 
maturation step is outlined in the left panel, while the characteristic properties of the DCs at each 
level is shown on the right side. Important appr: TLR, Toll-like receptor; ds, double stranded 
RNA; LC, Langerhans cell; PGE2, Prostaglandin E2; Flt3-L, fms-like tyrosine kinase 3 ligand. 
This scheme was drawn after [109]. 
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DCs use phagocytosis, endocytosis, pinocytosis and specific receptors to sample their 
environment and to capture cell debris, immunocomplexes, pathogens or other 
antigens to process and present it to T cells as other professional antigen presenting 
cells (APC) also do. Ag can be presented classically via MHC class II or class I, 
additionally DCs are also able to cross-present exogenous Ag via MHC class I. 
 
In order to be fully immunogenic all DCs have to undergo a process called 
maturation, which is a crucial step in the activation of the adaptive immune system. 
Maturation can be induced by a whole variety of stimuli provided by (a) components 
of pathogens like LPS or bacterial DNA (b) the local cytokine environment where 
inflammatory cytokines like TNFα or IFNγ drive maturation or finally (c) stimuli 
provided by membrane-bound ligands e.g. CD40L on T cells. The most potent 
inducers for maturation are the ligands for the TLRs expressed by the DCs [109,116]. 
The maturation process is outlined in Figure 1.6. 
 
1.1.3.3 The final outcome of antigen-presentation by DCs: induction of 
immunity or tolerance 
 
Dendritic cells constitutively phagocytose both microbial and host apoptotic cells 
[119]. This results in the induction of immunity against invading pathogens or 
tolerance to peripheral self antigens, respectively [107]. Toll-like receptor (TLR)-
induced dendritic cell activation makes DCs immunogenic, whereas the steady-state 
presentation of self antigens induces tolerance [107]. One mechanisms of self/non-
self discrimination is the TLR-inducible expression of co-stimulatory signals [118]. 
The question remains, if DCs are capable of distinguishing between the two sources 
of antigens for their selective presentation by MHC class II when both are 
encountered by dendritic cells during an infection. How is the immunogenic 
presentation of self antigens avoided by DCs? Very recently Blander et al. could 
describe a new mechanism of antigen selection on a subcellular level in DCs for 
presentation on MHC class II, which is based on the origin of the antigen [120]. They 
show that antigens are only presented when there are TLR ligands present within the 
cargo of the same phagosome. The degradation of the MHC class II-associated 
invariant chain (Ii) to CLIP seems to be TLR-dependent. Using this mechanism, DCs 
can distinguish between different sources of antigens if it is of self or non-self origin 
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at a subcellular level. The generation of peptide–MHC II complexes from pathogens 
takes only place in context of TLR-mediated co-stimulation, whereas presentation 
self-antigen is avoided in such a costimulatory context [120]. 
 
1.1.3.4 C-type lectin receptors on dendritic cells 
 
Many lectins on DCs are considered non-TLR pattern recognition receptors since 
they have been associated with antigen uptake, but there is more and more evidence 
that lectins are important for DC migration and interaction with other leukocytes. 
The structural aspects of lectins are discussed in detail in 1.1.7.1. C-type lectins bind 
sugar in a Ca2+-dependent manner using their so-called carbohydrate recognition 
domain (CRD), whereas the C-type lectin-like receptors lack the Ca2+ ligating 
elements and are not able to bind sugar residues in a manner analogous to the C-type 
lectins. C-type lectins are type I or type II transmembrane proteins depending on the 
orientation of the N termini. Type I transmembrane proteins have their N termini 
pointing outwards of the cell or into the cytoplasm for the type II proteins respectively 
[121]. Unfortunately, the same nomenclature is used for another distinction 
regarding lectins. Type I means also that the C-type lectins have more than one 
carbohydrate recognition domain (CRD) in contrast to type II, which have only one 
CRD. There are also soluble C-type lectins like the mannose binding protein known 
(MBP), which is present in the plasma [122]. 
 
The macrophage mannose receptor (MMR) is the prototype of lectins on DCs 
involved in antigen uptake. Using its CRD 4 and 5 MMR binds to mannosylated 
proteins on pathogens. MMR is constitutively internalized into early endosomes 
where under the acidic conditions MMR is unloaded and recycles back to the cell 
surface [123]. CD205 and DC-SIGN (dendritic cell-specific ICAM-3 grabbing non-
integrin) are just internalized after ligand binding. It was shown that up to 20% of the 
membrane-bound MMR is shed by the DCs and serves as agglutinins and opsonins by 
binding to the surface of pathogens [124]. The role of C-type lectins in cell migration 
and trafficking is demonstrated by the reported binding of the intercellular adhesion 
molecule 2 (ICAM-2) to DC-SIGN. ICAM-2 is expressed by endothelial cells and 
promotes the adhesion of DCs during migration [125]. Finally are C-type lectins 
involved in DC-T-cell interaction. DC-SIGN mediates transient adhesion with T cells 
by high-affinity binding to ICAM-3 expressed by T cells. Blocking of this interaction 
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inhibited DC-induced T cell proliferation [126]. 
 
 
Figure 1.7 C-type lectins on human dendritic cells. Type I means in this figure that the C-type 
lectins have more than one carbohydrate recognition domain (CRD) in contrast to type II, which 
have only one CRD. The cytoplasmic tails are very diverse and contain several motifs all related 
with antigen uptake: a tyrosin-containing motif, which targets into coated pits or a di-leucin 
motif. CLEC-1, C-type lectin receptor; DCIR, dendritic cell immunoreceptor; LLIR, lectin-like 
immunoreceptor; DC-SIGN, dendritic cell-specific ICAM-3 grabbing non-integrin; DCLEC, 
dendritic cell lectin; MMR, macrophage mannose receptor; dectin-1 und -2, DC-associated C-
type lectins 1 and 2; CLL-1, C-type lectin-like molecule 1; MICL, myeloid inhibitory C-type lectin 
-like receptor. MICL is a truncated form of CLL-1. This illustration was drawn after [126]. 
Additional data was compiled from: [127-130]. 
 
Dectin-1 (DC-associated C-type lectin 1) is a quite unusual C-type lectin like 
molecule. First its main ligand is a polysaccharide though its CRD lacks the known 
residues important for sugar binding. Dectin-1 binds β-glucans found in the cells 
walls of fungi, some bacteria and plants. It also binds to zymosan, which is a cell-wall 
extract of S. cerevisiae [131]. There is also evidence for proteinaceous ligand of Dectin 
on T cells. Blocking of this interaction inhibited Dectin-1-induced T cell proliferation 
[132]. Hence Dectin-1 could serve as a co-stimulatory molecule. This leads to the 
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second unusual property of Dectin-1. It contains in its cytoplasmic tail a single ITAM 
(YXXL) and is therefore the only known non-TLR pattern recognition receptor 
capable of mediating signals on its own. It is also the first description of signaling of 
C-type lectins occurs via the spleen tyrosin kinase (Syk) [43]. There is a second 
unusual ITAM repeat (YXXXL) present but it seems dispensable for signaling [43]. 
Dectin-1 was originally thought to be DC specific (hence its name) [132], but is now 
clear that it is also expressed by many cell types including macrophages, monocytes, a 
subset of T cells, eosinophils and B cells [133]. In mice, Dectin-1 expression can be 
increased by IL-4 and IL-13, cytokines associated with the alternative activation of 
macrophages (see 1.1.2.3 for details) and the expression is reduced by LPS [133]. 
After ligand binding Dectin-1 induces multiple responses ranging from cytokine and 
chemokine secretion (TNFα, CXCL2, IL-2, IL-10, IL-12), respiratory burst and 
ligand uptake through phagocytosis. However for some responses co-signaling via 
TLR is necessary e.g. TNFα secretion needs TLR2 triggering [134]. Such responses 
are also independent of Syk, however how such dectin-1 signaling integrates the TLR 
pathway is unknown [43]. Dectin-1 and TLR2 colocalize after zymosan-binding. So a 
signaling complex analog to the TLR2, MD2 and CD14 complex of the LPS signaling 
pathway seems possible [133]. 
 
C-type lectin-like molecule 1 (CLL-1) was described by three groups independently 
[127,128,135] (official gene symbol C-type lectin domain family 12, member A, 
CLEC12A). Consequently the C-type lectin-like molecule 1 (CLL-1), the myeloid 
inhibitory C-type lectin-like receptor (MICL) and the killer cell C-type lectin-like 
receptor L 1 are the same molecules (KLRL1). There have been three alternative 
splice forms described and the published MICL sequence is a truncated form of CLL-
1. CLEC12A is exclusively expressed on cells of the myeloid lineage. It contains an 
ITIM motif in its cytoplasmic tail and is rapidly internalized upon ligation with 
specific monoclonal antibodies [127,128,135]. 
 
As reflected by Table 1.3 lectins expressed on DCs are very diverse and different 
subsets of DCs or even different activations states of DCs show wide differences in 
surface expression. Beyond the role of C-type lectins on DCs in antigen capture C-
type lectins are important in DC migration and even more dominant in the emerging 
DC cross-talk with other players of the immune system. 
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Table 1.3 Functions of C-type lectins on dendritic cells in humans. Some receptors are 
discussed in more detail in the main text. Abbr.: actDCs, activated DCs; LCs, Langerhans cells; 
mono, monocytes, MΦ, macrophage; PBMC, polymorphic mononuclear cells; EC, endothelial 
cells; neutro, neutrophils, eosino, eosinophils; for more see Figure 1.7. Birbeck granules are 
cytoplasmic organelles in LC associated mature DCs only. Type I means that the C-type lectins 
have more than one carbohydrate recognition domain (CRD) in contrast to type II, which have 
only one CRD. Data compiled from [126] and the references cited within the table. ?, not known 
yet. $, expressed on RNA level. 
 
C-type 
lectin 
Type Location 
chrom. 
Expression Ligand Function Ref. 
MMR 
(CD206) I 10p13 
DCs, LCs, 
mono, MΦ 
Mannose, 
fucose, sialyl 
lewis X 
antigen uptake [136] 
DEC-205 
(CD205) I 2q24 
DCs, LCs, 
actDCs, 
thymic EC 
? antigen uptake [137] 
Dectin-1 II 12p13 
DCs, LCs, 
mono, MΦ, B 
cells, T cell 
subset, neutro, 
eosino, 
β-glucan 
zymosan 
T cell proliferation, 
cytokine release, antigen 
uptake, respiratory burst 
[132,133] 
Dectin-2 II 12p13 DCs, LCs 
mouse Dectin-
2 binds 
mannose 
antigen uptake, ligand(s) 
on regulatory T cells? 
[132] 
Langerin 
(CD207) II 2p13 LCs ? 
formation of Birbeck 
granules 
[138] 
DC-SIGN 
(CD209) II 19p13 DCs 
gp120 (HIV-
1), mannan, 
ICAM-2, 
ICAM-3 
antigen uptake [139] 
BDCA-2 
(CD303) 
HECL 
DLEC 
II 12p13 pDCs ? 
antigen uptake? 
induces Ca2+ influx, 
putative activating adapter 
molecule? 
induces IL-12 & type I 
interferons 
[140,141] 
DCIR 
(LLIR) II 12p13 
DCs, mono, 
MΦ, PMN, B 
cells 
? ? [142] 
CLEC-1 II 12p13 DCs$ ? ? [143] 
CLEC-2 II 12p13 liver$ ? ? [143] 
L-SIGN II ?? ?? ? ? [144] 
CLEC12A 
(CLL-1) 
[127] 
MICL [128] 
KLRL1 
II 12p13 
mono, gran, 
HL-60, U937, 
THP-1, blood 
DCs, 
? 
? 
ITIM 
[135] 
DCAL-1 II 12p13 DC, B cells ? truncated CRD, no sugar 
binding possible 
[130] 
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1.1.4 Pattern recognition in the innate immune system 
1.1.4.1 Pathogen-associated molecular patterns (PAMPs) and pattern-
recognition receptors (PRRs) 
 
The innate immune system employs a whole range of so called pattern- recognition-
receptors (PRRs), which recognize highly conserved molecular patterns found only 
in pathogens but not in mammalian cells and thereby activate the innate immune 
system. Important examples are the Toll-like receptor family (TLRs) or as already 
discussed in 1.1.3.4 the non-TLR dectin-1. The molecular structures recognizes by 
PRR are commonly called pathogen-associated molecular patterns (PAMPs). PAMPs 
are essential for the pathogens and are therefore in general immutable. The induction 
of an inflammatory immune response after a pathogen encounter is mainly mediated 
by the TLR family, but the non-TLRs can contribute to a TLR-mediated activation. 
Dectin-1 is so far the only example of a non-TLR PRR capable of inducing an 
inflammatory response [133]. 
 
Table 1.4 Non-TLR pattern-recognition-receptors (PRR). Abbr.: LBP, lipid binding protein; 
CR, complement receptor; LOX-1, lectin-like oxidized LDL receptor; MARCO, macrophage 
receptor with collagenous structure; LPS, lipopolysaccharide; MMR, macrophage mannose 
receptor; SP-A and SP-D, surfactant protein A and D; NOD1 and NOD2, nucleotide-binding 
oligomerization domain; NLR, NACHT-leucin-rich repeat. Data compiled from [133]. 
 
Class Member Recognized microorganism or PAMP. 
soluble in serum or tissue fluid 
Complement C3, C1q microbial surfaces, L. monocytogenes, E.coli 
Lipid transferases LBP LPS 
Collectins SP-A, SP-D influenza virus, A. fumigatus, C. albicans 
membrane-bound PRR 
Leucin-rich repeats proteins CD14 LPS, LTA, E.coli, peptidoglycan 
Scavenger proteins LOX-1, 
MARCO 
E.coli, L. monocytogenes, S. aureus, Heliobacter 
pylori, LPS, LTA, bacterial DNA 
classical C-type lectins MMR, DC-
SIGN 
C. albicans, E. coli, M. tuberculosis, zymosan, 
HIV, Ebola virus  
non-classical C-type lectins Dectin-1 C. albicans, S. cerevisiae, A. fumigatus zymosan
Integrins CR3, CR4 complement-coated microorganisms, LPS 
cytoplasmic 
NLR NOD1, NOD2 muramyl dipeptide, shigella flexneri 
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PRRs can be soluble in the serum or tissue fluid, membrane bound or cytoplasmic. 
Leukocytes can detect pathogens directly using PRRs or via so-called opsonic 
recognition, whereby opsonic receptors like the complement receptor 3 (CR3) bind to 
PRR-coated pathogens. Some PRR are acting intracellularly like the NACHT-leucin-
rich repeat (NLR) family [145]. In Table 1.4 some typical non-TLR PRR for each 
class of PRR are listed. 
 
1.1.4.2 Toll-like receptors 
 
Toll genes were described originally in Drosophila melanogaster by Nüsslein-Volhard 
and colleagues [146] where these proteins are involved in the establishment of dorso-
ventral polarity of the developing embryo [147] and anti-fungal immune response of 
the adult fly [148]. “Toll” is a German word and means "amazing" or "crazy". The 
similarities of the signaling pathways of Drosophila Toll and the mammalian IL-1 
receptor and the highly conserved cytoplasmic domains of both receptors led to the 
identification of a family of mammalian homologues of the Toll protein, the so called 
Toll-like receptors (TLRs) by Ruslan Medzhitov and Charles Janeway in 1997 [149]. 
This discovery turned out to be a fundamental breakthrough in the way we think 
about the innate immune system, since the TLRs are the key mediators of an 
inflammatory immune response after a pathogen encounter. So far the TLR family 
consists of 11 members in mammals [150-155] and specificity for different ligands 
either resides within one receptor itself or is mediated through heterodimerization. 
Nine out of eleven TLRs are conserved between human and mouse. The orphan 
TLR10 is non-functional in the mouse while TLR11 is not expressed in humans 
[155,156]. 
Only the biology of TLR4 will be discussed here in more detail. TLR4 is the receptor 
for lipopolysaccharide (LPS), which is the main component of the outer cell 
membrane of gram-negative bacteria. There are in addition to TLR4 several other 
molecules involved in the LPS-mediated cellular activation. In serum LPS forms 
micelles, which form a complex with the LPS-binding protein (LBP). This LPS-LBP 
complex binds to the GPI-anchored CD14 on the cell surface of cells of the myeloid 
lineage i.e. monocytes, macrophages and granulocytes. [157,158]. In contrast to in 
vitro-generated DCs freshly isolated DCs do not express TLR4 [118]. The 
CD14/LPS/LBP complex associates then with TLR4 [159,160] leading to the 
downstream activation of the receptor pathway. With MD-2 there is yet another 
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molecule involved in LPS-recognition. MD-2 is associated with the extracellular 
domain of TLR4 and binds directly to LPS and amplifies LPS responsiveness of cells 
[161,162]. 
Several other PAMPs from viruses like the F protein of RSV [163] or endogenous 
ligands like heat shock proteins [164] activate TLR4 in addition to LPS. It is thought 
that receptor agonists from endogenous origin, which are released from dead or 
injured cells, indicate an inflammatory process and therefore function as danger 
signals [165]. However, under certain conditions the TLR-mediated recognition of 
endogenous components may break tolerance and lead to autoimmunity [118]. 
 
 
Figure 1.8 Ligand specificities of Toll-like receptors (TLR). TLRs recognize a wide range of 
pathogen-derived products, which are indicated by the black arrows for each individual TLR. The 
TLR4 homodimer associates with the GPI-anchored CD14/LPS complex together with MD-2. 
TLR2 associated either with TLR1 or TLR6 to form a functional heterodimer. Abbr.: LP, 
lipoprotein; LPS, lipopolysaccharide; MALP-2, macrophage-activating lipopeptide; LAM, 
lipoarabinomannan; RSV, respiratory syncytial virus; HSP, heat shock protein; dsRNA, double 
stranded RNS; poly(I:C), polyinosinic: polycytidylic acid; CpG, cytosin-phosphatidyl-guanosin. 
The orphan TLR10 in humans is not shown. TLR10 is able to homodimerize, but also to 
heterodimerize with TLRs 1 and 2 [166]. Data was compiled from [118,167,168]. 
 
Upon binding of the respective specific ligand, TLR signaling is initiated by 
homodimerization (e.g. TLR4) or heterodimerization (e.g. TLR2 and TLR1). All 
TLRs except TLR3 signal via the adaptor protein MyD88 initiating several signaling 
pathways [118,169]. This triggers the expression of various genes that are involved in 
immune responses, such as inflammatory cytokines and costimulatory molecules on 
cells of the innate immune system. This activation is essential for the generation of 
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adaptive immune responses. DCs are central in priming of antigen-specific naïve T 
lymphocytes. For example TLR4-mediated LPS-recognition initiates DC maturation 
and migration to the draining lymph node [167]. Inside the draining lymph node the 
DCs provide naïve T cells with two signals necessary for T cell priming: the first via 
the T cell receptor and the second one via CD80/CD86 binding to CD28. The TLR 
mediated activation translates the signal received by the pathogen recognition into 
the clonal expansion of antigen specific T cells yielding to a TH1 response. There are 
some reports, however, that TLR2 ligands like Pam3Cys are able to induce a TH2 
response, which may play a role in the initiation of TH2-mediated immune disorders, 
such as asthma [170]. The different subsets of DCs show differential TLR expression 
(see Table 1.2 for details). Freshly isolated human pDCs express TLR7 and TLR9, 
whereas mDCs express TLR1, TLR2, TLR3, TLR5, TLR6, TLR7 and TLR8. 
Importantly both subsets do not express TLR4 [118]. It is also possible that the very 
same TLR ligands induce different answers in different DC subsets e.g. stimulation of 
human pDC with TLR7 induces Type I IFN but IL-12 secretion by mDCs [171]. 
 
1.1.5 Cytokines as regulators of innate and adaptive immunity 
An important component of innate immune reactions is the production of various 
cytokines by various cells in the body upon an activating stimulus. Type I interferons 
play a central role in innate immunity not only because of their antiviral activity, but 
also due to their role in the regulation of cells of the innate and adaptive immunity. 
Type I interferon secretion (IFNα by leukocytes and pDCs and IFNβ by fibroblasts), 
is induced by viral infection and is one of the first events in the innate immune 
response after antigen recognition [172]. Type I interferons induce resistance to viral 
replication in all cells, increase of MHC class I and II expression and the necessary 
antigen processing and presentation pathways, thus enabling effective T cell 
responses. Importantly IFNγ is not induced directly by viral infection however IFNα 
and IFNβ are strong activators of NK cells and NK-mediated IFNγ-release [173]. NK 
cells and certain T cell subsets like the CD8+ T cells, NKT or γδ T cells are the major 
source for IFNγ [174]. IFNγ in synergy with TNFα provide a differentiation and 
maturation signal for DCs [175]. In addition, IFNγ is crucial for the induction of 
Interleukin-12 (IL-12) secretion by phagocytic cells and DCs. 
IL-12 is a heterodimeric pro-inflammatory cytokine and plays a central role at the 
interface of innate and adaptive immunity. It has important effects on T cells and NK 
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cells and is produced mainly by activated inflammatory cells like monocytes, 
macrophages, neutrophils, DCs and to a minor extent by B cells. IL-12 was originally 
named natural killer cell stimulatory factor (NKSF) based on its NK-activating 
capacity and is also secreted by the EBV-transformed human B lymphoblastoid cell 
line RPMI 8866, which is frequently used for the in vitro proliferation of NK cells 
[176]. It is the major cytokine for TH1-cell differentiation allowing potent IFNγ 
production especially by NK cells [177]. Dependent on the presence of NK, NKT, and 
T cells, which IL-12 can drive towards their most active effector functions against 
tumors, this cytokine has a potent anti-tumor activity [178]. 
Activated monocytes/macrophages secrete in a TLR-mediated manner various 
cytokines and chemokines in response to pathogens such as IL-1β, TNFα, IL-6, IL-12 
and IL-8 (CXCL8). A central role plays here TNFα, which leads to local inflammation 
and the activation of the endothelial cell wall, which includes increased permeability 
for cells, immunoglobulins and complement. TNFα is also released by activated NK 
cells. The chemokine IL-8 attracts neutrophils, basophils and T cells to the site of 
infection. 
IL-18 is produced by the same cell populations as IL-12 and induces synergistically 
with IL-12 IFNγ secretion by NK and T cells leading to a TH1 polarization. 
Interestingly IL-18 alone in the absence of IL-12 can also stimulate TH2 responses 
[179]. 
Granulocyte-macrophage colony stimulating factor (GM-CSF) is mainly produced by 
T cells and NK cells and has essential effects on DC maturation necessary for the 
induction of potent adaptive immune responses [180]. 
The last cytokines to be discussed are IL-2 and IL-15 the latter originally called T-cell 
growth factor. The properties of IL-2 and IL-15 are detailed in Table 1.5. The 
receptors for IL-2 and IL-15 are members of the common cytokine-receptor γ-chain 
(γc) (also known as CD132) family of cytokine receptors which includes the receptors 
for IL-4, IL-7, IL-9, and IL-21 since all contain γc. Additionally the IL-2 receptor (IL-
2R) and the IL-15R have a second shared subunit, the β-chain IL-2/15Rβ, and the 
high affinity forms of both also contain a unique subunit, IL-2Rα (also known as 
CD25) or IL-15Rα, respectively [181]. Due to the shared receptor subunits many 
functions of IL-2 and IL-15 are overlapping like the proliferation and differentiation 
of NK cells, T and B cells. In adaptive immunity, however, there are significant 
differences (see Table 1.5 for details). IL-15 is secreted only in small quantities and is 
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mainly membrane-bound. IL-15 is especially important in NK biology since in the 
absence of IL-15Rα-mediated trans-presentation NK cells are not generated from 
bone marrow precursor cells and NK cells are also depend on IL-15 for their survival 
in vivo. Trans-presentation means that IL-15 is membrane-bound by IL-15Rα, which 
is mainly expressed on the surface of APCs like monocytes or dendritic cells. Such 
membrane-bound IL-15 binds in the immunological synapse to IL-2/15Rβ γc on NK 
cells or CD8+ T cells. 
 
Table 1.5 Key features of IL-2 and IL-15. Abbr.: AICD, activation-induced cell death; γc, 
common cytokine-receptor-chain; IL, interleukin; IL-2R, IL-2 receptor-chain; IL-2/15R, the γc -
chain of the IL-2 receptor and IL-15 receptor; IL-15R, IL-15 receptor-chain; TReg cell, 
CD4+CD25+ regulatory T cell. Table adapted from [181]. 
 
Properties IL-2 IL-15 
Producer cells activated T cells dendritic cells and monocytes 
Receptor IL-2R, IL-2/15R and γc are co-
expressed by activated T and B 
cells 
IL-15R on the surface of monocytes and 
dendritic cells presents in trans IL-15 to 
NK cells and CD8+ memory T cells 
expressing IL-2/15R and γc 
Function proliferation and differentiation 
of NK cells, and T and B cells; 
elimination of self-reactive T cells, 
mediated by AICD, maintenance 
of TReg cells 
Proliferation and differentiation of NK 
cells, and T and B cells; maintenance of 
CD8+CD44hi memory T cells 
Effect of cytokine 
or cytokine-
receptor 
knockout 
enlargement of peripheral 
lymphoid organs and polyclonal 
expansion of T- and B-cell 
populations; associated with 
autoimmune diseases 
strongly reduced number of NK and NKT 
cells and CD8+CD44hi memory T cells 
 
1.1.6 NK cell/DC crosstalk 
Having introduced most of the key components of the innate immune system, the 
original statement at the beginning of this introduction that the two arms of the 
immune system are closely connected and that many aspects of the adaptive immune 
response are in fact controlled by the innate immune system can be revisited again [2-
4,108]. Two key players of the immune system, the DCs and the NK cells took center 
stage in recent years in a process commonly called NK/DC crosstalk. In the past five 
years there have been many reports supporting the notion that NK cells and DCs not 
only influence innate and adaptive immunity but are also able to regulate both of 
them. However, NK cells are not the only innate lymphocytes committed in the cross-
Introduction 33
talk with DCs. The unconventional T cells subsets, γδ T cells and iNKT cells, are also 
crucially involved in the initiation of adaptive immunity. The next paragraph 1.1.6.1 
will summarize how innate lymphocytes mature DCs before the further sections 
discuss the NK/DC crosstalk in greater detail (1.1.6.2 -1.1.6.4). 
 
1.1.6.1 DC interaction with innate lymphocytes 
 
The induction of DC maturation is a critical step in the activation of adaptive 
immunity. Maturation can be initiated either by TLR ligands [118] or by interaction 
with innate lymphocytes like γδ T cells, NKT cells or most importantly with NK cells 
[182]. 
DC maturation has been shown after NK cell recognition of MHC class I low tumor 
cells [183], iNKT cell activation by α-GalCer presented by CD1d on DCs [184], and 
activation of phosphoantigen-specific and also CD1c-restricted γδ T cell subsets 
[78,185]. All above named innate lymphocyte subsets induced DC maturation, which 
is indicated by increased CD86 expression, IL-12 production, and T cell priming 
[183-186]. TNFα is hereby an important mediator of DC maturation [182]. 
Additionally, CD40 on iNKT cells plays a crucial role in DC maturation, since in 
CD40–/– mice DCs failed to initiate adaptive immunity after stimulation with α-
GalCer activated iNKT cells [187]. Thus, NK, iNKT, and γδ T cells are able to induce 
DC maturation by a cytokine- and cell contact–dependent signals [182]. 
 
In the innate lymphocyte-mediated DC maturation the nature of the ligands involved 
is quite different to the TLR ligands. γδ T cells and NK cells can be activated by stress-
induced self-antigens like the MHC class I related molecules (e.g. MICA/MICB in 
humans or T10/T22 in the mouse). In addition, γδ T cells recognize CD1c on the 
surface of immature DCs in the absence of a specific foreign antigen (which implies 
reactivity against yet to be identified self-lipids). iNKT are activated via CD1d-
presented glycopeptides expressed also on DCs (details of this NKT/DC cross-talk 
are already discussed in section 1.1.1.7). 
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Figure 1.9 Innate lymphocytes mature DCs. Innate lymphocytes like γδ T, iNKT, and NK cells 
recognize pathogen-derived and self-antigens on infected cells, tumors, and stressed self-tissues. 
Their activation leads to DC maturation, most likely under conditions where the DCs are also 
presenting ligands recognized by innate lymphocytes. The DCs further stimulate the innate 
response and also trigger adaptive immunity including antigen presentation of antigens derived 
from cells lyzed by innate lymphocytes. Cytokines and cell contact–dependent molecules mediate 
DC activation by different types of innate lymphocytes, whereas DCs produce cytokines that 
expand and differentiate additional innate and adaptive lymphocytes. Additionally, there are 
more yet unknown ligands systems involved in the cell-cell contact-dependent NK/DC cross-talk. 
This illustration was drawn after [182]. 
 
In detail, CD1c-restricted γδ T cells can mediate the maturation of DCs. The 
maturation is cell-cell contact-dependent as well as TNFα-mediated (which is 
secreted by the γδ T cells in response to CD1c recognition [185]). For the secretion of 
IL-12 by maturing DCs, both CD1-restricted γδ T cells and LPS are required. 
Importantly, DCs matured by CD1c-restricted γδ T cells were able to efficiently 
present peptide antigens to naïve CD4+ T cells [185]. 
Additionally, the lysis of infected or tumor cells by innate lymphocytes provides DC 
with antigenic material, which is presented either via MHC class I or class II. Figure 
1.9 outlines how innate lymphocytes mature DCs in response to different antigenic 
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stimuli and how matured DCs mediate via cytokines and co-stimulation the 
expansion and differentiation of innate and adaptive lymphocytes. 
 
1.1.6.2 DC/NK interactions in peripheral and in secondary lymphoid tissues 
 
Generally, triggering of an immune response takes place in peripheral tissues. DCs 
detect via their PRRs PAMPs on the surface of microorganisms (see 1.1.4) and 
attract other cells of the immune system via chemokines like RANTES/CCL5, 
fractalkine/CX3CL1 or IL-8/CXCL8. CD56
dim NK cells express the receptors for IL-8 
and fractalkine, whereas the CD56bright subset migrates in response to RANTES and 
others. It was shown in vivo, that DCs and NK cells encounter each other in Gleevec-
induced lichenoid dermatitis, were NK cells and DCs are recruited into inflamed 
tissues [188]. Gleevec (imatinib mesylate; an inhibitor for the kinase activity of the 
three related kinases: BCR/ABL, PDGFR, and KIT) was shown to be effective against 
gastrointestinal stromal tumors. Gleevec can act on host DCs to promote NK cell 
activation and IFNγ secretion resulting in an increased anti-tumor activity [188,189]. 
During maturation mDCs and pDCs undergo a complex remodelling. They also 
acquire CCR7, which allows them to enter the lymph node, where they encounter T 
cells as well as NK cells (e.g CD205+ mDCs and NK cells have been shown to co-
localize in the T cell zone of human lymph nodes [190]). The main NK subsets 
present in the lymph nodes resemble the subsets in the blood, however in an inverse 
composition. 90% of the lymph nodes NK cells belong to the CD56brightCD16negKIRneg 
subset [190,191]. Martin-Fontecha et al. could show when mature DCs are injected 
in the mouse, they migrate CCR7-dependently to the draining lymph node [192] and 
that NK cells are actively recruited to the lymph nodes in a CXCR3-dependent 
manner. NK cells then secrete IFNγ, which provides an early source of IFNγ in 
polarization towards TH1 responses [193]. 
 
1.1.6.3 Reciprocal activating cross-talk between NK cells and DCs 
 
Besides chemokines the most important DC-derived cytokines involved in NK 
activation are IL-12, IL-15, and IL-18 as well as type I interferons [108,194]. IL-12 is 
the key player in the induction of the secretion of IFNγ by NK cells, which was shown 
in several systems: LPS-activated human monocyte-derived DCs, human splenic DCs 
[190], or poly(I:C)-stimulated human blood myeloid DCs [195]. IL-18 acts in synergy 
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with IL-12 to induce the secretion of IFNγ but also to enhance cytotoxicity (shown 
with human cord-blood CD34+-derived DCs [196]). Type I IFN – mainly derived 
from pDCs, particularly when activated through TLR7 and TLR9 [111] – together 
with IL-15 have been shown to induce cytotoxicity of NK cells (demonstrated with 
human monocyte-derived DCs [186]). In response to bacteria, DC-derived IL-2 can 
induce IFNγ-secretion by NK cells in mice [197]. The role of DC-derived IL-15 is 
manifold; IL-2 secretion by DCs in humans and mice is IL-15 dependent [190,198]. 
IL-15 bound on human splenic DCs stimulates NK cell proliferation and is essential 
for their survival [190]. IL-15 leads (like IFNα) to the expression of the NKG2D 
ligands MICA/B by human monocyte-derived DCs as well as to an upregulation of 
NKG2D on NK cells itself [199,200]. 
 
 
 
Figure 1.10 TLR-induced reciprocal interplay between NK cells and DCs. (a) The DC-
mediated NK cell activation and proliferation is dependent on cell-cell contacts as well as soluble 
signals. NK activation by DCs leads to increased NK cytotoxicity, NK proliferation and survival. 
(b) NK-derived TNFα and IFNγ induces DC maturation in a reciprocal fashion. All data depicted 
have been derived from human in vitro monocytes-derived DCs (moDCs) 
[186,194,199,201,202]. This illustration was drawn after [108]. 
 
Soluble factors are not the only mediators of the NK/DC cross-talk. There have been 
many reports on the role of cell-cell contacts; however, the relevant molecules 
involved are poorly defined. The NKG2D and the CD48-2B4 ligand systems [203], 
the orphan activating NK receptor NKp30 as well as TRAIL and CD94/NKG2A-
meditated signals have been implicated in NK/DC cross-talk. Jinushi et al. showed, 
using trans-well experiments and MICA/B blocking antibodies, that IFNα-mediated 
MICA/B induction on DCs may be a mechanism by which IFNα indirectly activates 
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NK cells via DC-expressed NKG2D ligands [199]. 
 
The peculiar finding that immature human monocyte-derived DCs are killed by NK 
cells in an NKp30-dependent manner was published 2002 by different groups 
[186,201,202] and is depicted in Figure 1.11. It was proposed that this killing occurs 
after a rapid influx of both DCs and NK cells and NK cells abolish DC-mediated 
immune responses by killing immature DCs [189,204]. Piccioli et al. showed that the 
outcome between DC activation or killing depends on the DC/NK cell ratio [201]. At 
high NK:DC ratios (5 to 1) NK cell killing of immature DC was observed, whereas at 
low activated NK/immature DC ratios (1/5 and up to 1/40) both DC maturation by 
NK-derived IFNγ and DC cytokine production (TNFα, IL-12) was observed, which 
could be blocked selectively by an α-NKp30 mAb (and not by α-NKp44, NKp46, 
NKG2D, 2B4, NKp80 mAbs) [202]. In contrast, mature DCs are resistant to NK cell 
lysis, presumably due to the expression of inhibitory CD94/NKG2A ligands 
[201,202]. 
On the contrary, Gerosa et al. recently published similar experiments with freshly 
isolated myeloid and plasmacytoid blood DCs instead of monocyte-derived DCs and 
no killing of immature blood mDCs or pDCs could be observed [195]. The reason for 
this different susceptibility to NK cell-mediated lysis is not clear, but it emphasizes 
the problem regarding the physiological relevance of in vitro monocyte-derived DCs. 
Until the identification of reliable markers and isolation procedures for blood DCs 
(see 1.1.3.1 for details, [117]) the only feasible source for DCs have been the in vitro-
generated DCs, so most of above discussed findings result from in vitro monocyte-
derived DCs. 
 
 
 
Figure 1.11 NKp30-mediated lysis of immature moDCs by DCs. NKp30-mediated killing of 
immature in vitro generated monocyte-derived DCs (moDCs) was shown; however, immature 
blood mDCs as well as pDC are not lyzed by activated NK cells [195]. This illustration was drawn 
and modified after [108]. 
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Vitale et al. reported that upon NK/DC interaction NK cells produced TNFα and 
IFNγ and, in turn, promoted DC maturation Both effects were like the DC-killing 
NKp30-mediated [205]. Again these results were obtained by using monocyte-
derived DCs, however, this was corroborated by experiments using poly(I:C) 
stimulated blood myeloid DC, which induce NK cells also to produce IFNγ. This 
effect was dependent on both, IL-12 secretion and cell contact between NK cells and 
myeloid DC, but independent of type I IFN [195]. Reciprocally, NK cells also induce 
the maturation of myeloid and plasmacytoid dendritic cells, as well as their 
production of type I interferons and TNFα [195]. 
 
1.1.6.4 Cross-talk during viral infection 
 
In the very early phase of a viral infection, one of the most important cells are the 
pDCs, since in humans they express TLR7 and TLR9 (which recognize ssRNA and 
CpG DNA respectively; mouse pDCs express TLR8, which also recognizes ssRNA 
[206,207]. Both TLRs induce MyD88-dependent inflammation and type I IFN 
production. As discussed already in 1.1.5 type I IFN are potent activators of NK cell 
cytotoxicity [195,208]. 
After recognition of an activating ligand, NK cells kill the infected cells either via 
ADCC, granule exocytosis or death-receptor engagement, which all induces 
apoptosis. These infected apoptotic cells can be phagocytosed by mDCs and the viral 
components interact with TLR3 leading to mDC maturation. It was shown recently 
that this activation path way is particularly important for viral antigen cross-
presentation to CD8+ T cells [209]. This is an essential mechanism against viruses, 
which do not directly infect professional antigen-presenting cells [209]. 
 
1.1.7 Genes encoded in the natural killer gene complex (NKC) 
1.1.7.1 Structural aspects of C-type lectin-like molecules 
 
The term ‘C-type lectin’ was brought in to distinguish a group of Ca2+-dependent (C-
type) carbohydrate-binding lectins from the Ca2+-independent lectins [210]. The 
carbohydrate-binding activity is mediated by the carbohydrate recognition domain 
(CRD), which is present in all Ca2+-dependent lectins but not in other types of lectins. 
This domain has been called ‘C-type CRD’ or ‘C-type lectin domain’. Since not all 
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proteins containing C-type CRDs can actually bind carbohydrates or even Ca2+, a 
more general term “C-type lectin-like domains” (CTLD) is used to refer to such 
domains [210]. All proteins containing one or more such CTLD belong to the C-type 
lectin superfamily (CLSF), which can be subdivided into 14 groups designated I-XIV 
[211] and up to now there are more than a thousand known members most of them 
lacking the lectin capacity to bind to sugar. 
 
 
 
Figure 1.12 Structure of C-type lectin-like molecules encoded by the NKC. There are six 
conserved cysteines colored in green in the C-type lectin-like domain (CTLD), which form intra-
chain disulfide bonds. The highly conserved “WIGL” motif in black is a landmark of CTLD 
containing proteins. In the last line the sequence of rat mannose-binding protein (MBP) is 
aligned to the NKC-encoded proteins for comparison. The mannose binding residues 
represented by the “EPN” motif drawn in red is only present in the MBP indicating that none of 
the above aligned proteins are able to bind oligosaccharides. Between the CTLD domain and the 
transmembrane (TM) domain there is usually a stalk region (ST) of varying length. All NKC 
encoded proteins are type II transmembrane proteins with an amino-terminal end representing 
the cytoplasmic tail (Cyt). 
 
Each group can be distinguished by additional domains present. All group II and V 
members contain only one CTLD and originally it was thought that all group V 
members are NK receptors and were therefore assigned to the group V separately 
from group II, however, with the discovery of more gene products, which are not NK-
specific, the distinction of group II and V is not clear anymore. Within the NKC all 
proteins are either group II or V proteins [212] with only one CTLD and do not bind 
to carbohydrates, but are engaged in protein-protein interactions. 
A remarkable exception known so far is Dectin-1 as discussed in 1.1.3.4, which binds 
β-glucan in a Ca2+-independent manner. The lectin-like molecules can be classified 
into families. All C-type lectin-like molecules have related general structural features 
(Figure 1.12) but are only distantly related in sequence (25% amino-acid identity). 
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Figure 1.12 shows an alignment of 10 members of the human NKC together with the 
sugar-binding C-type lectin mannose-binding protein (MBP). Not all members of the 
NKC are dimers or heterodimers as some function as monomers like LOX-1 or 
Dectin-1. 
 
 
Figure 1.13 CTLD structure. A cartoon of the C-type lectin-like domain of DC-SIGN (pdb code 
1k9i [213]) was created using ProteinExplorer [27] (www.proteinexplorer.org). Only the amino 
acids ranging from Pro 244 to Ala 382 are shown. The three disulfide bonds created by the highly 
conserved cysteines (C1-C6) are depicted in red. The characteristic “WIGL” motif is located 
within the β2 strand, whereas the “EPN” motif is located in the long loop region, which is drawn 
in blue. DC-SIGN is able to bind to high-mannose oligosaccharides. Ca2+ binding sites are 
indicated by black arrows. 
 
Figure 1.13 provides a cartoon from the crystal structure of the C-type lectin-like 
domain (CTLD) of DC-SIGN, which binds Ca2+-dependent to high-mannose 
oligosaccharides [213]. Mannose-dependent interactions are also responsible for the 
ability of DC-SIGN to bind HIV [214]. The highly conserved cysteines are labeled C1-
C6 comparable to Figure 1.12. 
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1.1.7.2 Overall organization and evolution of the NKC 
 
The NKC is located in a single chromosomal region in man (12p13) and in the mouse 
(6), whereas in cattle it is spread onto two chromosomes. The human NKC 
encompasses ~25 genes (without pseudogenes) and 2.8 Megabases (Mb) in length, 
the mouse NKC ~57 genes (depending on the strain) and 8.7 Mb [212]. In the two-
page Figure 1.14 all known lectin-like molecules encoding the NKC of mouse and 
man are depicted. The killer cell lectin-like receptors (KLR) and the C-type lectins 
(CLEC) are clustered together except KLRF1 in humans and KLRB1 and KLRG1 in 
mouse and human, which are intermingled among the CLEC2 genes. 
 
Hao et al. [212] identified 28 lineages of orthologous genes (11 KLRs, 15 CLECs, 1 
OLR1 and 1 CD69) in human, mouse, rat, dog and cattle. In the mouse and rat NKC 
four gene lineages (CLEC4, CLEC2D, KLRA1 and KLRB1) have expanded e.g. the 
KLRA1 or Ly49 into 15 members compared to just one pseudogene in humans. These 
expansions have occurred mainly by tandem duplications. Since some of the KLRB1 
proteins bind to CLEC2D proteins and supported by the fact that the genes of these 
two lineages are intermingled, it could be that the observed expansion is related to the 
co-evolution of the receptor with its ligand [212]. 
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Figure 1.14 C-type lectins encoded in the natural killer gene complex (NKC). In humans the 
NKC is located on chromosome 12p13, in mouse on chromosome 6. Boxes colored in the same 
color indicate that the gene(s) have corresponding homologues in mouse and human. The 
distance between the genes is not drawn to scale. The four gene lineages KLRA, KLRB, CLEC2D 
and CLEC4 have expanded in mice compared to human, which is indicated by the curly braces. 
Some of the Klra1 genes are allelic variants only. NKC-encoded pseudogenes are not included 
except the human LY49L. // - segments indicate non-C-type lectins encoded by the NKC, which 
are also not depicted. This scheme was modified and updated from [212,215]. In mouse the 
official gene symbol assigned by Mouse Genome Informatics (MGI) 
(http://www.informatics.jax.org/) and in humans the official names provided by the HUGO 
Gene Nomenclature Committee (HUGO) (http://www.gene.ucl.ac.uk/nomen clature/) were 
used along with other commonly used names in literature. 
 
1.1.7.3 Important NKC-encoded receptors and their ligands 
 
The best-studied NKC family is the Ly49 family in the mouse, which is mainly 
responsible for the monitoring of allelic loss of MHC class I expression. Ly49A was 
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the first identified inhibitory receptor with specificity for MHC class I molecules 
[216]. Ly49A binds to allelic variants of H-2Dd molecules and is expressed on NK 
cells and T cells with a memory phenotype [25,216,217]. As Ly49A, many other 
members of the Ly49 family like Ly49C and Ly49G are MHC class I-specific 
inhibitory receptors and contain an ITIM (immunoreceptor-tyrosine-based inhibition 
motif) in their cytoplasmatic domains, whereas Ly49D and Ly49H contain charged 
amino acid residues in their transmembrane region and associate with the DAP12 
signaling adapter molecule [215]. They are predominantly monoallelically expressed 
[218,219] and bind to classical MHC class I molecules except for Ly49H, which binds 
a viral protein encoded by MCMV [6]. There is only one Ly49 gene in humans, Ly49L, 
which apparently gives rise to a non-functional molecule [220]. 
The members of the Nkrp1 family are listed in Table 1.6. and the genes are clustered 
near the CD69 locus. The best-known representative is the NK1.1 or Nkrp1c 
receptor, which is a well-established serological marker for C57BL/6J NK cells. 
Nkrp1c is an activating NK receptor due to the lack of an ITIM and its association 
with the ITAM-containing FcεRIγ chain [221]. Nkrp1d like Nkrp1b has an ITIM in 
their cytoplasmic tail in contrast to Nkrp1a and Nkrp1f, which are thought to 
associate also with the FcεRIγ chain [215]. In humans there is only one member of 
the NKRP1A family, the CD161 or KLRB1 molecule. 
 
Table 1.6 Members of the Nkrp1 family. Abbr.: Clr, C-type lectin-related molecules; MGI, 
Mouse Genome Informatics; HUGO, Human Genome Organisation. Data compiled from [222]. 
 
Species Genes 
Other names  
(MGI, HUGO) 
function, expression 
Mouse 
C57BL/6J Nkrp1a Klrb1a ligands? 
C57BL/6J Nkrp1c Klrb1c, NK1.1 
ligands?, serological NK marker in C57BL/6J 
mice, activating receptor, FcεRIγ associated 
C57BL/6J Nkrp1d Klrb1d binds to Clrb, ITIM 
C57BL/6J Nkrp1e Klrb1e pseudogene 
C57BL/6J Nkrp1f Klrb1f binds to Clrg 
SJL/j Nkrp1b Klrb1b ligands?, ITIM 
Human 
 CD161 KLRB1 binds to LLT1 
 
In 2003, it was shown that the Nkrp1d inhibitory receptor binds to the genetically-
linked Clrb molecule and the activating Nkrp1f receptor binds to Clrg molecules 
[223,224]. This was the first demonstration that the ligand of a C-type lectin-like 
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molecule is another C-type lectin-like molecule. The members of the C-type lectin-
related molecules (Clr) are listed in Table 1.7. 
 
Table 1.7 Members of the Clr family. The Clr family displays homology with CD69. Abbr.: Clr, 
C-type lectin-related molecules; MGI, Mouse Genome Informatics; HUGO, Human Genome 
Organisation. Data compiled from [222]. 
 
Species Genes 
Other names  
(MGI, HUGO) 
function, expression 
Mouse 
 Clra Clec2e no transcripts identified yet 
 Clrb Clec2d binds to Nkrp1d, transcripts found in NK 
 Clrc Clec2f no transcripts identified yet 
 Clrd Clec2g ? 
 Clre - pseudogene 
 Clrf Clec2h transcripts found in NK 
 Clrg Clec2i binds to Nkrp1f, transcripts found in NK 
Human 
 LLT1 CLEC2D binds to CD161, KLRB1 
 AICL CLEC2B ? 
 CD69 CLEC2C ? 
 DCAL - ? 
 
In 2005 two groups reported that with the binding of human KLRB1/CD161 to LLT1 
another genetically-linked receptor-ligand pair encoded by the NKC was discovered 
[225,226]. The functional consequences of these ligand-receptor interactions are 
only poorly understood. Expression of Ocil/Clrb on mouse tumor cell lines inhibits 
NK cell-mediated killing. The same inhibiting effect for NK-mediated cytotoxicity 
and IFNγ secretion was shown for binding of human LLT1 (the human homologue to 
Clrb) to is receptor CD161 [225,226]. Ocil/Clrb is expressed at high levels on nearly 
all hematopoietic cells, with the exception of erythrocytes, in a pattern that is similar 
to that of class I MHC molecules [224]. In contrast LLT1 is expressed only on some 
cell lines (the NK cell lines YT and NKL, the B cell lines 721.221 and RPMI 8866) 
and activated B and T cells (J. Pfeiffer, unpublished observations). Clrg specific 
reagents are not available yet. The proposed hypothesis that the Clr molecules 
constitute a MHC class I-independent back-up mechanism for tissues with low MHC 
class I expression like the liver or the brain in order to be protected against NK-
mediated lysis [223] has to be re-evaluated in the light of the new data. 
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1.1.7.4 The activating NK receptor NKp80/KLRF1 
 
Killer cell lectin-like receptor subfamily F1 (KLRF1), also known as NKp80, is 
encoded by the NKC. There are only a few reports regarding NKp80 in the literature. 
NKp80 has been reported to be expressed by NK cells as well as by a CD56+CD3+ 
subset [42]. None of the NK cell lines analyzed, including NKL, NK3.3 and YT 
expressed NKp80. Similar to NKG2D, NKp80 stimulates NK cytotoxicity and 
induces Ca2+-influx in human NK cells upon triggering by appropriate antibodies 
[42]. At difference to NKG2D, NKp80 contains neither charged amino acids in the 
transmembrane domain disfavouring association with activating adaptor proteins 
like CD3ζ, DAP12, DAP10 or FcεRIγ nor any known activation motifs in the 
cytoplasmic sequence. There is, also at difference to NKG2D, no known NKp80 
homologue in rodents impeding elucidation of its function in vivo [215]. Recently, 
two reports on NKp80 in non-human primates corroborated that NKp80 is a NK-
specific stimulatory receptor [227,228]. Using NKp80-specific monoclonal 
antibodies it was shown by immunoprecipitation that under non-reducing conditions 
a band of approximately 80 kDa could be detected (hence the name NKp80). Under 
reducing conditions the band displayed a molecular mass of 40 kDa, which indicates 
that the surface molecule is expressed at the NK cell surface as a dimer [42]. Adding 
mAb to Nkp80 reduces the lysis of T cell PHA blasts by polyclonal activated NK cells, 
which indicates that such PHA blasts express a putative NKp80 ligand. Analysis of 
NK clones in redirected killing experiments showed that only NKp46 expressing 
clones show NKp80-mediated killing, whereas NKp80+NKp46dull clones and 
NKp80dullNKp46dull clones do not kill via NKp80. Vitale et al. suggested therefore 
that NKp80 plays a rather costimulatory role in NK-mediated killing [42]. 
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1.2 Aims of the thesis 
NK cells are activated by several immunoglobulin-like and C-type lectin-like 
receptors. In humans, the cellular ligands of the major activating NK receptors, apart 
from NKG2D, remained unknown. The characterization of NKG2D ligands has 
profoundly improved our understanding of NK cell activation; this provided the 
rationale to identify ligand(s) of the orphan NK receptor NKp80, which like NKG2D, 
is encoded in the natural killer gene complex (NKC). 
 
Similar to NKG2D, the activating NK receptor NKp80, which was first described 5 
years ago [16], has been reported to stimulate NK cell cytotoxicity. However, in 
contrast to NKG2D, NKp80 is expressed almost exclusively on human NK cells [16]. 
Since the unknown nature of the NKp80-ligand(s) represents a major obstacle in 
elucidating the role of NKp80 for NK cell biology, it was the aim of this thesis to 
identify and characterize the ligand(s) of NKp80. 
 
Two approaches were chosen to identify NKp80-ligand (NKp80-L)-expressing cells: 
first, the generation of a reporter cell line expressing NKp80-CD3ζ reporter 
constructs, and second, the production of NKp80 ectodomains to generate NKp80 
tetramers using the BirA technology [229]. Both detecting systems should be used to 
screen for NKp80-L-expressing cDNA clones by expression cloning using cDNA 
from NKp80-L-expressing cells. Additionally, the soluble ectodomain should aid in 
the generation of NKp80-specific monoclonal antibodies. After identification of 
NKp80-ligand(s), the expression of NKp80-L and the biological relevance of the 
NKp80-NKp80-L interaction should be established and characterized. 
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2 Results and Discussion 
2.1 The biology of NKG2D and its ligands 
2.1.1 Selective intracellular retention of virally induced NKG2D ligands 
by the human cytomegalovirus UL16 glycoprotein 
This chapter has been published in European Journal of Immunology 33(1): 194-203 
(2003) by the following authors: 
 
Stefan Welte, Christian Sinzger, Stefan Lutz, Harpreet Singh-Jasuja, Kerstin Laib 
Sampaio, Ute Eknigk, Hans-Georg Rammensee and Alexander Steinle. 
 
The author of this thesis performed all experiments except following parts: HCMV 
infections, cloning UL16-EGFP expression construct, production of soluble 
recombinant proteins, generation of monoclonal antibodies and ELISA, (for details 
see the material section in 2.1.1.3). Harpreet Singh-Jasuja provided essential support 
with confocal microscopy. Parts of the work discussed in 2.1.1 have been performed 
during the diploma thesis of the author of this thesis. Further contributions are 
mentioned in the acknowledgements section. 
 
2.1.1.1 Abstract 
 
Human cytomegalovirus (HCMV) has evolved a multitude of molecular mechanisms 
to evade the antiviral immune defense of the host. Recently, using soluble 
recombinant molecules, the HCMV UL16 glycoprotein was shown to interact with 
some ligands of the activating immunoreceptor NKG2D and therefore may also 
function as a viral immunomodulator. However, the role of UL16 during the course of 
HCMV infection remained unclear. Here we demonstrate that HCMV infection of 
fibroblasts induces expression of all known NKG2D ligands (NKG2DL). However, 
solely MICA and ULBP3 reach the cellular surface to engage NKG2D, whereas 
MICB, ULBP1 and ULBP2 are selectively retained in the endoplasmic reticulum by 
UL16. UL16-mediated reduction of NKG2DL cell surface density diminished NK 
Results and Discussion 66 
cytotoxicity. Thus, UL16 functions by capturing activating ligands for cytotoxic 
lymphocytes that are synthesized in response to HCMV infection. 
 
2.1.1.2 Introduction 
 
Human cytomegalovirus (HCMV) is a β herpesvirus that establishes lifelong 
infections. The infection is critically controlled by the cellular immune system and 
associated with severe morbidity in immunocompromised individuals [1]. HCMV 
encodes a battery of immunomodulatory molecules that interfere with recognition of 
infected cells by NK and CD8+ T cells. In a concerted action, the HCMV glycoproteins 
US2, US3, US6 and US11 down-regulate MHC class I surface expression to prevent 
recognition of HCMV derived peptides by CD8+ αβ T cells (reviewed in [2,3]). As 
reduction of MHC class I molecules on the cell surface would render HCMV-infected 
cells susceptible to NK cell lysis, HCMV also expresses the MHC class I-like UL18 
and an UL40 encoded peptide ligand for HLA-E. Both UL18 and HLA-E/UL40 
suppress NK cell activity by engaging the inhibitory receptors LIR-1 and 
CD94/NKG2A, respectively [4-6]. 
Recently, evidence for an immunomodulatory function of the orphan HCMV UL16 
glycoprotein was provided [7]. UL16, a 50-kDa type I transmembrane glycoprotein, 
is dispensable for growth of HCMV in fibroblasts and lacks homology to other known 
proteins [8]. In a search for cellular targets of UL16, Cosman and co-workers 
identified the MHC class I-like molecules MICB, UL16 binding protein (ULBP)1 and 
ULBP2 which function as ligands of the activating immunoreceptor NKG2D [7]. 
NKG2D is a member of the C-type lectin-like receptor family expressed by most 
human CD8+ αβ T cells, γδ T cells and NK cells [9]. NKG2D homodimers form an 
activating immunoreceptor complex with DAP10 adaptor molecules that transmit 
signals through recruitment of the p85 subunit of the phosphatidylinositol-3-kinase 
(PI-3K) [10,11]. Engagement of NKG2D leads to costimulation of CD8+ αβ T cells 
and triggers effector functions of NK cells [7,9,12,13]. NKG2D interacts with several 
MHC class I-like cell surface glycoproteins, hereafter collectively designated as 
NKG2D ligands (NKG2DL). In humans, there are two families of NKG2DL, the MIC 
and ULBP molecules. MICA and MICB are highly polymorphic, MHC-encoded 
glycoproteins and their expression can be induced by cell stress [14,15]. In contrast to 
MHC class I molecules, MIC molecules do not associate with β2-microglobulin and 
antigenic peptides and their in vivo expression on healthy cells is highly restricted 
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[14]. However, MIC molecules were detected on many epithelial tumors and infected 
cells [12,16,17] which led to the hypothesis that they may act as danger signals 
[18,19]. 
ULBPs are atypical MHC class I-like molecules, since they lack a α3 domain and are 
attached to the cell surface via a glycosylphosphatidylinositol anchor. They are 
encoded by a multigene family which apparently contains at least six functional 
proteins [20]. However, NKG2D interaction has only been demonstrated for ULBP1, 
ULBP2 und ULBP3 [21, 22]. Like MIC molecules they trigger effector functions of 
NK cells [7]. Crystal structures of human NKG2D in complex with either MICA*01 
or ULBP3 show that NKG2DL interact in a similar fashion with NKG2D that is 
reminiscent of the T cell receptor binding to MHC molecules [23,24]. Thus far, ULBP 
protein expression has only been shown for cell lines and its regulation is largely 
unknown [7]. 
Soluble, recombinant UL16 binds ULBP1 and ULBP2, and also MICB, but not 
ULBP3 and MICA in vitro [7]. This was surprising since MICA and MICB are closely 
related by sequence, but only distantly related to ULBPs. Binding of soluble UL16 to 
soluble ULBP1 impaired the ULBP1/NKG2D interaction and thus, UL16 may block 
the NKG2D-mediated triggering of NK cell effector functions by MICB, ULBP1 and 
ULBP2 [7]. 
Since these findings suggested a suppression of NKG2D mediated 
immunosurveillance of HCMV-infected cells by UL16, it was unexpected when 
another group reported that HCMV infection caused induction of MIC expression on 
fibroblasts allowing recognition by HCMV-specific CD8+ T cells in spite of reduced 
MHC class I levels [12]. Accordingly, MIC molecules appear to function as potent 
enhancers of TCR mediated recognition of HCMV infected cells, thereby 
compensating for HCMV-mediated down-regulation of MHC class I. At this state, it 
was of interest to reconcile these contrasting findings on the role of NKG2DL for 
immunosurveillance of HCMV. Therefore, we scrutinized the induction of individual 
NKG2DL upon HCMV infection, the interference of UL16 with virally induced 
NKG2DL and its consequences for NKG2D-mediated recognition. 
 
2.1.1.3 Materials and Methods 
 
Cell lines, transfectants. The human embryonic kidney-derived cell line 293T and 
the mouse mastocytoma cell lines P815 were cultured in IMDM supplemented with 
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10% FCS, transfected 293T cells in 10% FCS-IMDM with 2.0 mg G418/ml. HFF and 
MRC-5 fibroblasts were cultured in alpha-MEM supplemented with 10% FCS. The 
NK cell line NKL, kindly provided by M. J. Robertson (Indiana University School of 
Medicine, Indianapolis, IN), was grown in RMPI 1640 with 15% FCS and 200 U/ml 
IL-2 (Proleukin, Chiron, Ratingen, Germany). 8 days prior to cellular cytotoxicity 
assays, NKL cells were cultured without IL-2. All media were supplemented with 
penicillin (100 IU/ml)/streptomycin (100 μg/ml) (Life Technologies, Karlsruhe, 
Germany), 2 mM L-glutamine and 1 mM sodium pyruvate. Transfections were 
performed with the FuGENE 6 reagent according to manufacturer’s intructions 
(Roche, Mannheim, Germany). 
 
HCMV infections. HFF, MRC-5, or 293T were grown to confluence and infected 
with HCMV AD169 at a multiplicity of infection (m.o.i.) of 5 to achieve an infection 
efficiency of ~100 %. Infections were performed with cell free supernatant from 
productively infected HFF cultures with 100 % late stage cytopathic effects; mock 
infections were done by using the same supernatants after removal of infectious virus 
by ultracentrifugation at 80.000xg for 70 min. Briefly, media were replaced by 
infectious or non-infectious supernatant, incubated for 2 h at 37°C, and finally 
replaced with fresh media. Cells were then incubated at 37°C in 5 % CO2 for time 
intervals (p.i.) as indicated. The exact efficiency of infection in the respective 
experiment was determined at 24 h p.i. by immunodetection of viral immediate early 
antigen using monoclonal antibody E13 (Biosoft, Paris, France) or at 72 h p.i. by the 
appearance of characteristic nuclear inclusions. 
 
UL16-EGFP expression construct. Viral DNA was prepared from HCMV AD169-
infected HFF monolayers 4 p.i. by phenol/chloroform extraction. The complete 
HCMV-UL16 ORF excluding the stop codon was amplified using the 
oligonucleotides 5’ATG GAG CGT CGC CGA GGT ACG GTA C 3’ (sense) and 5’ GTC 
CTC GGT GCG TAA CCG CTG GTA T 3’ (antisense) by PCR. PCR products were 
cloned into the EcoRI site of the EGFP-N3 vector (Clontech, Palo Alto, CA) in front of 
the EGFP ORF and verified by sequencing. The resulting UL16-EGFP ORF contains 
seventeen additional codons between the last UL16 codon (GAC) and the first EGFP 
codon (ATG). 
 
Production of soluble MICA*04, MICB*02 and NKG2D tetramers. Soluble MICA 
was produced and purified as previously described [21]. In brief, the cDNA encoding 
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the MICA*04 ectodomain (Glu1 through Lys276) in pET20b (Novagen, Madison, 
WI) was introduced in E. coli and MICA*04 production induced by addition of 
isopropyl thiogalactose (IPTG). Inclusion bodies were solubilized and successively 
dialyzed against decreasing concentrations of urea. Refolded MICA*04 was purified 
by gel filtration, dialyzed against PNEA (50 mM PIPES pH 7.0, 0.15 M NaCl, 1 mM 
EDTA, 0.02% NaN3) and eventually examined by SDS-PAGE and immunoblotting. 
Accordingly, the MICB*02 ectodomain was amplified with oligonucleotides 5’ ACA 
TGC ATA TGG AGC CCC ACA GTC TTC G-3’ (sense) and 5’-CTG ACT CGA GCT 
TCC CAG AGG GCA CAG GGT G-3’ (anti-sense), cloned in pET21a (Novagen) via 
NdeI and XhoI, and soluble MICB*02 produced as described above. The cDNA 
fragment encoding the extracellular portion of human NKG2D (Asn80 through 
Thr147) was amplified with oligonucleotides 5´-ATC ATA TGG AAA GTT ACT GTG 
GCC CAT GTC-3`(sense) and 5`- ATA AGC TTA CTC GTG CCA CTC GAT CTT TTG 
AGC CTC GAA GAT GTC GTT CAG AGT CCT TTG CAT GCA GAT GTA TG-3` (anti-
sense) adding a BirA recognition sequence at the carboxyterminus and ligated into 
pET20b. Soluble NKG2D was produced in E. coli as described above. Biotinylation of 
NKG2D was done overnight at 27°C with the BirA enzyme (Avidity, Denver, CO) 
according to manufacturer’s instruction. Excess biotin was removed by FPLC with a 
Superdex S75 HL 26/60 column and biotinylated NKG2D tetramerized by gradual 
addition of phycoerythrin-conjugated streptavidin (Molecular Probes, Leiden, 
Netherlands) over 4 h. 
 
Generation of monoclonal antibodies. The murine P815 mastocytoma cell line was 
transfected using FuGENE 6 with full length cDNA of MICA*01, MICA*04, 
MICB*02, ULBP1, ULBP2 and ULBP3 in RSV.5 neo, respectively [21]. 
Transfectants were selected with 1 mg/ml G418 and expression of the respective 
NKG2DL mRNA was verified by RT-PCR. BALB/c mice were immunized either with 
a mixture of MICA*01-, MICA*04-, and MICB*02- or ULBP1-, ULBP2-, and 
ULBP3- expressing P815 cells. Splenocytes of immunized mice were fused with 
P3X63Ag8.653 myeloma cells. Hybridoma supernatants were tested by indirect 
immunofluorescence using a FACSCalibur (Becton Dickinson, Heidelberg, 
Germany) for selective binding to P815-NKG2DL transfectants and to COS cells 
transiently transfected with the various NKG2DL cDNA. Hybridoma producing 
NKG2DL-specific mAbs were subcloned twice and immunoglobulins isotyped using 
an isotyping kit (Roche). BAMO-1 (IgG1) and BAMO-3 (IgG2a) recognize MICA and 
MICB, AMO-1 (IgG1) is MICA specific, BMO-1 (IgG1) and BMO-2 (IgG2a) MICB 
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specific, AUMO-1 (IgG1) ULBP1-specific, BUMO-1 (IgG1) ULBP2-specific and 
CUMO-1 and CUMO-2 (IgM) ULBP3-specific. 
 
Real-time RT-PCR. Total fibroblast RNA was prepared using TRIZOL (Life 
Technologies) followed by DNase I treatment and reverse transcription using 
SuperScript RTII (Invitrogen, Karlsruhe, Germany) according to the manufacturer’s 
protocol. The resulting cDNA was amplified with NKG2DL, UL16 and 18S rRNA 
specific primer pairs in duplicates (40 cycles, 95°C x 15 s, 60°C x 1 min) using 
SYBRGreen chemistry on the ABI PRISM 7000 Sequence Detection System (Applied 
Biosystems, Weiterstadt, Germany). Samples were independently analyzed 2 to 3 
times. Primers were selected to flank an intron, where possible, and specificity was 
validated using cloned NKG2DL. Data analysis was done by using the ΔCT method 
for relative quantification. Similar amplification efficiencies for NKG2DL and 18S 
were demonstrated by analyzing serial cDNA dilutions with values of the slope of log 
cDNA amount vs. ΔCT of < 0.1. Oligonucleotide sequences (forward; reverse) were 
for 18S rRNA: 5´-CGGCTACCACATCCAAGGAA-3´; 5´-
GCTGGAATTACCGCGGCT-3´; MICA: 5´-CCTTGGCCATGAACGTCAGG-3´; 5´-
CCTCTGAGGCCTCRCTGCG-3´; MICB: 5´-ACCTTGGCTATGAACGTCACA-3´; 5´-
CCCTCTGAGACCTCGCTGC A-3´; ULBP1: 5´-GTACTGGGAACAAATGCTGGAT-
3´; 5´-AACTCTCCTCATC TGCCAGCT-3´; ULBP2: 5´-
TTACTTCTCAATGGGAGACTGT-3´; 5´-TGTGCCT GAGGACATGGCGA-3´; 
ULBP3: 5´-CCTGATGCACAGGAAGAAGAG-3´; 5´-
TATGGCTTTGGGTTGAGCTAAG-3´; UL16: 5´-TAATCGAGCGCCTCTACGTC C-
3´; 5´-AAGGTCGCGGACAGTTCCTCG-3´. PCR products were analyzed on 3% 
agarose gels for purity. 
 
Flow cytometry. Cells were incubated with NKG2DL-specific mAb or appropriate 
mouse immunoglobulin isotypes and then, after washing, with goat anti-mouse-PE 
conjugate (1:100) (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) 
as secondary reagent. PE-labeled NKG2D tetramers were used at 5 μg/ml. 
Intracellular staining was done using Cytofix/Cytoperm following the manufacturer’s 
protocol (BD PharMingen, Heidelberg, Germany). Samples were analyzed on a 
FACSCalibur. 
 
Confocal microscopy. 293T-UL16-EGFP cells were seeded on round cover slips in 
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12-well culture plates and grown to ~50% confluency. Coverslips were washed in PBS 
and cells fixed with methanol/aceton (1:1, -20°C) for 20 min. After a washing step, 
cells were incubated for 20 min with the respective primary mAb. In case of Figs. 4C, 
E and F, cells were first stained with W6/32 (anti-MHC class I), then washed and 
fixed. As organelle-specific markers for ER and lysosomes, an anti-PDI mAb 
(Stressgen Biotechnologies, Victoria BC, Canada) and anti-lamp-1 (kindly provided 
by M. Fukuda, La Jolla Research Center, La Jolla, CA), respectively, were used. For 
detection, fixed cells were incubated with Alexa 546-conjugated anti-mouse IgG 
(Molecular Probes). Microscopy was done with a ZEISS LSM 510 laser scanning 
microscope (Carl Zeiss, Göttingen, Germany). "bleeding" of emission into other 
detection channels was excluded using the multitracking modus of the LSM 510. 
Thickness of the optical plane was adjusted by the pinhole to be <0.7 μm. 
 
Cellular cytotoxicity assays. Cytotoxicity was analyzed in a 24 h 51Cr assay. Target 
cells were labeled with 50 μCi of 51Cr (Amersham, Freiburg, Germany) for 2 h at 37°C 
and washed three times. In blocking experiments mAb were added at 10 μg/ml during 
labelling procedure. Effector cells were titrated on target cells and incubated for 24h 
at 37°C. Spontaneous release of target cells alone was less than 15% of the maximum 
release taken from target cells lyzed in 1% Triton X-100. Percentage of lysis was 
calculated as follows: 100 x (experimental release – spontaneous release): (maximum 
release – spontaneous release). Experiments were performed in duplicates. 
 
ELISA. For the detection of sMICA plates were coated with the capture anti-MICA 
mAb AMO-1 at 2 μg/ml in PBS, then blocked by addition of 15% BSA-PBS for 2 h at 
37°C and washed. Next, the standard (recombinant MICA*04 in 7.5% BSA-PBS) 
and samples were incubated for 2h at 37° C, plates were washed and the detection 
mAb BAMO-3 added at 5 μg/ml in 7.5% BSA-PBS and incubated for 2h at 37° C. 
Plates were then washed and incubated with anti-mouse IgG2a-HRP (1:8000 in 7.5% 
BSA-PBS) for 1 h at 37° C. Finally, plates were washed, developed using the TMB 
Peroxidase Substrate System (KPL, Gaithersburg, MD), and the absorbance 
measured at 450 nm. Results are shown as means of duplicates using recombinant 
sMICA*04 as a standard. A similar ELISA was established to detect sMICB by using 
the anti-MICA/B mAb BAMO-1 as capture antibody and the MICB specific mAb 
BMO-2 as detection antibody. For standardization, recombinant sMICB*02 was 
used. 
For analysis of release of sMICA and MICB, confluent 293T , 293T-UL16 and 293T-
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EGFP cells were cultured for 5 days, supernatants removed, tenfold concentrated 
using Centriprep (Amicon, Bedford, MA) and subjected to ELISA. 
 
2.1.1.4 Results 
 
 
 
Figure 2.1. Induction of NKG2DL mRNA expression upon HCMV infection. MRC-5 
monolayers were infected with HCMV AD169 3, 12, 24, 48 and 72 h, respectively, before RNA 
extraction. Relative copy numbers were determined by real-time PCR. Increase in relative copy 
numbers was calculated by defining relative copy numbers of mock-infected cells as 1, except for 
UL16 where relative copy numbers at 3 h p.i. were defined as 1. 
 
Induction of NKG2DL expression upon HCMV infection 
HCMV infection has been reported to induce MIC cell surface expression on 
fibroblasts [12]. However, it remained unclear whether HCMV infection induces 
surface expression of both human MIC species, MICA and MICB, and how it affects 
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ULBP expression. To investigate HCMV-induced expression of all known NKG2DL, 
we established NKG2DL specific real-time PCR using sets of oligonucleotides 
specific for MICA, MICB, ULBP1, ULBP2, and ULBP3, respectively.  
 
Human MRC-5 fibroblasts were infected with HCMV strain AD169 and harvested at 
3, 12, 24, 48 and 72 h p.i. Relative NKG2DL mRNA levels of infected fibroblasts were 
quantified by real-time PCR. Expression of all NKG2DL was strongly induced after 
HCMV infection and increased mRNA levels were detected already 12 h p.i. (Figure 
2.1) However, kinetics and induction rates substantially varied between the 
individual ligands. Both, MICA and MICB were induced about tenfold, but whereas 
MICA levels gradually reached a maximum at 48 h and slightly dropped at 72 h, 
kinetics of MICB were faster with a maximum at 24 h followed by a sharp decline. 
ULBP3 levels rose to about sixfold at 12 h p.i. and remained stable thereafter. In 
contrast, ULBP1 mRNAs gradually accumulated over 72 h to about 30 fold above 
background. ULBP2 mRNA levels were most dramatically induced to about 50 fold 
at 24 h p.i. and remained high until 72 h p.i. Altogether, all NKG2DL were clearly 
induced already 12 h p.i., but their maxima varied between 12 and 72 h p.i. To 
corroborate these results, we also analyzed mRNA levels of HCMV-infected primary 
human foreskin fibroblasts (HFF). Similarly to MRC-5, expression of all NKG2DL 
was strongly induced by HCMV infection and kinetics characteristically varied 
between the individual NKG2DL as described above (data not shown). 
Thus, HCMV infection concomitantly induces mRNA expression of all NKG2DL 
resulting in drastically increased NKG2DL mRNA levels throughout early and late 
stages of HCMV infection. 
 
Restricted NKG2DL surface expression on HCMV-infected fibroblasts 
Having shown that HCMV infection is paralleled by a pronounced increase in 
NKG2DL mRNA levels, we next investigated NKG2DL cell surface expression by 
HCMV infected fibroblasts. In order to survey expression of NKG2DL, we generated 
a panel of mAb specific for MICA, MICB, ULBP1, ULBP2, and ULBP3, respectively, 
by immunizing BALB/c mice with P815 cells transfected with the respective 
NKG2DL cDNAs. Specificity of the antibodies was demonstrated on P815, COS, and 
C1R cells transfected with the respective antigens. For MICA and MICB specific 
mAb, direct and mutually exclusive binding to recombinant MICA and MICB, 
respectively, was demonstrated by ELISA (data not shown). HFF and MRC-5 cells 
were infected with HCMV strain AD169 and surface NKG2DL expression analyzed at 
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24 h, 48 h, and 72 h p.i. by flow cytometry. For both, HFF and MRC-5, low 
constitutive expression of MICA and ULBP2 was detected, but not for MICB, ULBP1 
and ULBP3 (Figure 2.2a and data not shown). No significant changes were observed 
24h and 48h p.i., respectively (data not shown), but 72 h p.i. MICA surface 
expression was clearly increased, whereas ULBP2 was no more detectable. No MICB 
and ULBP1 molecules were detected at any time post-infection on the cell surface, 
whereas a pronounced expression of ULBP3 was detected 72 h p.i. 
Since NKG2DL mRNA induction was observed for all NKG2DL, we wondered 
whether MICB, ULBP1 and ULBP2 molecules were selectively retained in HCMV-
infected cells. To test interference of HCMV with NKG2DL expression, 293T cells 
which constitutively express all five NKG2DL on the cell surface were infected with 
HCMV strain AD169. In contrast to HFF and MRC-5 fibroblasts, infection of 293T 
cells was only partial as judged by detection of viral antigens and cytopathic effects. 
 
Figure 2.2. Selective NKG2DL surface expression upon HCMV infection. The human primary 
MRC-5 fibroblasts (a) and the 293T kidney fibroblast cell line (b) were infected with HCMV 
AD169 or mock-infected and NKG2DL surface expression monitored with NKG2DL mAbs in 
flow cytometry. The following mAbs were used: AMO-1 (MICA), BMO-1 (MICB), AUMO-1 
(ULBP1), BUMO-1 (ULBP2), CUMO-1 (ULBP3) and W6/32 (MHC class I). 
 
This is also reflected by partial down-regulation of MHC class I molecules (Figure 2.2 
b). Analysis of NKG2DL cell surface expression three and five days p.i. revealed that 
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MICA and ULBP3 expression remained unaffected by the HCMV infection. However, 
in parallel to MHC class I down-regulation, MICB and ULBP2 vanished on a 
subpopulation of 293T cells. HCMV-associated down-regulation was most 
impressive for ULBP2 where two distinct populations became apparent five days p.i.  
These results demonstrate that HCMV infection is associated with increased cell 
surface expression of MICA and ULBP3 and a loss of cell surface MICB and ULBP2. 
 
UL16 inhibits cell surface expression of MICB, ULBP1 and ULBP2  
Selective down-regulation of MICB and ULBP2, but not MICA and ULBP3 perfectly 
matches the binding preferences described for a recombinant soluble variant of the 
HCMV glycoprotein UL16 [7]. The UL16 ORF encodes a heavily glycosylated 230 
amino acid (aa) protein of 50 kDa [8]. It is predicted as a type I transmembrane 
protein with an N-terminal ER signal sequence, a large luminal domain (163 aa) 
containing eight potential N-linked glycosylation sites followed by a short 
transmembrane domain (17 aa) and positively charged cytoplasmic domain (25 aa). 
In order to investigate whether down-regulation of MICB and ULBP2 surface 
expression can be attributed to UL16, we generated an UL16 expression construct 
where the putative full length UL16 open reading frame was fused at the 
carboxyterminus to enhanced green fluorescent protein (EGFP). 293T cells were 
stably transfected with plasmids encoding UL16-EGFP or EGFP, respectively.  
For controlled assessment of changes in NKG2DL expression, we used transfectants 
representing mixtures of neomycin resistant UL16-EGFP positive and UL16-EGFP 
negative 293T cells. Cell surface expression of MICB, ULBP1 and ULBP2 was 
strongly reduced on UL16-EGFP expressing transfectants versus UL16-EGFP 
negative transfectants (Figure 2.3a). In contrast, expression of MICA, ULBP3 and 
MHC class I molecules did not differ between UL16-EGFP expressing and non-
expressing cells. Surface expression of NKG2DL was not altered on 293T-EGFP 
transfectants and comparable to untransfected 293T cells (data not shown). Failure 
to detect MICB, ULBP1 and ULBP2 on the cell surface of 293T-UL16-EGFP 
transfectants may be either due to their intracellular retention and/or degradation or 
to masking of the respective mAb epitopes by UL16. To address this issue we 
analyzed intracellular NKG2DL expression of permeabilized 293T-UL16-EGFP cells. 
Staining intensities for MICA and MHC class I did not significantly differ between 
intact and permeabilized UL16-EGFP positive and negative cells (Figure 2.3b and 
data not shown). In contrast, intracellular stainings of UL16-EGFP positive cells 
detected significantly higher MICB and ULBP2 levels as compared to cell surface 
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analysis and were almost (MICB) or fully equivalent (ULBP2) to levels of UL16-
EGFP negative cells. These results strongly suggested that MICB and ULBP2 are 
intracellularly retained by UL16 and do not reach the cell surface (Figure 2.3b. 
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Figure 2.3. UL16 impairs surface expression of MICB, ULBP1 and ULBP2. Cell surface (a) 
and total NKG2DL expression (b) of intact and permeabilized UL16-EGFP transfected 293T 
cells, respectively, were detected with NKG2DL specific mAbs. Following mAbs were used: 
AMO-1 (MICA), BMO-1 (MICB), AUMO-1 (ULBP1), BUMO-1 (ULBP2), CUMO-2 (ULBP3) 
and W6/32 (MHC class I). Cell permeability and integrity, respectively, was monitored by PDI-
staining. 
 
To corroborate these results we analyzed soluble MICA (sMICA) and MICB (sMICB) 
in the supernatants of 293T cells. We observed recently, using a highly sensitive 
ELISA for sMICA, that MICA molecules are shed from the surface of tumor cells by 
metalloproteinases [25]. To extend these studies, we also established a Sandwich-
ELISA for MICB with a comparable range of sensitivity. Here, we employed these 
ELISAs to analyze interference of UL16 with the release of MIC molecules. In full 
agreement with our other observations, we found no differences for release of sMICA 
between 293T, 293T-EGFP and 293T-UL16-EGFP cells (Figure 2.4). However, 
supernatants of 293T-UL16-EGFP cells contained 10-20 fold less MICB in 
comparison to 293T and 293T-EGFP cells, again suggesting that cell surface 
transport of MICB molecules is selectively inhibited by UL16. 
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Figure 2.4. UL16 selectively blocks release of sMICB. Release of sMICA and sMICB in culture 
supernatants by 293T, 293T-EGFP and 293T-UL16-EGFP was determined by a sMICA and a 
sMICB specific Sandwich-ELISA, respectively. 
 
Subcellular localization of UL16 
We used confocal microscopy to visualize the different fate of MICA and MICB in 
UL16 expressing cells and to localize UL16 intracellularly. Confirming flow 
cytometric results, MICA surface and intracellular staining was observed for both 
UL16-EGFP positive and negative 293T cells (Figure 2.5a). In contrast, surface and 
bright intracellular MICB staining was detected only for UL16-EGFP negative 293T 
cells, whereas only residual intracellular MICB was detected in UL16-EGFP positive 
cells (Figure 2.5b). 
These data further substantiated selective intracellular retention of MICB, but not 
MICA by UL16. To address cellular localization of UL16 we analyzed colocalization 
of UL16-EGFP with the ER-resident Protein-Disulfide-Isomerase (PDI), the 
lysosomal lamp-1 protein and surface MHC class I, respectively, in confocal 
microscopy. There was a prominent colocalization of UL16-EGFP with PDI 
expression (Figure 2.5c), a partial colocalization with lamp-1 (data not shown), but 
none with cell surface MHC class I molecules (Figure 2.5d-f).  
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Figure 2.5. Subcellular localization of UL16, MICA and MICB in 293T-UL16-EGFP cells. 
Confocal microscopy was implemented for colocalization studies of MICA (a), MICB (b), surface 
MHC class I (c), PDI (d) (all in red) with UL16-EGFP (green). Colocalization appears in yellow. 
For demonstration of mutually exclusive surface MHC class I and UL16-EGFP localization, 
single color photographs showing only surface MHC I (e) or UL16-EGFP stainings (f) were 
added. In a, b and d approximately 50% of the cells were UL16-EGFP negative 293T 
transfectants. 
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These results suggest that UL16 is mainly resident in the ER which is in concordance 
with predictions based on the UL16 primary sequence and the intracellular retention 
of MICB and ULBP2. They also indicate that UL16 does not reach the cell surface to 
block NKG2DL interaction with NKG2D in a direct fashion as proposed elsewhere 
[25]. At present, we do not know whether lysosomal localization is a feature of UL16 
or simply an experimental artifact due to overexpression of the UL16-EGFP fusion 
protein. Unambiguous organelle-assignment of UL16 has to be addressed in future 
studies when UL16 specific reagents become available. 
 
UL16 mediated NKG2DL down-regulation reduces NK cell reactivity  
The sole function known for MICB, ULBP1 and ULBP2 consists in their capacity to 
ligate NKG2D and thereby to trigger NK cells and costimulate CD8+ T cells 
[7,9,12,13]. To address the impact of UL16 on NKG2D-mediated immune 
responses, we analyzed binding of soluble human NKG2D tetramers to 293T-UL16-
EGFP transfectants. As expected, binding levels of sNKG2D were significantly 
reduced on UL16-EGFP expressing as compared to UL16-EGFP negative 
transfectants (Figure 2.6a). 
 
Next, we investigated whether UL16-mediated reduction of surface NKG2DL levels 
modulates NKG2D mediated recognition by NK cells. In first experiments, we 
analyzed recognition of 293T-EGFP and 293T-UL16-EGFP by polyclonal NK cells 
from healthy donors. However, both 293T transfectants were highly susceptible to 
lysis and addition of anti-NKG2D mAb did not greatly reduce lysis suggesting that 
293T cells express several other activating ligands besides NKG2DL recognized by 
the various activating receptors on polyclonal NK cells (data not shown). Therefore, 
we used the NK cell line NKL which has been well characterized for its NKG2D 
expression and NKG2D-mediated effector functions [9]. In cytotoxicity assays, both 
293T and 293T-EGFP cells were lyzed by NKL whereas lysis of 293T-UL16 cells was 
strongly reduced (Figure 2.6b). As MICA and ULBP3 remain the only known 
NKG2DL surface-expressed on 293T-UL16-EGFP cells, we addressed NK 
cytotoxicity in the presence of anti-MICA and anti-ULBP3 antibodies. Blocking 
interaction of NKG2D with MICA and ULBP3 completely abrogated lysis of 293T-
UL16 cells, and reduced lysis of 293T and 293T-EGFP cells by NKL (Figure 2.6c). 
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Figure 2.6. Reduced NKG2DL expression impairs NK cytotoxicity. (a) Binding of soluble 
NKG2D tetramers is reduced on UL16-EGFP expressing as compared to UL16-EGFP non-
expressing 293T cells (right panel). No staining was observed with streptavidin-PE (SA-PE) only 
(left panel). Lysis of 293T, 293T-EGFP and 293T-UL16-EGFP pretreated with AMO-1 and 
CUMO-1 (c) or irrelevant isotype-matched Ab (b) by NKL cells. 
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2.1.1.5 Discussion 
 
HCMV implements diverse molecular strategies to escape anti-viral NK and T cell 
responses. The concerted action of US2, US3/US11 and US6 proteins, for example, 
results in down-regulation of MHC class I molecules on HCMV infected cells 
minimizing CD8+ T cell reactivity [2,3]. In addition, products of the UL18 and UL40 
ORF are thought to provide protection against NK cell killing by constituting ligands 
engaged by inhibitory receptors on NK cells [4-6]. The HCMV UL16 glycoprotein 
now emerges as antagonist of another immune surveillance principle: the surface 
expression of cell-stress induced ligands of activating NK cell receptors. Our data 
demonstrate that UL16 intracellularly retains ligands of the activating receptor 
NKG2D which are induced in the course of HCMV infection. Cosman and colleagues 
proposed two models of action for UL16: intracellular retention of NKG2DL or 
masking NKG2D binding sites of NKG2DL on the cell surface [25]. Although our 
data clearly support the first model, we cannot rule out that some UL16 molecules 
reach the cell surface. 
We also demonstrate that expression of all five known NKG2DL is strongly induced 
upon HCMV infection. Only three of them (MICB, ULBP1, ULBP2) are retained by 
UL16, whereas MICA and ULBP3 reach the cell surface (Figure 2.7). These data 
reconcile the description of UL16 as an HCMV encoded NKG2D antagonist with 
findings that CD8+ T cell recognition of HCMV infected fibroblasts is augmented by 
virally induced MIC expression compensating for MHC class I down-regulation 
[7,12]. The selective binding of UL16 to NKG2DL is intriguing from a structural 
point of view, since MICA and MICB are closely related by sequence (~85% amino 
acid identity), but quite dissimilar from ULBPs (~25% identity) which are also more 
divergent amongst each other (~55% identity). One might speculate that UL16, as 
does NKG2D, rather recognizes a common structural element of NKG2DL, which is 
altered in MICA and ULBP3, than an array of particular amino acid side chains. 
MICA and MICB appear to be products of a recent gene duplication [26] and may 
have consequently evolved differently under selective pressure, one of which may be 
UL16 binding. Interestingly, MICA and ULBP3, but not MICB, ULBP1 and ULBP2, 
contain an N-linked glycosylation site at position 8 that is located in the center of the 
β-pleated sheet platform [27] and may be involved in precluding UL16 binding.  
Selective binding of UL16 to NKG2DL may also have been evolved as a consequence 
of different functions of the respective NKG2DL. For example, MIC and ULBP 
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molecules may also serve as ligands for receptors other than NKG2D. In fact, a recent 
report provides direct evidence for binding of MICA tetramers to γδ T cell receptors of 
some Vδ1 γδ T cells [28]. Of note, some allelic MICA variants and ULBP3 apparently 
have a lower affinity for NKG2D as compared to MICB, ULBP1 and ULBP2 [21,22]. 
Thus, UL16 is selective for higher affinity NKG2DL which may be sufficient to 
dampen a NKG2D-mediated anti-viral response. In this context, it will be of interest 
to compare anti-HCMV immune responses in individuals homozygous for low versus 
high affinity MICA allelic variants. 
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Figure 2.7. Model of UL16 function. Upon HCMV infection, expression of all five NKG2DL is 
induced, but only MICA and ULBP3 reach the cell surface. HCMV-encoded UL16 selectively 
binds to MICB, ULBP1, and ULBP2, retaining them in the ER. 
 
An urging question concerns the redundancy of NKG2DL. Besides differences in 
affinity for NKG2D and the interaction of MIC molecules with some γδ T cell 
receptors, there are no features known distinguishing NKG2DL with respect to their 
function. In particular, little is known about differences in regulation of gene 
expression. We show that expression of all NKG2DL is induced upon HCMV 
infection, but kinetics and induction rates varied considerably between the individual 
ligands. For example, induction of MICB was faster and shorter-lived as compared to 
MICA. This is in parallel with previous findings on induction of MICA and MICB by 
heat-shock [14]. Future studies have to establish whether NKG2DL are distinct in 
their expression kinetics. It also remains to be clarified what molecular events drive 
induction of NKG2DL expression in response to HCMV infection. It is known that 
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infection of adenoviruses and herpes viruses is accompanied by a cell-stress response 
and since promoters of MIC genes contain a heat-shock response element, expression 
of MIC genes during HCMV infection has been suggested to be regulated via heat-
shock factors [12,29]. 
Taken together, our data provide another example for the delicate balance between 
host immune defense mechanisms and viral evasion strategies. They also strengthen 
the notion of the NKG2D/NKG2DL system as a surveillance system for dysfunctional 
cells. 
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2.1.2 NKG2D dysfunction impairs NK and CD8+ T cell responses in vivo 
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2.1.2.1 Abstract 
 
The immunoreceptor NKG2D stimulates activation of cytotoxic lymphocytes upon 
engagement with MHC class I-related NKG2D-ligands (NKG2DL) of which at least 
some are inducibly expressed upon exposure to carcinogens, cell stress, or viruses. 
Here, we investigated consequences of a persistent NKG2DL expression in vivo by 
employing transgenic mice expressing MICA under control of the H2-Kb promoter. 
Although MICA functions as a potent activating ligand of mouse NKG2D, H2-Kb-
MICA mice appear healthy without aberrations in lymphocyte subsets. However, 
NKG2D-mediated cytotoxicity of H2-Kb-MICA NK cells is severely impaired in vitro 
and in vivo. This deficiency concurs with a pronounced down-regulation of surface 
NKG2D that is also seen on activated CD8+ T cells. As a consequence, H2-Kb-MICA 
mice fail to reject MICA-expressing tumors and to mount normal CD8+ T cell 
responses upon Listeria infection emphasizing the importance of NKG2D in 
immunity against tumors and intracellular infectious agents. 
 
2.1.2.2 Introduction 
 
NKG2D is a C-type lectin-like activating receptor broadly expressed on cytotoxic 
lymphocytes. In humans, NKG2D is present on most NK cells, CD8+ T cells, and γδ T 
cells in association with the adaptor protein DAP10 [1,2]. In mice, CD8+ T cells 
express NKG2D only upon activation, whereas NK cells, NKT cells and some γδ T 
cells constitutively express NKG2D [3,4]. At difference to humans, activated mouse 
NK cells generate a second NKG2D isoform with a shortened cytoplasmic domain 
(NKG2D-S) which is capable of pairing with both DAP10 and DAP12, whereas the 
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constitutively expressed NKG2D-L isoform exclusively associates with DAP10 [5,6]. 
DAP10 mediates costimulation of CD8+ T cells and 
triggers cytotoxicity by NK cells, whereas signal transduction via DAP12 augments 
cytotoxicity and is strictly required for activation of cytokine release [7-9]. 
A peculiarity of NKG2D resides in its interaction with a multitude of MHC class I-
related ligands of which at least the MIC molecules are inducibly expressed in 
association with cell stress, infection or malignant transformation [10-12]. Whereas 
the ectodomain of NKG2D is fairly conserved in mouse and man, the various MHC 
class I-related binding partners of NKG2D are highly diverged. In humans, the MHC-
encoded MIC molecules (MICA and MICB) and five members of the ULBP family 
(ULBP1-4; RAET1G) ligate NKG2D and consequently trigger NK cells [13-15]. In 
vitro, cell stress-inducible MIC molecules are expressed by many tumor cell lines and 
up-regulated upon infection with Human Cytomegalovirus, M. tuberculosis, and E. 
coli [12,16]. In vivo, MIC molecules are not detectable on most healthy tissues, but are 
expressed on gastrointestinal epithelium, on tumors and on Human 
Cytomegalovirus-infected cells [8,16]. Recently, MICA expression was reported for 
tissues affected by autoimmune reactions in patients with rheumatoid arthritis and 
celiac disease together with evidence for an involvement of NKG2D in the 
autoimmune pathogenesis of these diseases [17-19]. 
In mice, members of the RAE-1 protein family, the minor histocompatibility antigen 
H60, and MULT1 act as ligands of NKG2D [20-22]. Similarly to ULBP molecules 
they all lack an α3 domain. Recently, upregulation of RAE-1 molecules on 
macrophages by various ligands of Toll-like receptors has been demonstrated [23]. 
RAE-1 expression is also induced by carcinogens and stimulates anti-tumor activity 
of γδ T cells [24]. RAE-1-transduced tumor cell lines were rejected in vivo due to NK 
and CD8+ T cell responses and induced tumor immunity against the parental cell line 
supporting a role for NKG2D in tumor immunity [25,26], though no direct evidence 
for an involvement of NKG2D was provided.  
Recent findings that tumor cells release soluble MIC molecules may account for the 
failure of tumor surveillance by the NKG2D system in human cancer patients. MICA 
molecules are shed from tumor cells by metalloproteases resulting in a reduced 
NKG2DL surface density [27]. Further, sMICA was shown to down-regulate NKG2D 
surface expression and thereby to impair the anti-tumor reactivity of cytotoxic 
lymphocytes in vitro [28]. Substantial levels of sMICA were detected in sera of 
patients with various malignancies and correlated with a systemic NKG2D 
Results and Discussion  89
downregulation on peripheral NK and CD8+ T cells [27,29,30]. However, direct 
evidence for an in vivo impairment of NKG2D-mediated tumor immunosurveillance 
by persistent MICA expression was lacking. Another study reported NKG2D down-
regulation upon co-culture with NKG2DL expressing cells that was at least in part 
due to signaling of the DAP10 adaptor. In addition, down-regulation of NKG2D was 
observed for NK cells from NOD mice and attributed to co-expression of RAE-1 [31], 
but consequences for NK cell activation in vivo were not investigated. 
Here we explored implications of persistent NKG2DL expression in vivo. We 
investigated consequences of persistent MICA expression for NKG2D-mediated 
immunosurveillance as it may occur in cancer patients. In addition, we took 
advantage of the strongly impaired NKG2D function in H2-Kb-MICA mice to address 
the role of NKG2D for NK and CD8+ T cell responses in vivo. 
 
2.1.2.3 Materials and Methods 
 
Mice. C57BL/6 mice were obtained from Charles River Wiga. For the generation of 
mice constitutively expressing MICA, one-cell embryos of (C57BL/6 x SJL)F1/J 
hybrid mice were microinjected with a 4.75-kb XhoI/KpnI DNA fragment excised 
from the pHSE plasmid [32] containing the H2-Kb promoter followed by the 1.15-kb 
MICA*07 open reading frame (accession number AY750850) and the 3' untranslated 
region of the β-globin gene. Eggs were transferred into the oviducts of B6 CBA mice 
(transgenic mouse facility, Fred Hutchinson Cancer Research Center). Offspring 
were tested for the presence of the MICA transgene by PCR from genomic tail DNA 
using the oligonucleotides MICAEX2F (5'-GAC TTG ACA GGG AAC GGA AAG G-3') 
and MICAEX4R (5'-CCC CCC ACT GCT GGG TGT TG-3'). Several H2-Kb-MICA 
transgenic lines were obtained, and one of them (tg24) exhibiting high surface MICA 
expression was backcrossed with C57BL/6 mice at least 12 times for further studies. 
Litters were tested for MICA transgenes by PCR and/or for MICA surface expression 
on PBL by flow cytometry using biotinylated anti-MICA/B mAb BAMO1. RAG2-
deficient and β2-microglobulin-deficient C57BL/6 mice were kindly provided by H. 
Schild (University of Mainz, Mainz, Germany). Animals were maintained under 
specific pathogen-free conditions in the animal facilities of the Department of 
Immunology at the University of Tübingen. All animal experiments were conducted 
according to the German animal protection law. 
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Cell lines and transfectants. All cell culture media were supplemented with 10% FCS 
(PAA Laboratories), 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin 
(Cambrex), 1 mM sodium pyruvate (c.c. pro), and 50 μM 2-ME. The cell lines RMA 
(T cell lymphoma), RMA-S (TAP2-deficient RMA variant), and CHO (Chinese 
hamster ovary carcinoma) were cultured in RPMI 1640 (Cambrex). The RMA cell 
line was transfected by electroporation (250 V, 950 μF) using 15 μg of the vector 
RSV.5neo or RSV.5neo containing the MICA*07 open reading frame [15]. Stable 
transfectants (RMA-neo and RMA-MICA*07) were selected in RPMI 1640 
supplemented with 1 mg/ml G418 (PAA Laboratories).  
 
Cells. Thymocytes and splenocytes were prepared by passing the respective organs 
through a 40 μm cell strainer (BD Biosciences Europe). For analysis of PBL, blood 
was collected from the orbital sinus. RBC in PBL and splenocyte suspensions were 
lyzed by ammonium chloride treatment. For isolation of NK cells, nylon wool 
nonadherent cells were positively selected from splenocytes by magnetic cell sorting 
using DX5 MicroBeads (Miltenyi Biotec) according to the manufacturer’s 
instructions. Resulting cells were 65–85% NK1.1+. For in vitro analyses DX5-sorted 
cells were cultured in RPMI 1640 (Cambrex) supplemented with 1500 U/ml human 
IL-2 (R&D Systems). For analysis of in vivo-activated NK cells, mice were injected 
i.p. with 300 μg of polyinosinic-polycytidylic acid potassium salt (poly(I:C), Sigma-
Aldrich). Twelve to 18 h later, DX5-positive cells were isolated from splenocytes as 
described above. Con A blasts were generated by culturing splenocytes for 48 h in 
Alpha-MEM (Cambrex) containing 2.5 μg/ml Con A. Hepatocytes were isolated by a 
two-step perfusion protocol [33]. In brief, 60 ml of PBS containing 0.5 mM EGTA 
and 0.05 M HEPES was used as a first perfusate. Liver was perfused with 60 ml of 
collagenase (40 U/ml in RPMI 1640; Sigma-Aldrich) and subsequently excised from 
the body cavity, the gall bladder was removed, and the liver was pushed through a tea 
strainer and incubated for 10 min at 37°C in collagenase. To get a single-cell 
suspension, the digested liver was additionally rinsed through a 70-μm cell strainer 
(BD Biosciences Europe).  
For isolation of CD8+ T cells, nylon wool nonadherent splenocytes were first depleted 
for NK cells using DX5 MicroBeads (Miltenyi Biotec). DX5-depleted cells were then 
positively selected with anti-CD8 (clone Ly-2) MicroBeads (Miltenyi Biotec) 
according to the manufacturer’s instructions. Purified CD8+ T cells were either 
directly analyzed for NKG2D expression or after 3 days culture in anti-CD3 (clone 
17A2) coated microwells.  
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mAbs and recombinant proteins. Anti-CD3ε FITC (145-2C11), anti-H2-Kb FITC 
(AF6-88.5), anti-NK1.1 PE (PK136), anti-CD8 PE (Ly-2), anti-CD19 PE (1D3), 
anti-γδ TCR PE (GL3), anti-TNP-KLH PE (A110-1; rat Ig control), anti-TNP 
hamster IgG PE (A19-3; hamster Ig control), and anti-CD4 PerCP (GK1.5) were 
purchased from BD Pharmingen. Anti-NKG2D PE (CX5), anti-NKG2D 
allophycocyanin (CX5), and anti-NK1.1 FITC (PK136) were obtained from 
eBioscience. Anti-NKG2D mAb C7 was described elsewhere [3]. Rat IgG Abs, anti-
CD16/CD32 mAb (clone 2.4G2), anti-IFNγ mAb (XMG1.2), anti-CD8α mAb 
(YTS169), and anti-CD62L mAb (Mel-14) were purified from rat serum or 
hybridoma supernatants with protein G-Sepharose. mAbs were Cy5- or FITC-
conjugated according to standard protocols. The mAbs AMO1 and BAMO1 
recognizing MICA and MICA/B, respectively, were generated and purified as 
described [27]. BAMO1 was biotinylated using EZ-Link Sulfo-NHS-Biotin (Pierce) 
according to the manufacturer’s protocol. Streptavidin-PE (Molecular Probes) was 
used as a secondary reagent. Soluble mouse NKG2D was produced in insect cells 
using the baculovirus system as described elsewhere [15]. Binding of FLAG-tagged 
mouse NKG2D was detected with the biotinylated anti-FLAG mAb M2 (Sigma-
Aldrich) in combination with streptavidin-PE. Stained cells were analyzed on a 
FACSCalibur (BD Biosciences) using CellQuest software for evaluation. 
 
ELISA. Concentrations of sMICA in sera of H2-Kb-MICA and nontransgenic 
littermates (nontgLM) were determined by sandwich-ELISA using a modified 
protocol of the previously published MICA-ELISA [27]. In brief, plates were coated 
with 2 μg/ml of the MICA-specific capture mAb AMO1 overnight at 4°C. After 
blocking with 7.5% BSA-PBS, plates were washed with 0.05% Tween 20. Samples or 
recombinant sMICA*04 serving as a standard were added in 2% BSA-PBS. After 
incubation and washing, biotinylated BAMO1 was added at a concentration of 1 
μg/ml. After incubation and washing, HRP-conjugated streptavidin (BD 
Pharmingen) was applied as a 1/1000 dilution. Plates were washed extensively before 
adding the peroxidase substrate TMB (Kirkegaard & Perry Laboratories) according 
to the manufacturer’s instructions. HRP activity was stopped by addition of 1 M 
phosphoric acid, and absorbance was measured at 450 nm.  
 
Chromium release assay. Cytotoxicity of NK cells in vitro was assessed in a 51Cr 
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release assay. NK effector cells were isolated from splenocytes with DX5-coated 
beads and either used immediately or after 5 days of cultivation with human IL-2 at 
1500 U/ml (R&D Systems). Target cells were labeled with 50 μCi of 51Cr 
(Amersham) for 1 h at 37°C and washed three times. Effector cells were titrated on 
target cells and incubated for 4 h at 37°C unless noted otherwise. Spontaneous 
release of target cells alone was <15% of the maximum release taken from target cells 
lyzed in 1% Triton X-100. Percentage of lysis was calculated as follows: 100 x 
(experimental release – spontaneous release)/(maximum release – spontaneous 
release). Data are means of duplicates. For NKG2D blocking studies, NK cells were 
preincubated for 20 min with the mAb C7 (30 μg/ml) before addition to the target 
cells. Hamster Ig (ICN Pharmaceuticals) served as a control.  
 
Intracellular IFNγ analysis of NK cells. Purified NK cells were cocultured for 17 h 
with RMA transfectants at a ratio of 2:1 in medium containing 1000 U IL-2/ml. 
During the final 11 h of culture, GolgiStop (BD Biosciences) was added according to 
manufacturer’s instructions. Subsequently, cells were stained with FITC-conjugated 
anti-NK1.1, permeabilized with Cytofix/Cytoperm (BD Biosciences), and stained 
with PE-conjugated anti-IFNγ-mAb (BD Biosciences). After a further 20-min 
incubation, cells were washed and analyzed by flow cytometry.  
 
Real-time PCR. RNA was isolated from purified NK cells using TRIZOL (Invitrogen 
Life Technologies) followed by reverse transcription using SuperScript II (Invitrogen 
Life Technologies) according to the manufacturer’s protocol. The resulting cDNA 
was amplified with primer pairs specific for NKG2D, DAP10, DAP12, and 18S 
rRNA, respectively, in duplicates (40 cycles: 95°C x 15 s, 60°C x 1 min) using 
SYBRGreen chemistry on the ABI PRISM 7000 Sequence Detection System (Applied 
Biosystems). PCR products were analyzed on 3% agarose gels for purity und 
validated by direct sequencing. Data were analyzed by the ΔCT method for relative 
quantification and calculated as the relative increase in relative copy numbers. 
Oligonucleotide sequences (forward, reverse) are: 18S rRNA: 5'-
CGGCTACCACATCCAAGGAA-3', 5'-GCTGGAATTACCGCGGCT3'; NKG2D: 5'-
ACG TTT CAG CCA GTA TTG TGC-3', 5'-GGA AGC TTG GCT CTG GTT C-3'; 
DAP10: 5'-CCC AGG CTA CCT CCT GTT C-3', 5'-CTA CAA TTA GGA GTG ACA 
TGA CCG-3'; DAP12: 5'-CTG GGA TTG TTC TGG GTG AC-3', 5'-CTG AAG CTC 
CTG ATA AGG CG-3'. The NKG2D primer pair amplifies both the NKG2D-S and 
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NKG2D-L variants.  
 
In vivo cytotoxicity assay. Freshly isolated splenocytes were washed in PBS and 
resuspended at a final concentration of 2 x 107 cells/ml in PBS. Cells were labeled 
either with 8 μM CFSE (Molecular Probes) or with 5–7 μM PKH26 (Sigma-Aldrich) 
for 4 min at room temperature. The reaction was stopped by adding FCS, and cells 
were washed once in RPMI 1640 and twice in PBS. Labeled cells were mixed at 
defined ratios, and a total of 1.5 x 107 cells was adoptively transferred into H2-Kb-
MICA mice or nontgLM, respectively. Immediately after adoptive transfer, labeled 
cells were analyzed in the peripheral blood. Six or 14 h after transfer, mice were 
sacrificed and PBL, splenocytes, and lymph node cells were analyzed for labeled cells 
by flow cytometry.  
 
Tumor inoculation. Growth of RMA-neo and RMA-MICA*07 cells was analyzed in 
H2-Kb-MICA mice, nontgLM, and RAG2-deficient mice. Mice were injected s.c. with 
105 RMA-neo in the right flank and 105 RMA-MICA*07 cells in the left flank, 
respectively. Tumor growth was monitored by measuring tumor surface with a metric 
caliper at the indicated time points. Animals were sacrificed at day 17 when some 
tumors reached a size of 200 mm2. Data are representative of two independent 
experiments. 
 
Infection with Listeria monocytogenes. Mice were infected with L. monocytogenes 
strain EGD or with a L. monocytogenes strain recombinant for a secreted form of OVA 
[34]. For i.v. infection, listeriae were injected into a lateral tail vein. Inocula were 
controlled by plating serial dilutions on tryptic soy broth agar. 
 
Quantitation of T cell responses by analysis of cellular cytokine expression. For 
determination of cytokine expression, at day 9 postinfection, 4 x 106 splenocytes were 
stimulated for 5 h with 10–6 M of peptides derived from listeriolysin O (LLO190–
201, NEKYAQAYPNVS) or OVA (OVA257–264, SIINFEKL). During the final 4 h of 
culture, 5 μg/ml brefeldin A (Sigma-Aldrich) was added. Cultured cells were 
incubated for 10 min with rat IgG and anti-CD16/CD32 mAb. Subsequently, cells 
were stained with PE-conjugated anti-CD4 mAb or anti-CD8 mAb, and after 30 min 
on ice, fixed for 20 min at room temperature with PBS 4% paraformaldehyde. Cells 
were washed with PBS 0.1% BSA, permeabilized with PBS 0.1% BSA/0.5% saponin 
(Sigma-Aldrich), and incubated with rat IgG and anti-CD16/CD32 mAb. After 5 min, 
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FITC-conjugated anti-IFNγ-mAb was added. After a further 20 min incubation, cells 
were washed with PBS, fixed with PBS 1% paraformaldehyde, and analyzed by flow 
cytometry.  
 
Quantitation of CD8+ T cell responses by MHC class I tetramer staining. Modified 
full-length cDNA of H2-Kb and human β2-microglobulin were kindly provided by D. 
Busch (Technical University of Munich, Munich, Germany). H2-Kb/OVA257–264-
tetramers were generated as described [35]. For flow cytometric analysis, at day 9 
postinfection, 2 x 106 splenocytes were incubated for 15 min at 4°C with rat IgG, anti-
CD16/CD32 mAb, and streptavidin (Molecular Probes) in PBS with 0.5% BSA and 
0.01% sodium azide. After incubation, cells were stained for 60 min at 4°C either with 
Cy5-conjugated anti-CD8α mAb, FITC-conjugated anti-CD62L mAb, and PE-
conjugated MHC class I-OVA257–264-tetramers, or with allophycocyanin-
conjugated anti-NKG2D mAb, FITC-conjugated anti-CD8α mAb, and PE-
conjugated MHC class I-OVA257–264-tetramers. Subsequently, cells were washed 
with PBS 0.5% BSA/0.01% sodium azide and diluted in PBS. Propidium iodide was 
added before four-color flow cytometric analysis. 
 
2.1.2.4 Results 
 
MICA expression by H2-Kb-MICA mice. 
In order to gain insight into consequences of a persistent NKG2DL expression in vivo, 
we established transgenic mice constitutively and ubiquitously expressing the human 
NKG2DL MICA. We corroborated previous data of MIC-molecules acting as a 
ligands of mouse NKG2D by demonstrating that MICA*07-expressing cells bind 
soluble mouse NKG2D (Figure 2.8) [22,36]. To achieve constitutive and ubiquitous 
MICA expression, a transgene containing the coding sequence of MICA*07 under 
control of the MHC class I H2-Kb promoter was introduced into the germline of 
(C57BL/6 x SJL)F1/J mice (Figure 2.9a). Offspring expressing MICA on PBL was 
selected and a transgenic line (H2-Kb-MICA) established that was repeatedly 
backcrossed with C57BL/6 mice (B6 mice). 
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Figure 2.8. MICA*07 ligates NKG2D. Flow cytometric analysis of RMA cells ectopically 
expressing MICA*07 (RMA-MICA*07) with soluble mouse NKG2D (black histogram) and anti-
MICA/B mAb BAMO1 (gray histogram). Mock-transfected RMA cells (RMA-neo) did not bind 
mouse NKG2D (open histogram). 
 
H2-Kb-MICA mice presented phenotypically normal and healthy, and did not display 
any overt signs of autoimmunity. No significant alterations in frequencies of 
lymphocyte subsets were observed when splenocytes of H2-Kb-MICA mice and non-
transgenic littermates (nontgLM) were compared (data not shown). Most 
splenocytes from H2-Kb-MICA mice strongly expressed MICA (Figure 2.9b). In 
particular, B and NK cells expressed high levels of MICA, whereas MICA expression 
of CD4+ and CD8+ T cells reached intermediate levels (Figure 2.9c). Accordingly, 
MICA expression by PBL varied over a broad range (Figure 2.9b).  
 
In contrast, most thymocytes representing the CD4+/CD8+ subpopulation had only 
low amounts of MICA, while other thymocyte subsets displayed a more pronounced 
MICA expression (Figure 2.9b,c). As for thymocytes, MICA expression of 
hepatocytes paralleled H2-Kb expression levels (Figure 2.9b). No expansions of 
intraepithelial CD4+/CD8αα+ T cells were observed as previously described for 
transgenic mice with a gut-specific MICA expression [37] (data not shown). Sera 
from H2-Kb-MICA mice, but not from nontgLM, contained high levels of soluble 
MICA (~ 50 ng/ml) exceeding sMICA levels previously detected in tumor patients 
[27-29], suggesting substantial MICA shedding by non-malignant cells (Figure 
2.9d). 
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Figure 2.9. Constitutive MICA expression by H2-Kb-MICA mice. (a), H2-Kb-MICA transgene 
encompassing the H2-Kb promoter, the 1.15 kb MICA*07 coding sequence, and the 3’ 
untranslated region (UT) of the β-globin gene. (b) MICA cell surface expression by PBL, 
thymocytes, splenocytes, and hepatocytes of H2-Kb-MICA mice as detected by BAMO1. Cells 
were co-stained with anti-H2-Kb. (c) MICA expression by gated subpopulations of splenocytes 
and thymocytes from nontgLM (gray histograms) and H2-Kb-MICA mice (black histograms) as 
analyzed with BAMO1. (d) sMICA levels in sera of H2-Kb-MICA mice detected with a MICA-
Sandwich-ELISA. The mean of sMICA levels from four representative mice is shown. NontgLM 
tested negative (N. D. = not detectable). 
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Constitutive MICA expression induces NKG2D down-regulation and dysfunction. To 
address functional consequences of constitutive MICA expression, we analyzed 
expression and functionality of NKG2D on NK cells. NKG2D surface levels of NK 
cells from H2-Kb-MICA were reduced when compared to NK cells of nontgLM 
(Figure 2.10a). Differences in surface expression were even more pronounced when 
poly (I:C) activated NK cells of H2-Kb-MICA mice and nontgLM were analyzed ex 
vivo. NKG2D down-regulation coincided with a strong impairment of NKG2D 
function.  
In contrast to NK cells from nontgLM, poly (I:C) activated NK cells from H2-Kb-
MICA mice failed to lyze RMA-MICA*07 cells ex vivo (Figure 2.8, Figure 2.10b). 
When poly (I:C) activated NK cells from nontgLM were stimulated ex vivo with RMA-
MICA*07 cells, we observed a markedly higher frequency of NK1.1+ IFNγ producing 
cells (~16%) as opposed to simulation with RMA-neo cells (~ 8%). In contrast, 
frequencies of NK1.1+ cells from H2-Kb-MICA mice producing IFNγ were only 
slightly increased when stimulated with RMA-MICA*07 cells as compared to RMA-
neo stimulation (Figure 2.10c).  
 
To assess a general defect in cytotoxicity, we tested the lytic capacity of NK cells from 
H2-Kb-MICA mice towards CHO and RMA-S cells. CHO cells are recognized by 
mouse NK cells via the activating receptor Ly49D in complex with DAP12 [38]. 
Activated NK cells from H2-Kb-MICA mice and nontgLM displayed similar lytic 
potential for CHO cells arguing against a general impairment of cytotoxicity (Figure 
2.10d).  
Similarly, RMA-S cells that are also recognized NKG2D-independently were lyzed by 
NK cells from H2-Kb-MICA mice and nontgLM at comparable rates (Figure 2.10e). 
When NK cells from H2-Kb-MICA mice were cultivated in vitro with high dose of IL-2 
(1500 U/ml), NKG2D surface levels increased, but did not reach wildtype levels 
presumably due to MICA expression by NK cells (Figure 2.10f). 
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Figure 2.10. NKG2D on H2-Kb-MICA NK cells is dysfunctional. (a) NKG2D cell surface 
expression by resting and poly (I:C) activated NK cells from H2-Kb-MICA mice is strongly 
reduced. Purified NK cells from H2-Kb-MICA mice (black histograms) and nontgLM (gray 
histograms) were stained ex vivo with the anti-NKG2D mAb CX5 or with an isotype control 
(open histograms). Mean fluorescence intensities of gated NK1.1 cells are shown. (b) In contrast 
to poly (I:C) activated non-transgenic NK cells, poly (I:C) activated H2-Kb-MICA NK cells fail to 
lyze RMA-MICA*07 cells ex vivo in the presence (anti-NKG2D; control Ig) or absence (w/o mAb) 
of antibodies. Both types of NK cells fail to lyze RMA-neo cells (neg. control). Cytotoxicity was 
measured by a 12 h chromium-release assay. (c), IFNγ production by H2-Kb-MICA NK cells. 
Freshly isolated, poly (I:C) activated NK cells from H2-Kb-MICA mice and ntgLM were co-
cultured with RMA-neo or RMA-MICA cells. After 17h frequencies of IFNγ producing NK1.1+ 
cells were evaluated by intracellular staining. Data represent means of triplicates. (d,e) Lysis of 
CHO cells (d) and RMA-S cells (e) by poly (I:C) activated NK cells ex vivo isolated from H2-Kb-
MICA mice and nontgLM. (f) NKG2D expression of purified H2-Kb-MICA NK cells increases 
upon in vitro culture. NKG2D surface expression of NK1.1+ cells from H2-Kb-MICA mice (black 
histogram) and nontgLM (gray histogram) cultured for 5 days with IL-2 was analyzed with CX5. 
Isotype controls are shown as open histograms. (g) In vitro cultivated H2-Kb-MICA NK cells lyze 
RMA-MICA*07 cells. Purified NK cells from H2-Kb-MICA mice and nontgLM were cultivated 5 
days with IL-2 and subsequently assayed for lysis of RMA-MICA*07 cells. Lysis was blocked by 
mAb C7 (anti-NKG2D), but not by control immunoglobulin (control Ig). RMA-neo cells were not 
lyzed (neg. control). (h) NKG2D up-regulation on purified CD8+ T cells from H2-Kb-MICA mice 
and nontgLM upon in vitro stimulation with anti-CD3 mAb is comparable. NKG2D expression 
by freshly isolated CD8+ T cells or by purified CD8+ T cells after 3 days culture in the presence of 
anti-CD3 mAb was analyzed with PE-conjugated CX5. NKG2D surface expression of CD8+ 
gated cells from H2-Kb-MICA mice (black histogram) and nontgLM (gray histogram) are shown. 
Isotype controls are open histograms. 
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Accordingly, RMAMICA*07 cells were lyzed by IL-2 cultivated H2-Kb-MICA NK 
cells, but less efficiently when compared to lysis by non-transgenic NK cells (Figure 
2.10g). CD8+ T cells freshly isolated from H2-Kb-MICA mice and nontgLM contained 
a small fraction of NKG2D-positive cells which presumably are activated CD8+ T 
cells. Again, NKG2D expression was greatly reduced on cells from H2-Kb-MICA mice 
as compared to cells from nontgLM (Figure 2.10h). However, after three days of 
stimulation with anti-CD3, NKG2D expression of CD8+ T cells from both mice was 
almost indistinguishable. 
 
Reduced NKG2D staining was not due to epitope-masking by soluble MICA, since 
complexes formed between recombinant MICA and NKG2D bound anti-NKG2D and 
NKG2D staining of H2-Kb-MICA NK cells was not increased following mild acid 
treatment (data not shown). An impact of different transcriptional regulation on 
NKG2D expression was excluded by real-time PCR that did not reveal differences in 
NKG2D, DAP10, or DAP12 transcripts between NK cells from H2-Kb-MICA mice 
and nontgLM (Figure 2.11a). Previous reports described NKG2D down-regulation 
by NK cells upon exposure to NKG2DL-expressing cells in vitro and in vivo 
[23,28,31]. We observed that down-regulation of surface NKG2D on non-transgenic 
splenocytes was most pronounced after co-cultivation with splenocytes from mice in 
vitro, and only marginally following treatment with sera from H2-Kb-MICA mice, 
whereas incubation with control cells and sera from nontgLM, respectively, had no 
effect (Figure 2.11b,c). In vivo, NKG2D surface expression on splenocytes from B6 
mice was down-regulated after adoptive transfer into H2-Kb-MICA mice, but not after 
transfer into nontgLM (Figure 2.11d). Altogether, these data suggest that reduced 
surface NKG2D on H2-Kb-MICA NK cells results in NKG2D dysfunction and that 
NKG2D downregulation is primarily caused by a persistent exposure to cell-bound 
MICA in vivo. 
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Figure 2.11. NKG2D-downregulation by MICA. (a) Transcript levels of DAP10, DAP12, and 
NKG2D are unaltered in NK cells from H2-Kb-MICA mice as compared to nontgLM. Bars show 
the relative copy numbers in purified unstimulated NK cells from three individual H2-Kb-MICA 
mice (black bars) and three nontgLM (gray bars). (b,c) NKG2D downregulation by cell-bound 
and soluble MICA. (b) Splenocytes from nontgLM (5 x 105) were co-incubated with CFSE-
labeled splenocytes (1 x 106) either from H2-Kb-MICA mice or from nontgLM for 12 h in vitro 
and, subsequently, NKG2D surface expression of CFSE-negative cells analyzed by flow 
cytometry. (c) Splenocytes from nontgLM were incubated for 12 h in sera (1:2 dilution with 
medium) from H2-Kb-MICA mice and nontgLM, respectively, and, subsequently, analyzed for 
NKG2D surface expression. The fluorescence intensities of unlabeled NKG2D expressing cells 
after incubation were 55.0 ± 0.5 (nontg splenocytes co-culture), 37.9 ± 1.2 (H2-Kb-MICA 
splenocytes co-culture), 49.3 ± 0.4 (nontg serum), and 46.6 ± 1.3 (H2-Kb-MICA serum) 
representing means of triplicates of y mean fluorescence intensities. (d) NKG2D down-
regulation in vivo. 8 x 106 CFSE-labeled nylon wool nonadherent splenocytes from B6 mice were 
injected intravenously into H2-Kb-MICA mice or nontgLM. After 10 hours splenocytes were 
isolated and analyzed for NKG2D surface expression on CFSE-labeled cells with APC-
conjugated CX5. 
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Figure 2.12. Deficient NKG2D-mediated natural cytotoxicity in H2-Kb-MICA mice. (a) poly 
(I:C) activated B6 NK cells ex vivo lyze Con A blasts from H2-Kb-MICA mice (w/o mAb). Lysis 
was inhibited by addition of the mAb C7 (anti-NKG2D), but not by control immunoglobulin 
(control Ig). Con A blasts from B6 mice were not lyzed (neg. control). (b-d) H2-Kb-MICA 
splenocytes are readily eliminated in non-transgenic mice, but not in H2-Kb-MICA mice. 
Splenocytes of H2-Kb-MICA mice (CFSE-labeled) and nontgLM (PKH26-labeled) were 
adoptively co-transferred into nontgLM (b) or in H2-Kb-MICA mice (c) and their presence 
among PBL was analyzed by flow cytometry 1 min and 6 h post-injection (p.i.). In addition to 
PBL, spleen and lymph nodes were analyzed 6h p.i. and all results are summarized in (d). The 
number of MICA-negative splenocytes was set as 1 and the relative number of MICA-positive 
splenocytes recovered from nontgLM (black bars) or H2-Kb-MICA (gray bars) calculated 
accordingly. Data represent the means of the relative number of transferred MICA-positive 
splenocytes from three mice per indicated organ. Results are representative of two independent 
experiments. (e) Splenocytes of CFSE-labeled β2-microglobulin-deficient (β2M-/-) and PKH26-
labeled wildtype controls were adoptively cotransferred and analyzed by flow cytometry 1 min 
and 14 h p.i. in PBL, spleens and lymph nodes of nontgLM (black bars) or H2-Kb-MICA mice 
(gray bars). 
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NKG2D-mediated natural cytotoxicity is deficient in H2-Kb-MICA mice. 
To address functional consequences of NKG2D down-regulation for NK cell 
activation in vivo, we took advantage of H2-Kb-MICA splenocytes. In contrast to 
Concanavalin A-activated splenocytes (Con A blasts) from B6 mice, H2-Kb-MICA 
Con A blasts were subject of substantial lysis by freshly isolated poly (I:C) activated 
B6 NK cells, and lysis was blocked by addition of anti-NKG2D antibody (Figure 
2.12a). To test the efficacy of NKG2D-mediated NK cytotoxicity in vivo, we 
adoptively co-transferred CFSE-labeled MICA-transgenic and PKH26-labeled non-
transgenic splenocytes into nontgLM. Within six hours, the relative number of 
MICA-expressing splenocytes in the peripheral blood was reduced to one third 
(Figure 2.12b) indicating an efficient and preferential elimination of MICA-
expressing cells in vivo. A similar preferential elimination of H2-Kb-MICA splenocytes 
was observed when lymph nodes and spleens were analyzed (Figure 2.12d). 
However, when CFSE-labeled MICA-transgenic splenocytes were adoptively co-
transferred together with PKH26-labeled non-transgenic splenocytes into H2-Kb-
MICA mice, relative numbers of MICA-transgenic splenocytes were only slightly 
decreased indicating that NKG2D-mediated activation of NK cytotoxicity is deficient 
in H2-Kb-MICA mice (Figure 2.12c,d). To address functionality of NKG2D-
independent NK cytotoxicity, we adoptively transferred CFSE-labeled splenocytes 
from β2-microglobulin-deficient mice. Both H2-Kb-MICA mice and nontgLM 
exhibited similar clearance rates of β2-microglobulin-deficient cells excluding a 
general impairment of NK cytotoxicity in H2-Kb-MICA mice (Figure 2.12e). 
 
Impaired tumor rejection by H2-Kb-MICA mice. 
Tumor cells ectopically expressing NKG2DL stimulate tumor immunity. For 
example, RAE-1-expressing RMA cells have been shown to be rejected by NK cells 
and/or CD8+ T cells [25,26]. We adopted this experimental setting to evaluate 
functional consequences of NKG2D impairment in vivo and injected 105 RMA-neo 
and 105 RMA-MICA*07 cells into the right and left flank, respectively, of nontgLM. 
As expected RMA-neo cells gave rise to tumors in all mice, but RMA-MICA*07 cells 
were rejected analogous to previous findings with RAE-1-expressing RMA cells 
[25,26] (Figure 2.13). To assess a potential contribution of T cells recognizing 
putative MICA peptides presented by MHC class I in the rejection of RMA-MICA 
cells, we tested RAG2-deficient mice: RMA-MICA*07 cells were rejected by RAG2-
deficient mice whereas RMA-neo cells expanded to tumors demonstrating that 
Results and Discussion  103
rejection of RMA-MICA*07 cells occurred independently of T cell recognition, but 
rather is due to the NKG2D-mediated activation of NK cells reaffirming the 
functionality of MICA as surrogate ligand of mouse NKG2D. However, when we 
challenged H2-Kb-MICA mice with injections of RMA cells, both RMA-neo and 
RMA-MICA*07 gave rise to tumors demonstrating that the NKG2D-mediated tumor 
rejection is strongly impaired in these mice (Figure 2.13). 
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Figure 2.13. NKG2D-mediated tumor rejection is impaired in H2-Kb-MICA mice. H2-Kb-
MICA mice, nontgLM, and B6 RAG2-deficient mice, respectively, were inoculated 
subcutaneously with 1x105 RMA-neo (into the right flank) and 1x105 RMA-MICA*07 cells (left 
flank). Each panel displays the tumor growth of RMA-neo (open circles) and RMAMICA (closed 
circles) in four mice monitored for 17 days post-inoculation. 
 
NKG2D dysfunction compromises CD8+ T cell responses to Listeria 
monocytogenes. 
To address the role of NKG2D in the immune defence against infectious pathogens 
and for the generation of T cell responses, we scrutinized the immune response of H2-
Kb-MICA mice upon infection with L. monocytogenes. The control of the intracellular 
pathogen L. monocytogenes involves both cells of the innate and of the acquired 
immune system [39]. To evaluate consequences of NKG2D impairment for the early 
control of L. monocytogenes by innate mechanisms, H2-Kb-MICA mice and nontgLM 
were infected with 5 x 104 listeriae, and the bacteria titers in spleen and liver were 
determined at day 2 and 3 post-infection. Both groups of mice did not differ 
significantly in their bacterial load, indicating that NKG2D-mediated effector 
functions of NK cells are not relevant for the early control of L. monocytogenes (data 
not shown).  
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Figure 2.14. Impaired anti-Listeria CD8+ T cell response in H2-Kb-MICA mice. H2-Kb-MICA 
mice and nontgLM were i. v. infected with 5 x 103 listeriae encoding a secreted form of 
ovalbumin. On day 9 post-infection, spleen cells of infected mice were analyzed. (a) NKG2D 
surface expression by H2-Kb/OVA257-264-tetramer-positive cells.  Only viable CD8+-gated 
splenocytes stained with anti-NKG2D mAb CX5 are shown. (b) Frequencies of H2-Kb/OVA257-
264-tetramer-positive CD62LlowCD8+ T cells in H2-Kb-MICA mice (black bars) versus nontgLM 
(gray bars) as assessed by flow cytometry. (c) Frequencies of IFNγ-producing CD8+ T cells after 
in vitro stimulation with peptide OVA257-264 analyzed by intracellular cytokine staining. (d) 
Frequencies of IFNγ-producing CD4+ T cells after in vitro stimulation with peptide LLO190-201 
analyzed by intracellular cytokine staining. (b-d) Values represent means of three infected mice 
per group. 
 
For the analysis of listeria-specific T cell responses, we applied a L. monocytogenes 
strain recombinant for a secreted form of ovalbumin [34]. This strain induces a 
strong ovalbumin-specific CD8+ T cell response, which can be detected with H2-
Kb/OVA257-264-tetramers. At the peak of the primary T cell response against L. 
monocytogenes (day 9 post-infection), we analyzed tetramer-positive T cells in both 
H2-Kb-MICA mice and nontgLM. Co-staining with anti-NKG2D mAb revealed a 
significant NKG2D expression on the majority of tetramer-positive cells from non-
transgenic mice. This in accord with earlier studies reporting that CD8+ T cells, but 
not CD4+ T cells, show induced NKG2D expression several days after antigenic 
activation [4]. In contrast to non-transgenic mice, NKG2D surface expression of 
tetramer-positive cells from H2-Kb-MICA mice was strongly reduced (Figure 2.14a). 
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Interestingly, spleens of H2-Kb-MICA mice contained significant lower frequencies 
and total numbers of tetramer-positive CD8+ T cells (Figure 2.14b and data not 
shown). These results were confirmed by the analysis of frequencies and numbers of 
CD8+ T cells responding to in vitro peptide stimulation with IFNγ production (Figure 
2.14c and data not shown). When we compared the frequencies of CD62Llow cells 
among CD8+ T cells of infected mice, H2-Kb-MICA mice had a significantly reduced 
percentage of CD62Llow cells (20,0 ± 3,7 % and 32,8 ± 3,8 % in H2-Kb-MICA mice 
and littermate controls, respectively), revealing a general impairment of the anti-
Listeria CD8+ T cell response in H2-Kb-MICA mice. In contrast, listeria-specific CD4+ 
T cell responses were only marginally affected in H2-Kb-MICA mice. Compared to 
littermate controls, H2-Kb-MICA mice showed similar frequencies and only slightly 
reduced total numbers of CD4+ T cells responding to the immunodominant listeria 
epitope LLO190-201 (Figure 2.14d and data not shown). 
 
2.1.2.5 Discussion 
 
A hallmark of the NKG2D/NKG2DL-system is the inducible surface expression of at 
least some of the MHC class I-related NKG2DL in response to cell stress, microbial 
infection or malignant transformation, thereby marking dysfunctional cells for 
elimination by cytotoxic lymphocytes via NKG2D-mediated mechanisms (“induced-
self” hypothesis) [10,11,40]. Conversely, a sustained NKG2DL expression as 
described in patients with malignant or autoimmune diseases may desensitize 
NKG2D-mediated immune responses. Here, we analyzed transgenic mice 
constitutively expressing MICA to address functional consequences of persistent 
NKG2DL expression in vivo. MICA was chosen, because it is the bestcharacterized 
NKG2DL with regard to expression in normal and diseased tissues, regulation of 
expression and soluble release, and availability of biochemical and structural data 
[10,12]. Although the amino acid sequence of the MICA ectodomain is fairly 
divergent from any mouse NKG2DL, crystal structures of MICA and RAE1 α1/α2 
platform domains interacting with NKG2D are highly related as are crystal structures 
of human and mouse NKG2D ectodomains [41-43]. Structural homology is reflected 
in functional equivalence of MICA/B and RAE1 with regard to mouse NKG2D 
ligation and NKG2D-mediated activation of mouse NK cells qualifying MICA as a 
bona fide surrogate ligand of mouse NKG2D (Figure 2.8) [22,36]. MICA expression 
in H2-Kb-MICA mice generally parallels H2-Kb expression with a strong expression 
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by B and NK cells and an intermediate to low expression by thymocytes and 
hepatocytes. A disparate expression of Kb and MICA molecules was only observed for 
peripheral CD4+ and CD8+ T cells that remains to be addressed. MICA-expressing 
splenocytes were utilized to evaluate the efficiency of NKG2D-mediated activation of 
natural cytotoxicity in vivo. Hitherto, NKG2D-mediated cytotoxicity has been 
extensively demonstrated in vitro using tumor cell lines expressing NKG2DL. 
Previous studies also demonstrated that ectopic expression of NKG2DL by tumors 
induces strong NK and CTL responses in vivo, however, no direct evidence for an 
involvement of NKG2D-mediated cytotoxicity in the rejection of NKG2DL-
expressing tumor cells was provided [25, 26]. 
By adoptive transfer of MICA-expressing splenocytes, we here demonstrate that 
ectopic expression of NKG2DL renders “normal” syngeneic cells highly susceptible 
to cytotoxicity in vivo, vividly underscoring that NKG2DL-expression potently 
overrides inhibitory signals by MHC class I molecules for NK cell activation. 
 
To our surprise, H2-Kb-MICA mice were vital, fertile and did not exhibit any overt 
signs of autoimmunity in spite of a strong MICA surface expression. A previous study 
reported hyperkeratosis and leukocytosis in transgenic mice with a MICB cDNA 
under control of a chicken beta-actin promoter, but neither the underlying molecular 
cause nor functionality of NKG2D was analyzed [44]. The difference in phenotype of 
these mice as compared to the H2-Kb-MICA mice may be due to a different tissue 
expression of the MIC molecules though no evidence for MICB protein expression 
was provided by the authors. It turned out that in H2-Kb-MICA mice “tolerance” 
towards MICA expressing cells is established by downmodulation of NKG2D which 
is due to permanent exposure to MICA. In fact, downmodulation of surface NKG2D 
by NK cells after exposure to NKG2DL-expressing cells in vitro and in vivo has been 
previously reported [23,31]. It remains to be investigated whether a high local 
NKG2D ligand expression also leads to a systemic NKG2D down-regulation and 
dysfunction or rather stimulates local immune reactions. Previous studies on 
rejection of NKG2DL-expressing tumor cell lines and on the role of NKG2D in the 
pathogenesis of diabetes in NOD mice, respectively, suggest the latter [25,26,45]. 
 
A down-modulation of NKG2D has also been reported in human cancer patients, 
where tumors express and release substantial amounts of soluble MICA [28]. 
Interestingly, H2-Kb- MICA mice also contain high serum levels of sMICA that exceed 
levels observed in cancer patients at least tenfold [29] and thus is not a peculiarity of 
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malignant cells. This is in line with the detection of soluble MICA in patients with 
autoimmune diseases and raises the question whether MICA shedding is of 
physiological relevance, e. g. in regulating MIC cell surface levels. Characterization of 
the MIC- shedding activity may resolve this issue. Conflicting results exist regarding 
the down-regulation of NKG2D by soluble MICA. Whereas MICAcontaining sera of 
patients with malignancies reportedly cause systemic NKG2D downregulation 
correlating with reduced NKG2D expression on CD8+ T cells and NK cells in cancer 
patients [8,30,46], NKG2D surface expression is not altered in patients with 
rheumatoid arthritis and celiac disease in spite of similar sera levels of sMICA 
[17,18]. Our in vitro experiments indicate that NKG2D down-regulation in H2-Kb-
MICA mice is mainly due to engagement of cell-bound MICA as sMICA had little 
effect on NKG2D surface expression of non-transgenic NK cells. Possibly, MICA 
released from tumor cells and benign cells, respectively, may be subjected to different 
post-translational modifications differentially affecting NKG2D down-regulation. 
 
Irrespective of the exact molecular mechanism, our results now provide direct in vivo 
evidence that persistent MICA expression results in down-modulation of NKG2D and 
impacts tumor immunity as H2-Kb-MICA mice failed to reject MICA-expressing RMA 
cells in contrast to nontgLM or RAG2-deficient mice. Though our mouse model does 
not mirror the localized MICA expression by tumors, it does strongly support the 
notion that ligand-induced NKG2D down-modulation is detrimental for tumor 
immunosurveillance. 
In H2-Kb-MICA mice, down-modulation of surface NKG2D on NK cells was not 
complete raising the possibility that the observed dysfunction may in part also be due 
to an impaired signal transduction. However, lysis of CHO cells by H2-Kb-MICA NK 
cells was similar to lysis by non-transgenic NK cells suggesting that the DAP12 
signaling pathway is not affected. Upon in vitro cultivation, H2-Kb-MICA NK cells 
acquired higher NKG2D expression levels and regained functional activity 
demonstrating that NKG2D-ligand induced silencing of NKG2D is reversible. 
Failure to completely restore NKG2D surface expression levels may also be due to a 
MICA-NKG2D cis-interaction within same cells as postulated for activated NK cells 
from NOD mice [31]. In humans, MICA expression has also been reported for thymic 
epithelial cells raising the possibility that NKG2D is involved in thymic selection of T 
cells [47]. Since MICA costimulates T cells via NKG2D and represents a ligand of 
some human γδ TCR, constitutive MICA expression might also affect the generation 
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and/or expansion of lymphocyte subpopulations bearing NKG2D or γδ TCR 
[1,8,15,48,49]. However, we did not detect any major alterations in the total number 
or composition of lymphocyte subpopulations in naïve H2-Kb-MICA mice. In 
particular, numbers of splenic NK cells, CD8+ T cells and γδ T cells were not 
significantly altered as compared to nontgLM. Recently, a transgenic mouse with a 
gut-specific MICA expression directed by the T3b-promoter was described with 
expansions of CD4+CD8αα+ intraepithelial T cells [37]. But a functional involvement 
of NKG2D was not examined and also no other mechanisms presented that may 
account for this expansion. In H2-Kb-MICA mice, frequencies of CD4+CD8αα+ 
intraepithelial T cells did not significantly differ from nontgLM. 
 
Since H2-Kb-MICA mice exhibit a profound NKG2D dysfunction, we implemented 
these mice to address the relevance of NKG2D in staging immune responses towards 
infectious pathogens. Infection with Listeria monocytogenes was chosen, because 
Listeriae activate both innate and adaptive immune responses. Further, induction of 
RAE1-expression by macrophages incubated with L. monocytogenes has recently 
been reported [23]. When we compared the pathogen load of H2-Kb-MICA mice and 
nontgLM at days 2 and 3 postinfection, we found no significant differences, 
indicating that NKG2D dysfunction on NK cells had no major impact at an early 
stage of infection. However, NKG2DL expression induced by L. monocytogenes may 
trigger cytokine release by NK cells that in turn may contribute to the generation of an 
anti-Listeria specific T cell response. NK cells of H2-Kb-MICA mice showed an 
impaired IFNγ production upon NKG2D triggering ex vivo that may also result in a 
impaired anti-Listeria TH1 response in vivo. T cells are of major importance for the 
immune control and clearance of Listeria [39]. We analyzed the anti-Listeria T cell 
response at day 9 post-infection and found the number and frequency of Listeria-
specific CD8+ T cells strongly reduced in H2-Kb-MICA, while Listeria-specific CD4+ T 
cells were not affected. At present, it is unclear why the CD8+ T cell response is 
impaired in Listeria-infected H2-Kb-MICA mice. Down-regulation of NKG2D on 
activated CD8+ T cells may reduce costimulatory signals for proliferation and cell 
survival. In fact, it has been reported that NKG2D-mediated signal transduction via 
DAP10 also involves activation of the serine/threonine kinase Akt that promotes 
cellular proliferation [50]. Alternatively, an impaired activation of NK cells by 
NKG2D may result in reduced cytokine secretion and/or cell lysis generating a 
suboptimal TH1 response. 
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In summary, we demonstrate that the persistent expression of MICA results in a 
pronounced down-modulation of NKG2D on NK cells and activated CD8+ T cells in 
vivo. The resulting NKG2D dysfunction strongly impacts immunity against 
NKG2DL-expressing tumor cells and impairs the generation and/or expansion of 
Listeria-specific CD8+ T cells emphasizing an important function of NKG2D for 
immunity against tumors and intracellular pathogens. 
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2.2  Modulation of the innate immune system 
2.2.1 A CD14 domain with lipopolysaccharide-binding and -
neutralizing activity 
This chapter has been published in ChemBioChem 7(2): 275-286 (2006) by the 
following authors: 
 
Söhnke Voss, Stefan Welte, Mariola Fotin-Mleczek, Rainer Fischer, Artur J. Ulmer, 
Günther Jung, Karl-Heinz Wiesmüller and Roland Brock 
 
The author of this thesis performed the site-directed mutagenesis and contributed to 
the analysis of the CD14 mutants by flow cytometry. 
 
2.2.1.1 Abstract 
 
The interaction of lipopolysaccharide with CD14 plays a key role in signaling that 
activates an early defense against pathogens but also contributes to the development 
of sepsis and septic shock. Here we have mapped the entire 356-amino-acid protein 
with synthetic 20-amino-acid peptides and have identified a new lipopolysaccharide-
binding domain with a strong LPS-neutralizing activity. Moreover, analysis of the 
structure-activity relationship of this peptide, which corresponds to amino acids 81-
100 of human CD14, revealed that leucines 87, 91, and 94 are essential for these 
activities. The functional relevance of these residues was confirmed by cellular 
expression of mutant CD14 proteins that are no longer able to bind LPS. 
Furthermore, the peptide provided a basis for the generation of highly soluble analogs 
with stronger lipopolysaccharide-neutralizing activity. 
 
2.2.1.2 Introduction 
 
Release of lipopolysaccharide (LPS) from the cell walls of Gram-negative bacteria 
into the blood is a strong immunomodulatory stimulus. Low concentrations in blood 
produce moderate immune responses in healthy humans, but higher concentrations 
may induce massive release of cytokines, resulting in life-threatening disorders such 
as septic shock [1]. Once released from the bacterial cell wall, LPS is sequestered by 
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the serum protein lipopolysaccharide-binding protein (LBP), which transfers LPS to 
CD14 [2]. The endotoxin-CD14 complex binds a heterodimer consisting of Toll-like 
receptor 4 (TLR4) and the coreceptor MD-2 [3,4]. TLR4 belongs to a family of at 
least eleven receptors that mediate immune responses to a large number of diverse 
molecules of bacterial and viral origin. CD14 is a 55 kDa glycoprotein of 356 amino 
acids expressed both in a GPI-anchored and in a soluble form. The GPI-anchored 
form is preferentially expressed on cells of the myeloid lineage (i.e., monocytes, 
macrophages, and polymorphonuclear granulocytes) [5,6], whilst the soluble form 
(sCD14) plays a role in the LPS responses of endothelial and epithelial cells [7-9]. In 
addition to LPS, CD14 also binds a panel of components of Gram-negative and -
positive bacteria that are implicated in the initiation of signal transduction via TLR2. 
These components include lipoarabinomannan from Mycobacterium tuberculosis, 
peptidoglycan, lipoteichoic acid, and spirochetal outer membrane lipoproteins and 
lipopeptides [10-13]. For this reason, CD14 has been defined as a pattern recognition 
receptor in innate immunity [14]. 
 
Because of CD14s central role, several studies have focused on the identification of 
structural elements of this protein involved in ligand recognition and binding. It has 
been shown that the N-terminal part comprising amino acids 1-152 is sufficient for 
binding and for enabling cellular responses to LPS, both in the soluble and the 
membrane-bound forms [15,16]. Hydrophilic regions and amino acids within the N-
terminal portion were identified for serum-dependent binding of LPS to CD14 
through the construction of a series of single and combined deletion mutants of 
membrane-anchored CD14 [17], although only one of these mutations affected the 
LPS-binding of sCD14 in a further study [18]. Because of these discrepancies, the 
authors proposed that different structural determinants may contribute to LPS 
receptor function in the soluble and the membrane-anchored forms of CD14. The 
involvement of individual hydrophilic amino acids within the N-terminal 66 amino 
acids in the binding of soluble CD14 to LPS was further investigated by serine 
replacement and charge reversal [19,20], but only charge reversal of these amino acid 
side chains abolished the function of the protein. Amino acids 57 to 64 were found to 
be protected by LPS from the action of Asp-N protease and chymotrypsin, and 
deletion of this particular region resulted in a nonfunctional mutant that neither 
bound LPS nor triggered cellular responses to LPS [21,22]. Evidence for a 
contribution to LPS-binding by amino acids 39 to 44 was obtained from a mutant in 
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which all these amino acids were exchanged for a stretch of alanine residues [23]. 
Alternatively, a further study suggested that the LPS-binding site might be a 
conformational epitope comprising several other regions of the protein [24]. 
Furthermore, one report showed that amino acids 9 to 13 and 91 to 101 participate in 
sCD14-mediated signaling, though not for all of the tested immunologically relevant 
cell types [25]. In summary, in spite of these investigations, many questions on the 
function of CD14 still remain. 
 
Synthetic peptides corresponding to parts of a protein offer an alternative strategy for 
the identification of ligand-binding domains. Peptides derived from Tachypleus anti-
LPS factor [26], Limulus anti-LPS factor (LALF) [27,28], bactericidal/permeability 
increasing protein (BPI) [29], human cationic antibacterial protein of 18 kDa 
(hCAP18) [30,31], lactoferrin [32], LPS-binding protein [33], as well as the peptide 
antibiotic polymyxin B [34] have been identified as endotoxin-binding and -
neutralizing agents. A structural comparison of these LPS-binding peptides and 
further analyses of structure-activity relationships showed that an amphiphilic 
structure with a net positive charge together with a considerable hydrophobicity are a 
general characteristic of these molecules. The spatial organization of the positive and 
hydrophobic moieties determines the LPS-binding and -neutralizing activity [35-37]. 
It can be assumed that the positively charged amino acid residues interact with the 
negatively charged moieties of the LPS, such as the phosphate groups, whereas 
hydrophobic amino acids may bind to the fatty acid chains of LPS [38]. 
 
LPS-binding molecules might possess potential as drugs for the treatment of sepsis 
and septic shock and for the generation of affinity reagents for the removal of LPS 
from the bloodstream [31,39-41]. Analyses of structure-activity relationships of LPS-
binding peptides that contribute to an understanding of the mode of binding are 
therefore highly relevant for the generation of optimized LPS-neutralizing agents. 
 
Here we present the identification of an LPS-binding domain of CD14, obtained from 
a mapping of the full-length 356-amino-acid protein with 20-amino-acid peptides. 
This domain includes leucine residues 87, 91, and 94 of human CD14, which are 
shown to be essential for the LPS-binding activity of the protein. The corresponding 
peptide, comprising amino acids 81 to 100, is sufficient to bind and neutralize LPS. 
Analysis of the structure-activity relationship of this peptide resulted in the rational 
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design of some LPS-neutralizing analog with improved activity. 
 
2.2.1.3 Materials and Methods 
 
Reagents. Lipopolysaccharide (phenol-extracted and purified by ion-exchange 
chromatography) and fluorescein isothiocyanate- labeled lipopolysaccharide (FITC-
LPS), both from E. coli serotype O111:B4, lipopolysaccharides from Pseudomonas 
aeroginosa, Klebsiella pneumoniae, Salmonella friedenau, Salmonella typhimurium 
and Rd-LPS from E. coli, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) and phorbol 12-myristate 13-acetate (PMA) were obtained from 
Sigma (Taufkirchen, Germany), Limulus amebocyte lysate assay from BioWhittaker 
(Walkersville, MD, USA). Fmoc amino acids were purchased from Novabiochem 
(Laufelfingen, Switzerland), Senn Chemicals (Dielsdorf, Switzerland) and Orpegen 
Pharma (Heidelberg, Germany). The isomeric mixture of 5(6)-carboxyfluorescein 
was obtained from Fluka (Deisenhofen, Germany). G418 was obtained from Gibco 
(Karlsruhe, Germany), and hygromycin from PAN Biotech (Aidenbach, Germany). 
Standard chemicals were purchased from Fluka and Merck (Darmstadt, Germany). 
 
Peptide synthesis and labeling. Parallel peptide amide synthesis was performed by 
solid-phase Fmoc/tert-butyl chemistry with use of an automated peptide synthesizer 
for multiple peptide synthesis (Syro, MultiSynTech, Bochum, Germany) by a 
procedure described elsewhere [59,60] Peptide amides were synthesized on Rink 
amide resin (Rapp Polymere, Tübingen, Germany). N-Terminal labeling of the 
peptide amides with 5(6)-carboxyfluorescein was performed on the resin as 
previously described [42] Conjugation of biotin to N termini of resin-bound peptides 
was performed with biotin (5 equiv), 2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium tetrafluoroborate (5 equiv), 1-hydroxybenzotriazole (5 equiv) 
and N,N-diisopropylethylamine in N-methylpyrrolidone (10 equiv) for 16 h. 
Completeness of all labeling was confirmed by Kaiser test [61]. 
 
Cell culture. The human myelomonocytic cell line THP-1 was obtained from the 
Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, 
Braunschweig, Germany) [62]. The cells were cultured in RPMI 1640 medium (PAN 
Biotech) supplemented with FCS (10 %, PAN Biotech) in a humidified CO2 
atmosphere (5 %) at 37 °C. HEK 293T cells were cultured in IMDM (PAN Biotech) 
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supplemented with FCS (10 %). The engineering of the CD14-expressing Chinese 
hamster ovary (CHO)-K1 reporter cell line CHO/CD14/TLR2.elam.tac has been 
described previously [63]. The cells were grown in RPMI 1640 medium containing 
FCS (10 %), G418 (400 g ml-1) and hygromycin B (400 units ml-1). Adherent cells 
were harvested with trypsin/EDTA (Biochrom, Berlin, Germany). Cells were 
passaged every third to fourth day. 
 
ELISA. THP-1 cells were incubated with peptides at the indicated concentrations for 
10 min at 37 °C. LPS (20 ng ml-1) was added to the samples, and after 5 h cell-free 
supernatants were collected and frozen at -80 °C. The supernatants were analyzed by 
a human IL-8-specific ELISA (clone G265-5 and clone G265-8, BDPharMingen, San 
Diego, CA, USA) or a human TNFα-specific ELISA (clone MAb1 and clone MAb11, 
BDPharMingen) according to protocols provided by the manufacturer. To render 
THP-1 cells competent for LPS-induced TNFα secretion, they were treated with 
phorbol 12-myristate 13-acetate (PMA; 30 ng ml-1) for 72 h at 37 °C prior to addition 
of peptides [64]. 
 
Cell viability assay. After removal of the supernatant (120 μl) for ELISA, cells were 
incubated with MTT (1 mg ml-1) for 4 h. The formazan product was solubilized with 
SDS [10 % (m/v) in HCl (10 mM)]. Cell viability was determined by measuring the 
absorbance of each sample at 570 nm with the microplate reader. 
 
Detection of FITC-LPS-binding to biotinylated bead-immobilized peptides by 
laser scanning microscopy. A suspension of high-performance streptavidin-
Sepharose in ethanol (20 %, v/v, 100 μl; Amersham Bioscience, Uppsala, Sweden) 
was washed three times with phosphate-buffered saline (PBS) and resuspended in 
PBS (1 ml). Biotinylated peptides (20 μM) were incubated with the streptavidin-bead 
suspension for 60 min at 4 °C on a shaker. Unbound peptides were removed by 
washing the beads three times with PBS, and the beads were subsequently 
resuspended in PBS (350 μl). This suspension (50 μl) was further diluted with PBS 
(950 L). FITC-LPS was solubilized (2 mg ml-1) by sonication for 5 min at 50 °C and 
FITC-LPS (2 μg/ml) was incubated with the bead suspension for a further 60 min on 
a shaker at 4 °C. For competition experiments FITC-LPS was incubated with the 
beads in the presence of an unlabeled LPS-binding peptide (2 and 20 μM) or a 50-fold 
excess of unlabeled LPS. Subsequently the beads were washed three times with 
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PBS/Tween 20 (0.2 %, v/v) and imaged by laser scanning microscopy with an 
inverted LSM510 microscope (Carl Zeiss, Göttingen, Germany) fitted with a Plan-
Apochromat 63×1.4 N. A. objective. Fluorescein was excited with a 488 nm argon-ion 
laser. Fluorescence was detected with a BP 505-550 nm band pass filter. 
 
Inhibition of the Limulus amebocyte lysate response to LPS. LPS (2 endotoxin 
units per ml) was prepared according to the manufacturer’s protocol in endotoxin-
free water. Peptide amides were prepared at varying concentrations in endotoxin-free 
water and the respective peptide amide solution was mixed with the LPS solution at a 
ratio of 1:1 in a 96-well microtiter plate (Becton Dickinson, Franklin Lakes, NJ, USA) 
and incubated at 37 °C on a shaker. After 45 min Limulus amebocyte lysate (25 μl, 
Quantitative Chromogenic LAL Kit, Whittaker Bioproducts, Walkersville, USA) was 
added to each well and incubation was continued for a further 15 min. Chromogenic 
substrate (50 μl), prepared according to the manufacturer’s specifications, was then 
added and the reaction was stopped after 10 min by addition of acetic acid (100 μl, 25 
% v/v) to each well. Absorbance at 405 nm was determined with a microplate reader. 
 
Inhibition of cellular binding of FITC-LPS by CD14-derived peptide amides. 
RPMI 1640 (200 μl), containing FITC-conjugated LPS (1.2 μg ml-1), was incubated 
either in the absence or in the presence of CD14-derived peptide amides for 5 min at 
37 °C. Subsequently, this mixture (50 μl) was added to CHO-CD14 cells (1×106 cells 
per mL in 100 μl serum-containing RPMI 1640) in a 96-well plate. After incubation, 
cells were washed twice with ice-cold medium, detached by trypsinization, suspended 
in ice-cold PBS and washed once in ice-cold PBS. Binding of FITC-conjugated LPS to 
the cells was analyzed by flow cytometry (BD FACSCalibur System, Becton 
Dickinson, Heidelberg, Germany). In each case, the median fluorescence intensity of 
8000 vital cells was determined. Vital cells were gated on the basis of sideward and 
forward scatter. 
 
CD spectroscopy. CD spectra were measured on a JASCO J-720 dichrograph 
spectrometer (Jasco, Easton, MD, US). Stock solutions of the peptide amides (1 mM) 
were prepared in 1,1,1,3,3,3-hexafluoropropan-2-ol. CD spectra of peptides (10 μM) 
were recorded either in sodium phosphate buffer (10 mM, pH 7.4) or in sodium 
phosphate buffer (10 mM, pH 7.4) diluted with trifluoroethanol (TFE, 20 % v/v) at 
room temperature from 195 to 250 nm at 0.2 nm intervals, with a spectral band width 
of 1 nm and a scan speed of 20 nm min-1. The spectra were corrected for buffer alone 
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and the mean residue molar ellipticity ([Θ]) was plotted versus wavelength. The 
fractional helical content was estimated by using the spectral deconvolution method 
JFIT provided by Dr. B. Rupp (Lawrence Livermore National Laboratory, Livermore, 
CA, USA). 
 
Site-directed mutagenesis. The full-length CD14 ORF was cloned into the pcDNA3 
vector. Site-directed mutagenesis was performed with the QuikChange II site-
directed mutagenesis kit (Stratagene Europe, Amsterdam, NL) according to the 
manufacturer’s instructions with use of the following primers: 5-
ctcagctaccggtaggcgccccgcgtgtgccagcgtactc-3 and 5-gagtacgctggcacacgcgggg 
cgcctaccggtagctgag-3 for the triple L to P exchange, and 5-
ctcagctacaggtaggcgcccagcgtgtgcaagcgtactc-3 and 5-gagtacgcttgcacacgctgggcg 
cctacctgtagctgag-3 for the triple L to Q exchange (obtained from biomers.net, Ulm, 
Germany). The correct sequences were verified by sequencing. The plasmid DNA was 
purified by use of the Endofree Plasmid Maxi Kit from Qiagen (Hilden, Germany). 
 
Analysis of the binding of FITC-LPS to HEK 293T cells expressing wild-type and 
mutant CD14. For transfection, HEK 293T cells were harvested with trypsin/EDTA, 
washed with medium and suspended in medium containing the indicated plasmid. 
Cells (2×106 cells per ml) were electroporated in 4 mm cuvettes (Peqlab, Erlangen, 
Germany), with use of a 15 millisecond pulse (330 V and 1700 μF maximal 
resistance; Fischer Electroporator, Heidelberg, Germany). After electroporation, cells 
were incubated in cuvettes for a further 30 min and seeded in 6-well plates (Sarstedt, 
Nümbrecht, Germany, 500 000 cells per well) or in 8-well chambered cover glasses 
(Nunc, Wiesbaden, Germany; 40 000 cells per well), for further analysis. For flow 
cytometry, cells were trypsinized after 16 h at 37 °C and seeded in 96-well plates in 
serum-containing RPMI 1640 (100 000 per well). Cells were washed with medium, 
resuspended in medium (200 μl) containing FITC-LPS (1 g ml-1), and incubated for 1 
h at 4 °C. Subsequently, cells were washed three times with medium, followed by 
incubation in ice-cold PBS/BSA (0.1 % v/w, 50 μl) containing a polyclonal sheep 
anti-human CD14 antibody (R&D Systems, Minneapolis, MN, USA; 5 g ml-1) for 1 h 
at 4 °C. After washing three times in ice-cold PBS/BSA, cells were incubated with 
PBS/BSA (50 μl) containing a phycoerythrin-conjugated donkey anti-sheep 
secondary antibody (Dianova, Hamburg, Germany; 1:100 dilution), for 1 h at 4 °C. 
After washing, cells were suspended in ice-cold PBS/BSA and measured immediately 
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by flow cytometry. In each case, the fluorescence of 10 000 vital cells was acquired. 
For confocal microscopy, electroporated HEK 293T cells were seeded in 8-well 
chambered cover glasses (40 000 per well). One day later, cells were washed once 
with serum-containing RPMI 1640, followed by incubation with medium containing 
FITC-LPS on ice and stained for CD14 by indirect immunofluorescence with use of 
the same reagents as described above. After staining, living cells were imaged 
immediately. For double detection of FITC-LPS and phycoerythrin-labeled antibody 
the 488 nm line of an argon ion laser and the light of a 543 nm helium/neon laser 
were directed over an HFT UV/488/543/633 beam splitter and fluorescence was 
detected with an NFT 545 beam splitter in combination with a BP 505-530 band pass 
filter for fluorescein detection and a BP 560-615 band pass filter for phycoerythrin 
detection. 
 
2.2.1.4 Results 
 
Screening of overlapping 20-amino-acid peptides for inhibition of LPS-induced 
IL-8 production in THP-1 cells. 
To identify functional domains of human CD14 that would interfere with LPS-
dependent signaling, the entire mature 356-amino-acid protein was covered by 35 
synthetic 20-amino-acid peptides with 10-amino-acid overlaps. All peptides were 
synthesized as 5(6)-carboxyfluorescein-labeled (Fluo-labeled) peptide amides by 
parallel solid-phase peptide synthesis based on 9-fluorenylmethoxycarbonyl (Fmoc) 
chemistry. N-Terminal coupling of carboxyfluorescein was performed by use of 
optimized procedures for the parallel labeling of peptide collections with reproducible 
and uniform yields [42]. Labeling with carboxyfluorescein: i) allowed the reliable 
determination of peptide concentrations from the absorption of the fluorophore, and 
ii) enabled the detection of potential interactions with living cells by fluorescence 
microscopy and flow cytometry. Except for the peptide corresponding to amino acids 
21 to 40, all peptides were obtained in purities exceeding 75 % as determined by 
reversed-phase HPLC. For some of the more hydrophobic peptides, precipitate 
formation was observed upon dilution of dimethyl sulfoxide (Me2SO) stock solutions 
into aqueous buffers. This problem was circumvented by first diluting the Me2SO 
stock solutions 1:10 in tert-butyl alcohol/H2O (4:1) followed by dilution in aqueous 
buffers to the working concentrations. 
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Figure 2.15. Inhibition of LPS-induced IL-8 secretion in THP-1 cells by 20-amino-acid 
peptide amides derived from human CD14. (A) Mapping of the entire human CD14 protein. 
Despite the use of several synthetic approaches, peptide CD14 (21-40) was not obtained in 
sufficient purity (>75 %). The individual 20 amino acid peptide amides are specified by their 
amino acid positions. After 10 min incubation with fluorescein-labeled peptide amides (10 μM), 
cells were treated with LPS (20 ng ml-1) for 5 h in the presence of peptide amides. (B) Fine 
mapping of the region covering amino acids 73 to 108 of human CD14. (C) Concentration 
dependence of the inhibitory activity of CD14 (81-100). (D) To identify residues critical for CD14 
(81-100) activity, fluorescent peptide amides with single alanine substitutions were screened for 
their ability to inhibit the IL-8 production of LPS-stimulated THP-1 cells. The secretion of IL-8 
was detected by ELISA in cell-free supernatants. The LPS-induced IL-8 secretion is shown in 
relation to a sample incubated with buffer only containing solvent at a concentration 
corresponding to the one of the peptide-containing samples and stimulated with LPS. Error bars 
represent the standard deviation of triplicates in one representative experiment. 
 
Peptides were tested for their ability to interfere with IL-8 secretion induced by LPS 
serotype O111:B4 from E. coli in human monocyte-derived THP-1 myelomonocytic 
leukaemia cells. At a concentration of 10 μM, one peptide - corresponding to amino 
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acids 81 to 100 of human CD14 - reduced the secretion of IL-8 by 80 %. All other 
peptides exhibited no significant inhibitory activity (Figure 2.15A). 
For fine mapping of this functional domain of the protein, a further set of eight 20-
amino-acid peptides - covering amino acids 73 to 108 with 18-amino-acid overlaps -  
was synthesized. This second scan again confirmed CD14 (81-100) as the most active 
peptide (Figure 2.15B) and the inhibitory effect was concentration-dependent 
(Figure 2.15C). Viability of cells was fully preserved for all peptides, as determined by 
an MTT-assay (data not shown). 
 
 
 
Figure 2.16. LPS-binding by CD14 (81-100). Incubation of streptavidin beads loaded with 
biotinylated CD14 (81-100) with: (A) FITC-LPS (2 μg ml-1), (B) coincubation with FITC-LPS 
and 150 μg ml-1 unlabeled LPS, and coincubation with (C) 20 μM or (D) 2 μM unlabeled peptide 
31 (Table 2.1). The specificity of LPS binding was confirmed by (E) incubation of peptide-free 
streptavidin beads with FITC-LPS and (F) incubation of streptavidin beads loaded with 
biotinylated peptide CD14 (171-190) with FITC-LPS. Beads were analyzed by fluorescence 
microscopy. The scale bar corresponds to 200 μm. 
 
Residues important for the inhibitory capacity of CD14 (81-100) were identified by 
performing an alanine scan through the entire 20-amino-acid sequence (Figure 
2.15D). When the leucine residues at positions 11 and 14, corresponding to positions 
91 and 94 in mature CD14, were replaced by alanine residues the ability of the peptide 
to inhibit the LPS-induced IL-8 secretion was almost or fully lost. In peptides mutated 
at the amino acids at positions 6, 7, 9, 12, and 16-20, the capacity to inhibit LPS-
induced IL-8 secretion was 50 to 70 % of that of the most active peptide. In contrast, 
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exchange of amino acids 1-3, 5, 8, and 13 by alanine residues did not affect the 
activity. 
 
Mode of action of CD14 (81-100). 
To clarify whether the inhibitory activity of CD14 (81-100) was associated with an 
interaction between the peptide and components of the plasma membrane, THP-1 
cells were tested for binding of the fluorescein-labeled analog by confocal laser 
scanning microscopy and flow cytometry. However, no binding of the analog to the 
cell surface could be detected (data not shown). 
We next investigated whether CD14 (81-100) exerted its inhibitory activity on IL-8 
secretion through direct interaction with LPS. An analog of CD14 (81-100), N-
terminally elongated with two 8-amino-3,6-dioxaoctanoic acid spacer moieties and 
biotin, was synthesized and bound to streptavidin-conjugated Sepharose beads. The 
interaction of LPS with the peptide was then investigated by incubation of 
fluorescein-labeled LPS with beads loaded with CD14 (81-100; Figure 2.16A). 
 
Table 2.1. Fluorescein-labeled and acetylated peptide amide analogs of CD14 (81-100). 
Peptides 11-24 represent analogs with enhanced solubility and amphipathicity relative to the 
native sequence. In the peptide amides 23 and 24, the leucine residues at positions 11 and 14 
were replaced by alanine residues in order to confirm the significance of these residues for the 
LPS-neutralizing activity. 
 
 
Peptide 
 
 
Sequence 
 
Peptide 1 Fluo-QVPAQLLVGALRVLAYSRLK-NH2 
Peptide 11 Fluo-QVPAKLLVKALRKLAYKRLK-NH2 
Peptide 12 Fluo-QVPAKLLVEALRKLAYERLK-NH2 
Peptide 13 Fluo-QVPAELLVKALRELAYKRLE-NH2 
Peptide 14 Fluo-QVPAELLVEALRELAYERLE-NH2 
Peptide 21 Fluo-QVPAQLLVGALRVLAYSRLKKKKK-NH2 
Peptide 22 Fluo-QVPAQLLVGALRVLAYSRLKEEEEE-NH2 
Peptide 23 Fluo-QVPAQLLVGAARVLAYSRLKKKKK-NH2 
Peptide 24 Fluo-QVPAQLLVGALRVAAYSRLKKKKK-NH2 
Peptide 30 Ac-QVPAQLLVGALRVLAYSRLK-NH2 
Peptide 31 Ac-QVPAKLLVKALRKLAYKRLK-NH2 
Peptide 32 Ac-QVPAKLLVKAARKLAYKRLK-NH2 
Peptide 33 Ac-QVPAKLLVKAARKAAYKRLK-NH2 
Peptide 34 Ac-QVPAKLLVKAQRKLAYKRLK-NH2 
Peptide 35 Ac-QVPAKLLVPALRKLAYKRLK-NH2 
Peptide 36 Ac-QVAAKLLVKALRKLAYKRLK-NH2 
Peptide 37 Ac-QVPAQLLVGAARVLAYSRLK-NH2 
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Figure 2.17. Binding of LPS to HEK 293 T cells expressing wild-type and mutated CD14. (A) 
Wild-type CD14, (B) CD14 [Leu87, 91, 94 Gln], and (C) [Leu87, 91, 94 Pro] were expressed in 
HEK 293T cells, and binding of FITC-LPS was determined by flow cytometry and fluorescence 
microscopy. (D) Cells electroporated with the vector alone served as a negative control. 
Electroporated cells were seeded at a density of 100 000 per well in 96-well plates or 40 000 cells 
per well in 8-well chambered cover glasses for analysis by flow cytometry or confocal laser 
scanning microscopy, respectively. Cells were incubated with FITC-LPS (1 g ml-1) for 1 h at 4 °C 
and were then incubated with a polyclonal sheep anti-human CD14 antibody (5 μg ml-1), 
followed by incubation with a phycoerythrin-conjugated donkey anti-sheep antibody (1:100 
dilution) for 1 h in each case. Dot plots of phycoerythrin-fluorescence versus fluorescein 
fluorescence of cells analyzed by flow cytometry and confocal microscopy images of HEK 293T 
cells expressing the wild-type or mutant proteins are shown. The scale bar represents 20 μm. The 
cell-associated fluorescence is given in arbitrary units. 
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Validation of the LPS-binding site in the full-length protein. 
The alanine scan suggested that leucine residues are required for the LPS-binding 
activity in the CD14-derived peptide. We next investigated whether this domain, and 
especially the leucine residues, contribute to the LPS-binding domain of the entire 
protein. Mutant CD14 proteins in which the relevant leucine residues had been 
replaced by either glutamine or proline residues were therefore expressed in HEK 
293T cells, and binding of FITC-LPS was analyzed by flow cytometry and confocal 
laser scanning microscopy (Figure 2.17).  
 
Cells expressing the wild-type CD14 protein bound FITC-LPS efficiently, whereas 
cells expressing the mutant CD14 proteins at comparable levels did not show any 
LPS-binding capacity. Cells expressing high levels of the mutant proteins at the 
plasma membrane were specifically investigated by confocal laser scanning 
microscopy. Again, no binding of FITC-LPS was detected, demonstrating that the 
exchange of these residues had abolished LPS binding. 
 
LPS-neutralizing activity of higher-solubility derivatives of CD14 (81-100). 
LPS-binding peptides derived from LPS-binding proteins represent a valuable source 
of LPS-neutralizing agents with therapeutic potential. However, CD14 (81-100) 
exhibited only poor solubility, so we sought to generate analogs of CD14 (81-100) 
with improved solubility in aqueous buffers. Two different strategies to enhance 
peptide solubility were pursued: i) C-terminal elongation of the peptide with a 
tetralysine or a pentaglutamic acid stretch, and ii) replacement of uncharged amino 
acids within the peptide by lysine and glutamic acid residues. The results of the 
alanine scan (Figure 2.15D) suggested that the amino acids at positions 5, 9, 13, and 
17 should be exchangeable with minimum loss of biological activity. A total of four 
internally substituted analogs with either lysine or glutamic acid residues in all four 
positions or with alternating substitutions of lysine/glutamic acid or glutamic 
acid/lysine residues were synthesized (Table 2.1). The substitutions markedly 
increased the solubilities of all peptides, so that concentrations up to 50 μM could be 
tested in aqueous buffers. However, only for the peptide in which all residues had 
been substituted by lysine residues (peptide 11) and the peptide with the C-terminal 
tetra-lysine stretch (peptide 21) were the capacities to inhibit IL-8 secretion preserved 
or even improved (Figure 2.18A,B). For the latter an IC50 value of about 500 nM and 
a maximum inhibition of 80 % at a concentration of 1 μM were determined, whilst for 
peptide 11, with the internal lysine substitutions, IL-8 secretion was  
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Figure 2.18. LPS-neutralizing activities of CD14 (81-100) analogs with increased solubility. 
The peptides were tested for their abilities to suppress LPS-induced IL-8 secretion in THP-1 cells 
(A,B) and LPS-induced TNFα-secretion in THP-1 cells differentiated with PMA (C,D). After 
incubation with varying concentrations of fluorescent peptide amides (10 min), cells were 
stimulated with LPS (20 ng ml-1) for 5 h. The higher toxicities of the analogs with substitutions 
within the peptide (peptides 11-14) precluded testing of concentrations above 1 μM. The symbols 
correspond to the following fluorescent peptide amides (see Table 2.1): peptide 11: ○; peptide 
12: ◊; peptide 13: □; peptide 14: Δ; peptide 21: ▲; peptide 22: x; peptide 23: ♦; peptide 24: ■. Error 
bars represent the standard deviations of triplicates. (E) Inhibition of the endotoxin-induced LAL 
reaction by acetylated peptide amide analogs of CD14 (81-100). Increasing concentrations of 
peptide amides were incubated with LPS (1 endotoxin unit) for 45 min and subsequently the LAL 
reaction was performed. Absorbance was quantitated at a wavelength of 405 nm. Symbols 
correspond to the following acetylated peptide amides (Table 2.1): peptide 31: ♦; peptide 32: ■; 
peptide 33: ▲; peptide 34: ●; peptide 35: ; peptide 36: x. (F) Inhibition of the LAL reaction 
induced by P. aeroginosa, K. pneumoniae, S. friedenau, S. typhimurium and E. coli Rd-LPS and 
O111:B4 LPS by the acetylated peptide amide analog of CD (81-100) with enhanced solubility. 
Peptide 31 (50 μM) was incubated with LPS (2 endotoxin units) for 45 min prior to the LAL 
reaction. The activity in the LAL assay for various LPSs in the presence of peptide in relation to 
the activity in the absence of peptide is shown. Error bars represent mean deviations of 
triplicates. 
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inhibited by 50 % at a concentration of 1 μM. In agreement with the results of the 
alanine scan, lysine-elongated analogs containing alanine substitutions of leucine 
residues at positions 11 (peptide 23) or 14 (peptide 24) exhibited significant 
decreases in antagonistic activity in the applied concentration range. 
In view of the significance of TNFα in the clinical progression of septic shock [43, 
44], the analogs with higher solubilities were also tested for their capacity to inhibit 
the secretion of this cytokine. Peptides 11 and 21 inhibited LPS-induced TNFα-
secretion in a dose-dependent manner (Figure 2.18C,D). Consistently with the 
results obtained for the inhibition of IL-8 induction, the introduction of negative 
charges within the peptide (peptides 12, 13, and 14) or at the C terminus (peptide 22) 
abolished the antagonistic activity. Substitution of the leucine residues at positions 11 
(peptide 23) and 14 (peptide 24) reduced but did not fully abolish the inhibitory 
activity of the peptides. 
 
To validate the LPS-neutralizing capacity of the CD14-derived peptides by a further 
well established assay, the chromogenic Limulus amebocyte lysate (LAL) assay was 
performed. Initial experiments had shown that peptide concentrations in the lower to 
mean micromolar range were required to determine the activity in the LAL test, so 
this analysis was restricted to the analogs with higher solubility containing lysine 
substitutions at positions 5, 9, 13, and 17. To exclude disturbance of the readout of 
the LAL test by the fluorescein moiety, all peptides for this study were N-terminally 
acetylated instead of fluorescein-labeled (Table 2.1). 
Unlike in the native sequence, the substitution of a relevant leucine residue at position 
11 by an alanine residue (peptide 32) in this assay did not decrease the antagonistic 
activity. However, when both relevant leucine residues at positions 11 and 14 were 
replaced by alanine residues (peptide 33), a decrease in activity of about 50 % was 
observed. Both the exchange of the leucine residue at position 11 for a glutamine 
residue (peptide 34) and the exchange of a lysine residue for a proline residue at 
position 9 (peptide 35) resulted in complete loss of activity in the tested concentration 
range of up to 50 μM. In contrast, substitution of the naturally occurring proline 
residue at position 3 by an alanine residue (peptide 36) increased the activity more 
than twofold, yielding an IC50 of about 10 μM (Figure 2.18E). 
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Inhibition of the cellular binding of FITC-LPS by CD14-derived peptides 
To define the inhibitory mode of action of the CD14-derived peptides further, we 
lastly determined whether these peptides prevented LPS from binding to cells or 
whether the LPS-peptide complexes could still bind but failed to activate the receptor. 
For this purpose CD14-expressing CHO cells were incubated with FITC-conjugated 
LPS in the presence or absence of CD14-derived peptides, and the cell-associated 
fluorescence was determined by flow cytometry. Peptide amides 30, 31, and 36 
reduced the binding of FITC-LPS by 70 to 80 % at concentrations of 16, 6.5, and 2.5 
μM respectively (Figure 2.19A). Peptides with enhanced amphipathicity (peptides 
31 and 36) were more efficient than the peptide corresponding to the native sequence 
(peptide 30) in inhibiting the binding of FITC-LPS. The highest activity was again 
observed for the peptide in which the proline residue at position 3 had been 
exchanged for an alanine residue (peptide 36). In contrast, peptides 34 (Leu11 to 
Gln) and 35 (Lys9 to Pro) at concentrations of 2.5 μM had no inhibitory effect 
(Figure 2.19B). 
 
 
 
Figure 2.19. Effects of CD14-derived acetylated peptide amides on the binding of FITC-LPS 
to CHO-CD14 cells. Cells were incubated with FITC-LPS (400 ng ml-1) in the presence of: (A) 
peptide 30 (15 μM), peptide 31 (6.5 μM), peptide 36 (2.5 μM), or (B) peptides 34-36 (2.5 μM) for 
2 h at 37 °C. For peptides 30, 31, and 36 the concentrations of the individual peptides were 
selected according to their ability to inhibit the binding of FITC-LPS by 70 to 80 %. After the cells 
had been washed twice with medium, trypsinized and washed once with PBS, fluorescence was 
determined by flow cytometry. Columns represent median fluorescence of vital cells in the 
presence of peptide and FITC-LPS relative to cells treated only with FITC-LPS. Error bars 
represent the mean deviations of duplicates. 
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Determination of peptide conformation by CD spectroscopy 
An α-helical conformation is a prerequisite for the alignment of the leucine side 
chains required for the LPS-neutralizing activity of the peptide on one face of the 
molecule. Circular dichroism measurements allowed estimations of the α-helical 
contents of these peptides. In phosphate buffer, peptides 30 (native sequence), 31 
(more soluble analog), and 37 (leucine residue in position 11 substituted by an 
alanine) possessed little secondary structure, as evidenced by negative ellipticity at 
200 nm (Figure 2.20A). Addition of 20 % (v/v) TFE, an organic solvent often used as 
a membrane mimetic, strongly increased the estimated α-helix contents to 52, 64, 
and 62 % for peptides 30, 31, and 37, respectively. The CD spectra of the individual 
peptides were almost indistinguishable from each other (Figure 2.20B). The reduced 
hydrophobicity and enhanced amphipathicity of peptide 31 only slightly enhanced 
the α-helical content relative to the native sequence. These results indicate that the 
lower activities of the peptides with leucine to alanine residue exchanges were not due 
to structural effects but rather to loss of molecular contacts required for tight binding 
of LPS. 
 
 
 
Figure 2.20. Secondary structures of CD14 (81-100) and analogs in solution. The secondary 
structures of CD14-derived peptides were determined by CD spectroscopy. Far UV-CD spectra of 
three CD14-derived acetylated peptide amides are shown as mean residue molar ellipticity ([Θ]) 
versus wavelength (nm). The spectra were recorded at peptide concentrations of 10 μM at room 
temperature: (A) in 10 mM sodium phosphate buffer, pH 7.4, or (B) in 10 mM phosphate buffer 
to which TFE had been added to 20 % (v/v). 
 
2.2.1.5 Discussion 
 
LPS-binding domain of CD14 
Mapping of the full-length human CD14 protein with synthetic 20-amino-acid 
peptide amides overlapping by 10 amino acids identified a single peptide amide with 
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LPS-neutralizing activity, corresponding to amino acids 81-100 of the mature 
protein. By using peptide-functionalized Sepharose beads it was shown that this 
peptide binds FITC-LPS from E. coli serotype O111:B4. A crystal structure of murine 
CD14, obtained in the absence of ligand, was recently published [45]. Amino acids 
82-94 comprise an α-helix with one side oriented towards an intramolecular pocket 
and the other side directed outwards. Analysis of the structure-activity relationship of 
the peptide revealed that the leucine residues corresponding to residues 87, 91, and 
94 are required for biological activity. These residues are all located on the side of the 
helix facing into the interior of the protein. The physiological significance of these 
residues for binding of LPS was confirmed by the failure of mutant proteins in which 
these residues had been exchanged for either glutamine or proline residues to bind 
LPS. Our peptide mapping approach therefore provides strong evidence that the 
LPS-binding domain of CD14 is located in the interior of the protein and identifies 
residues directly involved in binding of LPS (Figure 2.21). 
 
 
Figure 2.21. Structure of murine CD14. Residues 81-100, comprising helix 4, are in green, 
whilst side chains of leucine residues 87, 91 and 94 are highlighted in red. The leucine side chains 
point into the N-terminal pocket, which represents a putative LPS-binding site of the protein. 
 
Several studies have focused on the identification of LPS-binding and -signal-
transducing domains of human CD14. The failure to detect the LPS-binding activity 
of amino acids 81 to 100 previously may be due to the different strategies applied for 
the identification of the binding sites. For an LPS-binding domain formed by several 
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separate binding sites, limited mutation of only one site may only slightly affect the 
affinity of the entire protein. Through our analysis of the structure–activity 
relationship for the peptide we have been able to identify amino acids involved in LPS 
binding and to confirm their relevance for the full-length protein by simultaneous 
site-specific mutation for amino acids with different physicochemical properties or 
conformational characteristics. The reason why CD14 (81–100) was the only peptide 
to exhibit LPS-neutralizing activity in our assays might be that this peptide be the 
only one, among those peptides corresponding to parts of the LPS-binding domain, 
to assume a conformation similar to that of the corresponding region in the native 
protein. CD spectroscopy confirmed that peptides derived from CD14 (81–100) 
displayed considerable α-helix contents under relatively mild helix-inducing 
conditions, consistently with the secondary structure of this domain observed in the 
crystal structure. 
Given the previous observation that mutations of residues 91 to 101 affected the 
signal-transducing capacity, we hypothesized that CD14 (81–100) might also have 
the ability to mimic the functional domain of CD14 responsible for binding to cellular 
receptors. However, no binding could be detected when the fluorescein-labeled 
analog of the peptide was incubated with signaling-competent THP-1 cells. 
The CD14-derived peptide with enhanced solubility (peptide 31) neutralized smooth 
LPS from different bacterial strains in the LAL assay but failed to inhibit the LAL 
reaction induced by rough LPS. This differential activity might be due to an 
interaction of the peptide with the O-antigen of LPS rather than the lipid A moiety. 
Conflicting results have been presented with respect to the discrimination of rough 
and smooth LPS by CD14. In an investigation of the interaction of different LPS with 
CD14-transfected cells, interaction of both rough and smooth LPS was shown [46], 
although this interaction depended strongly on the presence of LBP. In contrast, 
Gangloff et al. have very recently demonstrated that CD14 preferentially mediates 
cellular activation by LPS containing the O-antigen [47].
 
With truncation of the 
carbohydrate moiety, activation of cells by rough LPS variants was increasingly 
CD14-independent and needed higher concentrations to achieve comparable 
activation of cells. Additional experiments will be required to reveal the basis of these 
discrepancies and to better understand the contributions of individual domains in 
CD14 to the recognition of different LPS ligands.  
Our data indicate that the CD14-derived peptides neutralize the cell-stimulating and -
binding properties of LPS through complex formation. We did not directly determine 
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whether the binding of LPS with other LPS-binding molecules involved in the 
activation of TLR4 was inhibited by our peptide or whether the peptide interfered 
with the activity once LPS was bound to one of these molecules. Effective molecular 
recognition of endotoxin requires the concerted action of several extracellular and cell 
surface proteins (in addition to TLR4) that bind and transfer LPS. In serum, LPS 
micelles form complexes with the lipid transfer protein LBP. LBP potently enhances 
the agonistic activity of LPS [48,49]
 
by accelerating the transfer of monomeric LPS 
molecules to CD14 [49-51]. CD14-bound endotoxin is then transferred to MD-2 and 
TLR4 [52,53]. Given this molecular mechanism it seems unlikely that LPS (once 
bound to a cofactor) is accessible to the LPS neutralizing peptides. In our 
experiments, we observed that the inhibitory activity of the CD14-derived peptides 
was enhanced when the dilution of the LPS stock solution to working concentrations 
was performed under serum-free conditions. Serum represents a source of LBP, so 
complex formation between LPS and LBP during dilution in a serum-containing 
buffer might therefore limit the inhibitory activity of the peptides. It was previously 
shown that several structurally diverse LPS-neutralizing cationic peptides inhibit the 
interaction of LPS with LBP [54].
 
From these observations and our own, we propose 
that our peptides might block the initial binding to LBP. However, this still needs to 
be determined in future experiments. 
 
Comparison of CD14 (81–100) with LPS-binding peptides from other proteins  
Recent approaches to the development of molecules that neutralize endotoxin have 
concentrated on characterizing LPS-binding regions fromendotoxin-binding 
peptides and proteins. The crystal structure of LALF revealed a positively charged 
amphipathic loop with the basic residues facing to one side of the molecule that 
contributes to LPS binding [27]. Similar motifs have been proposed for other 
endotoxin-binding proteins: namely BPI, LBP [27,28], heparin-binding protein [55], 
and lactoferrin [56]. 
In addition, a variety of α-helical cationic peptides exhibit strong LPS-binding and -
neutralizing activity. These include antimicrobial peptides derived from silk moth 
cecropin and bee mellitin [57,40], human CAP18 [30,31], and guinea-pig CAP11 
[58]. 
The results obtained from the analysis of the structure–activity relationship and CD 
spectroscopy revealed that the CD14-derived LPS-neutralizing peptides share 
properties characteristic of the class of α-helical peptides with antimicrobial activity. 
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The leucine residues 11 and 14 critical for biological activity are three residues apart. 
In addition, the lysine-substituted variant of the native sequence exhibits a pattern of 
aliphatic and cationic amino acid residues that is characteristic of cationic 
amphipathic a-helices. Similar properties have been reported for the LPS-binding 
and -neutralizing 18-amino-acid peptide derived fromthe C-terminal part of CAP18 
[31,37]. Further evidence for an α-helical conformation of CD14 (81–100) was 
obtained by removal or introduction of proline residues. Mutation of the proline to an 
alanine residue at position 3 yielded a more potent peptide as shown by the 
significantly enhanced LPSneutralizing activity in the LAL test. In contrast, the 
activity of the peptide was significantly reduced when the lysine residue at position 9 
was substituted by a proline residue. Moreover, the more soluble CD14 (81–100) 
analog (peptide 31) inhibited growth of E. coli down to a concentration of 1 mM (data 
not shown).  
Up to this point it has not been possible to determine the degree to which the 
increases in activity of the lysine-substituted analog and the analog containing a tetra-
lysine stretch were due to enhanced peptide solubility or to additional molecular 
interactions of the positively charged amino acid side chains with the negatively 
charged groups of LPS. The observation that the C-terminal elongation of the peptide 
increased the activity even more strongly than the internal lysine substitutions 
indicates that the higher solubility was the major contribution to the higher activity. 
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2.2.2 Mutual activation of natural killer cells and monocytes mediated 
by interaction between the human NK receptor NKp80 and the 
myeloid-specific receptor AICL 
This chapter has been published in Nat.Immunol. 7 (12):1334-42 (2006) by the 
following authors: 
 
Stefan Welte, Sabrina Kuttruff, Inja Waldhauer and Alexander Steinle 
 
The author of this thesis designed and performed all experiments described herein, 
except the CD107a degranulation and intracellular cytokine assays (Figure 2.24d-f, 
Sabrina Kuttruff), Western Blotting (Figure 2.28f, Inja Waldhauer), BIAcore 
measurements (Alexander Steinle, Figure 2.26d,e) and the contributions by others 
mentioned in the acknowledgements section. 
 
2.2.2.1 Abstract 
 
Receptors encoded by the natural killer gene complex (NKC) (e.g. NKG2D) govern 
reactivity of natural killer (NK) cells. However, the function and ligand(s) of the 
NKC-encoded human NK receptor NKp80 remain elusive. Here we demonstrated 
that NKp80 binds to the genetically linked orphan receptor AICL, which like NKp80 
is absent in rodents. We defined AICL as a myeloid-specific activating receptor that is 
up-regulated by Toll-like receptor stimulation. AICL-NKp80 interactions promoted 
NK cell-mediated cytolysis of malignant myeloid cells. In addition, during cross-talk 
between NK cells and monocytes, NKp80 stimulated the release of pro-inflammatory 
cytokines from both cell types. Thus, by specifically bridging NK cells and myeloid 
cells, NKp80-AICL interactions may contribute to the initiation and maintenance of 
immune responses at sites of inflammation. 
 
2.2.2.2 Introduction 
 
Originally, natural killer (NK) cells were primarily considered to be innate immune 
effector cells capable of spontaneously destroying infected or transformed cells [1]. 
NK cells detect malignant or virus-infected cells through the recognition modes of 
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‘missing-self’ and ‘induced-self’, which regulate cytokine secretion and cytotoxicity 
and ultimately lead to the elimination of harmful cells [2,3].  
Emerging evidence now also attributes to NK cells an important role in the initiation 
and modulation of adaptive immune responses [4,5]. Specifically, by providing an 
early source of interferon-γ (IFNγ), NK cells are instrumental in initiating T helper 
type 1 (TH1) T cell responses [6]. However, the molecular and cellular events 
involving NK cells at the initiation of adaptive immune responses remain unclear. In 
this regard, the cellular cross-talk between NK cells and myeloid cells is currently of 
major interest, since it is thought to crucially program subsequent immune 
responses. Several studies demonstrated a mutual activation of NK cells and 
dendritic cells (DCs), in which both soluble factors and cell contact-dependent events 
have been implicated [5,7-10]. Other recent reports also define a reciprocal activation 
between human NK cells and monocytes and macrophages [11,12]. Like NK-DC 
interactions, the stimulatory cross-talk between NK cells and monocytes is partially 
cell contact-dependent; hence an involvement of hitherto undefined receptors was 
postulated [12]. 
NK cell activation is balanced by inhibitory signals provided by MHC class I-specific 
NK receptors (which allow detection of ‘missing-self’) and activating signals received 
by several immunoglobulin-like and C-type lectin-like receptors like NKG2D (which 
allows detection of ‘induced self’). In humans, a number of activating NK receptors 
including NKp30, NKp44, NKp46, NKp80 and NKG2D has been characterized, but 
apart from NKG2D, the unidentified nature of the corresponding cellular ligands 
strongly hampers further advances in understanding their role in NK cell-mediated 
immunoregulation and immunosurveillance [3,13].  
NKG2D and NKp80 (also called KLRF1) are both C-type lectin-like homodimeric 
receptors encoded within the human NKC [14-17]. NKG2D is expressed by virtually 
all human NK cells, γδ T cells and CD8+ T cells and, together with the adaptor protein 
DAP10, assembles into an activating immunoreceptor complex [3,14]. Upon 
recognition of its MHC class I-related, stress-inducible ligands encoded by the MIC 
and ULBP genes, NKG2D stimulates NK cytotoxicity and cytokine secretion [14,18]. 
Since NKG2D ligands are inducibly expressed in cells subjected to genotoxic stress 
and are associated with malignant transformation, the hypothesis was put forward 
that NKG2D may detect and orchestrate the elimination of harmful infected or 
transformed cells [3,14,19,20]. In fact, recent studies illustrate that NKG2D provides 
protection from spontaneous tumors in vivo [21,22]. 
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In comparison, much less is known about NKp80 which, unlike NKG2D, has been 
reported to be expressed exclusively on NK cells [16]. In fact, NKp80 was described 
during the course of a search for novel NK cell-specific surface markers [26]. Like 
NKG2D, NKp80 stimulates NK cell cytotoxicity and induces Ca2+ influx in human 
NK cells upon triggering by appropriate antibodies [16]. In contrast to NKG2D, 
NKp80 lacks charged amino acids in its transmembrane domain (thereby 
disfavouring association with activating adaptor proteins like CD3ζ, DAP12, DAP10 
or FcεRIγ) and consensus activation motifs in its cytoplasmic domain. Also in 
contrast to NKG2D, NKp80 lacks a homologue in rodents [17]; this distinction may 
have impeded investigation of NKp80 function in vivo. Recently, two studies of non-
human primates confirmed that NKp80 is an NK cell-specific stimulatory receptor 
[23,24]. However, these reports also were limited by the unknown identity of NKp80 
ligand(s).  
Driven by the knowledge that characterization of NKG2D ligands profoundly 
improved our understanding of NK cell activation, we set out to identify ligand(s) of 
NKp80, the only known NKC-encoded activating receptor exclusively expressed on 
human NK cells. Here, we identified the NKC-encoded orphan receptor AICL (also 
called CLEC2B) as a ligand of NKp80. Using newly generated AICL-specific 
monoclonal antibodies we showed that AICL is a novel myeloid-specific receptor 
expressed by monocytes, macrophages and granulocytes. Cross-linking of both 
NKp80 and AICL stimulated secretion of pro-inflammatory cytokines, and in co-
cultures of NK cells and monocytes, cytokine release was partially dependent on 
NKp80 engagement. Hence, our findings suggest that the NKp80-AICL interaction is 
involved in the activating cross-talk between NK cells and myeloid cells, and thus may 
influence the initiation and maintenance of immune responses in humans. 
 
2.2.2.3 Materials and Methods 
 
Cells. Peripheral blood leukocytes of healthy donors were isolated according to the 
guidelines of and as approved by the local ethic committee and cultured in X-Vivo 15 
(Cambrex) with 10% FCS. NK cells were purified by the NK cell isolation kit II and 
monocytes by the CD16+ Monocyte Isolation Kit (for NK co-culture), by the 
Monocyte Negative Isolation Kit (for cytokine secretion assays), or by CD14 
microbeads (all from Miltenyi). Cell purity was between 90-98%. Granulocytes were 
isolated as described [40]. Monocytes were differentiated to macrophages with 50 
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ng/ml hM-CSF. Cytokines were from R&D Systems except hIL-15 and hIL-2 
(PromoCell). Monocytes were cultured 24 h with 1 μg/ml LPS from S. typhimurium, 
50 μg/ml poly(I:C) (Sigma), 1 μM S-[2,3-bis(palmitoyloxy)propyl]-cysteine-(Lys)4
 
(Pam2Cys SK4; EMC Microcollections),
 and 10 ng/ml R-848 (S. Bauer, Munich). NK 
cells and CD16+ monocytes were co-cultured at 4×105 cells/well for 12 h at a 1:1 ratio 
(total 8×105 cells/well) with 100 U IL-2/ml. IL-15 and IL-18 (both at 10 ng/ml), and 
F(ab’)2 of 5D12, 7F12, or NP (4-hydroxy-3-nitrophenylacetyl)-specific IgG1 (all at 10 
μg/ml), respectively, were added where indicated. CD56
+ cells were stained for 
intracellular IFNγ, and CD14dim16+HLA-DRbright cells for intracellular TNF. To 
calculate monocyte-dependent increases in frequencies of IFNγ-producing NK cells, 
monocyte-dependent increase in presence of NP-specific IgG1 (Fab’)2 was set as 
100% ((%IFNγ-producing NK cells with monocytes) - (%IFNγ-producing NK cells 
without monocytes) = 100%). Increase in frequencies of TNF+ monocytes by co-
cultivation with NK cells was calculated accordingly. 
 
NKp80- and AICL-specific monoclonal antibodies. Splenocytes of mice repeatedly 
immunized with NKp80-ED or AICL-ED, respectively, were fused with 
P3X63Ag8.653 myeloma cells as described [41]. Hybridoma supernatants were 
screened with mixtures of Jurkat-neo or Jurkat-NKp80 transfectants and mixtures of 
AICL-ED or LLT1-ED-coated microspheres by immunofluorescence. 
Immunoglobulins were purified from supernatants with Protein A (Biorad). 5D12, 
10E4 and 12D11 antibodies are NKp80-specific, 7F12 and 7G4 antibodies are AICL-
specific, and all antibodies are of IgG1 isotype. Antibodies were labeled using Alexa 
Fluor 647 carboxylic acid-succinimidyl ester according to the manufacturer’s 
protocol (Molecular Probes). (Fab’)2 fragments were generated by pepsin digestion 
und purified from endotoxin by Triton 114 extraction [42]. Endotoxins in mAb and 
(Fab’)2 preparations were tested using a Limulus amebocyte lysate assay (QCL-1000, 
Cambrex) and were below 0.1 EU/μg antibody. 
 
Antibodies. PE-conjugated anti-NKp46 and anti-CD56 were from Immunotech, 
CD14-FITC and isotype control from Immunotools, CD14-PE-Cy7 and isotype 
control from BioLegend, anti-NKp46 and anti-TREM-1 from R&D Systems, anti-
FLAG M2 from Sigma, anti-penta-His from Qiagen, and goat anti-mouse-Ig-PE 
conjugate from Jackson Laboratories. The anti-NP IgG1 mAb was a kind gift from 
Jörg Kirberg, Max-Planck-Institute for Immunobiology, Freiburg, Germany. All other 
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antibodies were from BD Biosciences. 
 
Cytotoxicity, degranulation and cytokine analysis. Cytotoxicity was analyzed in a 4 
h 51chromium-release assay as described [41]. Degranulating NK cells were 
quantified by analysis of surface CD107a after 6 h incubation with plate-bound 
antibody in the presence of 10 μg/ml Brefeldin A (Sigma) as described [43]. Likewise, 
frequencies of cytokine-producing NK cells were determined by intracellular staining 
with PE-anti-IFNγ after 6 h incubation with plate-bound antibody in the presence of 
10 μg/ml Brefeldin A and 100 U IL-2/ml. Ionomycin (Sigma) and PMA (Cell 
Signaling Technology) were used at concentrations of 1 nM and 10 ng/ml, 
respectively. TNF levels in supernatants of purified NK cells stimulated for 24 h with 
plate-bound antibody and 100 U IL-2/ml were determined using ELISA CytoSets 
from BioSource. TNF in supernatants of purified monocytes was measured after 24 h 
stimulation with plate-bound, endotoxin-low antibody. 
 
Soluble ectodomains (ED) of C-type lectin-like receptors. Ectodomains of NKp80 
(Gln64 through Tyr231), AICL (Lys26 through His149), LLT1 (Ala61 through 
Val191), and CD161 (Ile66 through Ser225) were expressed in 293T cells transfected 
with the corresponding cDNA containing an N-terminal BirA-tag and C-terminal c-
myc- and six-histidine-tags. EDs were isolated from supernatants of 293T-
transfectants by affinity chromatography with anti-c-myc columns and biotinylated 
using BirA Ligase [41] and purified by size exclusion chromatography. Before use, 
biotinylated EDs were either immobilized on streptavidin-coated microspheres 
(Bangs Laboratories) or tetramerized using PE- or APC-labeled streptavidin 
(Molecular Probes). 
 
SPR measurements. Using a BIAcore X apparatus (BIAcore AB) AICL ectodomains 
were immobilized to CM5 chips by amine coupling. In kinetic analyses (flow rate: 50 
μl/min), RU from the control flow cell (imLLT1-ED) were subtracted from RU of the 
AICL-derivatized surface (black traces) with overlayed gray traces representing 
fitting of a 1:1 Langmuir model to the association and dissociation phases. In steady-
state analyses (15 μl/min) RU from the AICL-derivatized surface were corrected by 
RU from the non-derivatized control cell. Raw data were analyzed and illustrated 
using the BIAevaluation software (BIAcore AB). 
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Immunoblot analysis. Immunoblotting was performed as previously described [44]. 
Treatment with Peptide:N-Glycanase F (PNGaseF) (New England Biolabs) was for 1 
h at 37°C. Samples were blotted and analyzed with 30 μg 7F12/ml.  
 
Statistical analysis. Statistical analysis was done either using the two-tailed unpaired 
Student’s t test or the nonparametric two-tailed Mann-Whitney Rank Sum test both 
with α = 0.050 and SigmaStat 3.1 software (Systat Software). P-values less than 0.04 
were considered significant. 
 
Real-time RT-PCR. Total RNA was prepared using TRIZOL (Invitrogen) and 
reverse transcribed by SuperScript II (Invitrogen). cDNA was amplified with NKp80, 
AICL and 18S rRNA-specific primer pairs in duplicates (40 cycles, 95°C for 15 s, 
60°C for 1 min) using SYBRGreen chemistry on the ABI PRISM 7000 Sequence 
Detection System (Applied Biosystems). Primers were designed to flank an intron, 
where possible, and specificity was validated using cloned cDNA. Data analysis was 
by the ΔCT method for relative quantification. Similar amplification efficiencies for 
NKp80, AICL and 18S were demonstrated by analyzing serial cDNA dilutions with 
values of the slope of log cDNA amount vs. ΔCT of < 0.1. Oligonucleotide sequences 
(forward; reverse) were 18S rRNA: 5´-CGGCTACCACATCCAAGGAA-3´; 5´-
GCTGGAATTACCGCGGCT-3´; NKp80: 5´- TTCAGTGACGTTGCACTGGT-3´; 5´- 
CTCCCTGAGAAACCAACAGGA-3´; AICL: 5´-TACCAAATCGTTTGGCATGA-3´; 5´-
CTGCAAATCCATTTTCTTTCG-3´. Purity of PCR products was analyzed on 3% 
agarose gels. 
 
Transfectants. Jurkat cells were transfected by electroporation with an NKp80-
hybrid cDNA encoding the cytoplasmic and transmembrane domains of human 
CD69 (Met1 through Gly70), the NKp80 ectodomain (Gly85 through Tyr231), and a 
C-terminal FLAG-tag followed by a six-histidine-tag in RSV.5 neo. COS-7 cells were 
transiently transfected using FuGene6 (Roche) with an AICL hybrid cDNA 
encompassing the cytoplasmic domain of mouse CD3ζ (Arg52 through Arg164), the 
transmembrane domain of mouse Ly-49A (Ser40 through Met90), the AICL 
ectodomain (Lys26 through His149), and a C-terminal FLAG-tag followed by a six-
histidine-tag in RSV.5 neo or with a bicistronic expression vector with full-length 
cDNA of AICL or LLT1 (first cistron) followed by the EGFP cDNA (second cistron). 
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2.2.2.4 Results 
 
NKp80 stimulates NK cell degranulation and cytokine release 
To analyze NKp80 expression and function, we generated a panel of NKp80-specific 
monoclonal antibodies by immunizing mice with the NKp80 ectodomain (NKp80-
ED). The tagged NKp80-ED construct was expressed in 293T cells and purified from 
supernatants by affinity chromatography (Figure 2.22). 
 
 
Figure 2.22 Recombinant soluble ectodomains (ED) of various C-type lectin-like receptors. 
(a) SDS-PAGE of soluble CD161-ED, NKp80-ED, LLT1-ED, and AICL-ED affinity-purified 
from supernatants of transfected 293T cells. (b) SDS-PAGE of soluble AICL-ED untreated (–) or 
treated (+) with PNGase F. 
 
Specificity of the resulting NKp80-specific antibodies 5D12, 10E4, and 12D11 was 
verified in binding analyses using microsphere-immobilized NKp80-ED and NKp80-
transfected Jurkat cells (Figure 2.23). In accord with previous reports, the NKp80-
specific antibody bound to nearly all freshly isolated human NK cells [16] (Figure 
2.24a). We also noted that the CD56bright NK subset, which is a primary source of 
monokine-stimulated NK cell cytokine production [25], also expressed high amounts 
of NKp80. NKp80 expression has also been reported to be expressed on CD3+CD56+ 
cells from some donors [16]. Accordingly, we found NKp80 on varying fractions of 
CD56+CD3+ cells (range 29-61%, median 43%) (Figure 2.24b). 
Results and Discussion 150 
 
Figure 2.23 Specificity of NKp80-specific antibodies 5D12, 10E4, and 12D11. (a) 5D12, 
10E4, and 12D11 binding to microsphere-immobilized NKp80 (imNKp80) (filled histograms) 
and imLLT1 (open histograms). (b) 5D12, 10E4, 12D11, and anti-FLAG binding to a mixture of 
Jurkat cells transfected with the FLAG-tagged NKp80-CD69 hybrid cDNA and NKp80-hybrid-
negative Jurkat transfectants (gray histograms). Black line represents the isotype control 
staining. 
 
However, we also detected NKp80 on a substantial proportion of γδ T cells. This 
expression varied widely among individual donors (range 16%-70%, median 26%), 
and likely accounted for the few NKp80+ CD56–CD3+ T cells (Figure 2.24b). In 
contrast, B cells, monocytes, and other T cells subsets including CD4+ and CD8+ αβ T 
cells (CD3+CD56–) were devoid of surface NKp80, as were all tested cell lines (data 
not shown). These findings were supported by real-time RT-PCR analyses, which 
revealed a high abundance of transcripts encoding NKp80 in NK cells (Figure 2.25). 
The impact of NKp80 triggering on cytokine release by NK cells has not yet been 
addressed. To investigate the consequences of NKp80 triggering on NK cell effector 
functions independently of other NK receptors, we incubated freshly purified NK 
cells with plate-bound anti-NKp80 NKp80 cross-linking triggered secretion of TNF 
(Figure 2.24c). Simultaneous stimulation with anti-NKp80 and anti-NKp46 further 
amplified TNF secretion. Similar results were obtained when assessing NK cell IFNγ 
production (Figure 2.24d). In accordance with published data on NKp80-mediated 
stimulation of NK cell cytotoxicity [16], we observed that immobilized anti-NKp80 
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also induced enhanced cell surface exposure of CD107a (also called lysosomal-
associated membrane protein (LAMP-1)) which is indicative of NK cell 
degranulation, in a manner similar to anti-NKp46, again with a pronounced 
cooperative effect of simultaneous ligation of both receptors (Figure 2.24e, f). 
 
Figure 2.24. NKp80 stimulates granule exocytosis and cytokine secretion. (a) Expression of 
the indicated molecules on the surface of human resting NK cells was determined by flow 
cytometry. Plots depict freshly isolated PBMC where CD3+ cells were excluded by electronic 
gating. (b) Frequencies of NKp80+ cells among indicated subpopulations from eight healthy 
donors. Medians are indicated by horizontal bars, and each dot depicts one individual donor. (c-f) 
Freshly purified NK cells were incubated with the indicated plate-bound antibodies. (c) 
Concentrations of TNF in culture supernatants were determined by ELISA. Results depict means 
of triplicate samples, and error bars represent s.d. Results are representative of 3 independent 
experiments. (d,e) Frequencies of IFNγ+ cells (d) and CD107a+ cells (e) among CD56+ NK cells 
were determined by flow cytometry. Results are shown as means of triplicates with s.d. (f) 
Representative analysis of CD107a+ NK cells after stimulation with indicated immobilized 
antibodies or K562 cells. Percentages of CD107a+ cells of all CD56+ NK cells (upper right 
quadrant) are depicted. Results in (d-f) are representative of 6 independent experiments. 
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Figure 2.25. Abundance of AICL and NKp80 transcripts in leukocyte subpopulations. (a, b) 
CD3+CD8+ (CD8+ T cells), CD3+CD4+ (CD4+ T cells), CD3+γδ TCR+ (γδ T cells), CD19+ (B cells), 
CD66b+ (granulocytes), CD14+ (monocytes) and CD3–CD56+ (NK cells) cells were sorted from 
the peripheral blood of a healthy donor. CT values for NKp80 (a) and AICL (b) transcripts were 
calculated by normalization with 18S RNA and relative copy numbers were determined by setting 
the ΔCT value of B cells as 1. 
 
NKp80 engages AICL 
Further elucidation of the immunological relevance of NKp80-mediated NK cell 
activation necessitated the identification of NKp80 ligands (NKp80-L). We 
attempted to identify NKp80-L bearing cells by using BWZ.36 cells expressing 
NKp80-CD3ζ reporter constructs, because ligands of the NKC-encoded mouse 
Nkrp1 receptors were previously identified using BWZ.36 cells expressing Nkrp1-
CD3ζ reporter constructs [26,27]. These reports revealed that mouse Nkrp1 
receptors and their ligands, called C-type lectin-related (Clr) molecules, are all 
encoded in close genetic linkage within the NKC [17,26,27]. 
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Because this strategy failed to identify NKp80-L expressing cells, we considered the 
possibility that, like Nkrp1-Clr receptor-ligand pairs, the orphan genes encoding 
Lectin-Like Transcript 1 (LLT1) and Activation-Induced C-type Lectin (AICL), 
which are located in close proximity to the gene encoding NKp80 in the human NKC, 
might be ligands of NKp80 (Figure 2.26a). In fact, while this work was in progress, 
LLT1 was reported as a ligand of the single human representative of the Nkrp1 
receptor family, NKR-P1A (also called CD161) [28,29]; this receptor-ligand pair is 
also genetically linked within the NKC. In contrast to CD161, no known mouse 
homologues of NKp80 or for AICL have been identified [17]. Hence, to directly assay 
a possible interaction between NKp80 and AICL or LLT1, we produced soluble 
ectodomains of AICL (AICL-ED) and LLT1 (LLT1-ED) using stably transfected 
293T cells (Figure 2.22). AICL-ED or LLT1-ED, respectively, were immobilized on 
streptavidin-coated microspheres and directly tested for binding to fluorochrome-
labeled NKp80-ED or CD161-ED tetramers, respectively, via flow cytometry. As 
expected, CD161-ED-tetramers bound immobilized LLT1, although staining was 
fairly weak, indicating a low affinity interaction in agreement with recent reports 
[28,29] (Figure 2.26b). In contrast, NKp80-ED-tetramers did not bind to LLT1, but 
exhibited strong binding to immobilized AICL (Figure 2.26b). Similar results were 
obtained in a ‘reverse’ setting in which immobilized NKp80-ED specifically 
interacted with AICL-ED-tetramers (Figure 2.26c). These data suggest that AICL, 
but not LLT1, is a ligand for NKp80. 
Using surface plasmon resonance (SPR) technology, we determined the affinity of 
the NKp80-AICL interaction. Soluble NKp80 ectodomains bound to immobilized 
AICL-ED with an intermediate association rate (kon = 1.6 × 10
4 M-1s-1) and 
dissociated relatively rapidly (koff = 6.7 × 10
-2 s-1) (Figure 2.26d). The affinity for the 
NKp80-AICL interaction calculated from on- and off-rates (KD,calc = 4.1 μM at 25°C) 
is comparable to the affinity determined during steady-state analyses (KD ~ 2.3 μM at 
25°C) (Figure 2.26e). Pre-incubation of NKp80-ED-coated microspheres with 
various NKp80-specific antibodies blocked binding of AICL-ED-tetramers (Figure 
2.26f). Importantly, AICL-ED-tetramers also stained freshly isolated NK cells and 
binding was blocked by pre-treatment of NK cells with NKp80-specific antibodies, 
demonstrating that AICL is a natural ligand of NKp80 (Figure 2.26g). 
 
Results and Discussion 154 
 
Figure 2.26. NKp80 engages AICL. (a) Scheme of a subregion of the human NKC with KLRF1 
and CLEC2B encoding NKp80 and AICL, respectively. Ly49L marks the centromeric end of the 
NKC. Boxes and arrows represent genes and transcriptional orientation, respectively. (b) 
Staining of immobilized sAICL-ED (imAICL) (black fill), imLLT1 (black line) or imNKp80 (dashed 
line) with indicated tetramers. (c) Staining of imNKp80 (black fill), imCD161 (black line), imAICL 
(dashed line, left panel) or imLLT1 (dashed line, right panel) with indicated tetramers. (d) 
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Kinetics of binding of sNKp80-ED (0.12, 0.25, 0.5, 1.0, 2.0 μM) to immobilized AICL-ED as 
described in Methods. RU, resonance units. (e) Affinity of NKp80 to AICL was determined by 
injecting sNKp80-ED (0.05, 0.1, 0.2, 0.25, 0.5, 1.0, 2.0 μM) over immobilized AICL (left panel). 
Dotted trace indicates control injection (2 μM sCD161-ED) and arrow averaged interval for a 
best-fit curve (right panel) (f) Binding of sAICL-ED tetramer to NKp80 after pre-incubation with 
5D12 (gray line) and 10E4 (dashed line), IgG1 isotype control (black fill), or to imAICL (black 
line). (g) Left, binding of sAICL-ED tetramers to NK cells after pre-incubation with 10E4 (gray 
fill) and IgG1 control (black fill) or of sCD161-ED tetramers (black line) to NK cells. Right, 
surface NKp80 detected by 5D12 (black fill) and isotype control (black line). (h) Binding of 
sNKp80-ED tetramers to imAICL after incubation with 7F12 (black line) and 7G4 (gray line) or 
IgG1 isotype control (black fill). Staining of imNKp80 served as negative control (dotted line). (i) 
Binding of indicated reagents to COS-7 cells transfected with indicated bicistronic EGFP 
constructs after pre-incubation with indicated antibodies. Data (b-i) are representative of at least 
two independent experiments. 
 
AICL is a myeloid-specific surface receptor  
A single study reported differential expression of AICL mRNA expression in T and B 
lymphocytes, monocytes and granulocytes [30]. By real-time PCR, we confirmed that 
AICL transcripts were most abundantly expressed in granulocytes, and found these 
more prominently in NK cells and γδ T cells than in αβ T cells or B cells (Figure 
2.25). However, due to a prior lack of AICL-specific antibodies, AICL protein 
expression was not examined in previous studies. Thus, to explore AICL expression, 
we generated AICL-specific antibodies by immunizing mice with AICL-ED. Two 
antibodies, 7F12 and 7G4, bound immobilized AICL-ED, but not LLT1-ED, NKp80-
ED or CD161-ED; these antibodies also stained COS-7 cells transiently transfected 
with AICL-Ly49A-CD3ζ hybrid constructs, in which transmembrane and 
cytoplasmic sequences of AICL were replaced by those of mouse Ly49A 
(transmembrane) and mouse CD3ζ (cytoplasmic) sequences (Figure 2.27, and data 
not shown). 
 
Pre-incubation of microsphere-immobilized AICL with 7F12, but not with 7G4, 
reduced binding of NKp80-ED tetramers indicating that 7F12 partially hinders the 
NKp80-AICL interaction (Figure 2.26h). Importantly, NKp80-ED tetramers also 
bound AICL expressed on the surface of transfected COS-7 cells, and addition of 
7F12 interfered with binding (Figure 2.26i and Figure 2.27). 
Next, we analyzed AICL surface expression on various cell lines, and detected AICL 
on the surface of myeloid cell lines U937, THP-1 and MEG-01 (Figure 2.28a and 
Table 2.2). U937 cells, which expressed the highest amounts of AICL, also bound 
high amounts of NKp80-ED tetramers, and pre-incubation with 7F12 markedly 
reduced NKp80-ED binding (Figure 2.28b). 
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In contrast to myeloid cell lines, AICL was not detectable on non-myeloid 
hematopoietic or on non-hematopoietic cell lines (Figure 2.28a and Table 2.2) 
suggesting that AICL is preferentially expressed on the surface of myeloid cells. 
 
Thus, we analyzed AICL expression on peripheral blood leukocytes and observed 
specific binding of 7F12 and 7G4 to monocytes, macrophages and granulocytes, but 
not to T cells, B cells, or NK cells (Figure 2.28c,d and Figure 2.27). Among 
monocytes, the CD14dimCD16+ subset, which is a major source of TNF [31] exhibited 
substantially higher AICL surface expression than the CD14brightCD16– subset 
(Figure 2.28d).  
 
We also assessed AICL expression on DCs, because the cellular cross-talk between 
NK cells and DCs has attained much interest [5]. Interestingly, AICL expression 
decreased when monocytes were differentiated in vitro to immature DCs (Figure 
2.28e) indicating that NKp80-AICL interactions may not be involved in the 
interaction of NK cells with monocyte-derived DCs. A previous report suggested that 
NKp80-L may be expressed on activated T cells, because NK cell-mediated 
cytotoxicity against PHA-activated T cells was partially reduced by addition of 
NKp80-specific antibodies [42]. However, we were unable to detect AICL on the 
surface of activated T cells (Table 2.2). Myeloid-specific AICL expression was 
surprising given that a previous report [30] and our analyses detected AICL 
transcripts also in lymphocytes. 
 
Therefore we analyzed AICL protein in whole cell lysates using 7F12 and detected 
AICL in lysates of U937 cells and monocytes, but not in lysates of non-myeloid cell 
lines or lymphocytes (Figure 2.28f). Together these data define AICL as a myeloid-
specific surface receptor capable of binding NKp80 on NK cells. 
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Figure 2.27. (a) 7F12 and 7G4 binding to microsphere-immobilized AICL (imAICL) (solid line), 
to imNKp80 (dashed line), and to a 2:1 mixture of imNKp80-microspheres and imAICL-
microspheres (gray histograms). (b) Staining of 7G4 of freshly isolated T cells (CD3+), NK cells 
(CD56+) and B cells (CD19+) (filled histogram). Open histograms represent isotype control 
stainings. (c) NKp80-ED tetramer binding to COS-7 cells transiently transfected with an AICL-
Ly49A-CD3ζ hybrid after pre-incubation with or without 7F12. NKp80-ED tetramer binding to 
mock-transfected COS-7 cells is indicated. AICL-hybrid expression was monitored by staining 
with the FLAG-specific antibody M2. Percentages of stained cells (upper left quadrant) are given. 
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Figure 2.28. AICL is a myeloid-specifc receptor. (a) Staining with AICL-specific antibody 7F12 
(black fill) or IgG1 isotype control (gray line) on myeloid cell lines U937 and THP-1 and the T cell 
line Jurkat, as determined by flow cytometry. (b) Binding of NKp80-ED tetramers to U937 cells 
with and without pre-incubation with 7F12 (gray fill) or IgG1 isotype control (black fill). Negative 
control, staining with PE-conjugated streptavidin (black line). (c) Staining of freshly isolated 
granulocytes and in vitro matured macrophages with AICL-specific antibody 7G4 (black fill) and 
IgG1 isotype control (gray line). (d) Expression of indicated molecules on the surface of freshly 
isolated monocytes. Gray cells in right panel depict cells within R2 in left panel. (e) AICL 
expression on purified monocytes at day 0 (black fill) or after 6 days culture with GM-CSF and IL-
4 (gray line). IgG1 isotype control stainings at day 0 (dashed line) and day 6 (gray fill) are 
indicated. (f) AICL in lysates of indicated cell lines (left), freshly isolated monocytes and 
lymphocytes (PBLs) (right) was detected by immunoblotting with 7F12. Lysates were 
deglycosylated with PNGase F where indicated. Recombinant AICL-ED is included as positive 
control. Data (a-f) are representative of at least two independent experiments. 
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Table 2.2. AICL surface expression on human primary cells and tumor cell lines. Primary 
cells and tumor cell lines were analyzed by flow cytometry for reactivity with AICL-specific 
antibodies 7F12 and 7G4. Mean fluorescence intensity (MFI): 10 (-); 10 to 15 (+/-); 15 to 50 
(+); 50 to 200 (++), above 200 (+++). nd (not done). 
 
 
 
Cells 
 
Histotype 7F12 7G4 
 
Resting NK cells  - - 
Activated NK cells  - - 
Resting T cells  - - 
PHA blasts  - - 
Resting B cells  - - 
Monocytes  + + 
LPS-activated monocytes  ++ ++ 
Granulocytes  + + 
Macrophages  + + 
immature monocyte-derived DC  -/+ nd 
mature monocyte-derived DC  - nd 
    
YT NK cell line - -/+ 
NKL NK cell line - - 
CEM T leukemia - - 
MOLT4 T leukemia - - 
Jurkat T leukemia - - 
HBP EBV-transformed B cell line - - 
LCL 721.221 EBV-transformed B cell line - - 
WT51 LCL - - 
T1 B-LCL 721.174xCEMR.3 - - 
C1R EBV-transformed B cell line - - 
RPMI 8866 EBV-transformed B cell line - - 
K562 erythroleukemia - - 
THP-1 acute monocytic leukemia + + 
MEG-01 chronic myelogenous leukemia ++ ++ 
U937 human histiocytic lymphoma +++ +++ 
HL60 acute promyelocytic leukemia - - 
NB4 acute promyelocytic leukemia - - 
293T embryonic fibroblasts - - 
AML-01 acute myeloid leukemia - - 
BV173 chronic myeloid leukemia - - 
KYO-1 chronic myeloid leukemia -/+ -/+ 
CaCo-2 colon carcinoma - - 
MelJuso melanoma - - 
Ma-Mel-8a melanoma - - 
HCT116 colon carcinoma - - 
SW756 cervix carcinoma - - 
MG63 osteosarcoma - - 
WEHI-3B mouse myelomonocytic 
leukemia - - 
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AICL triggers monocyte cytokine release 
Ligands of Toll-like receptors (TLRs) modulate the cell surface expression of various 
immunoreceptors, including TREM-1, CD80 and CD83 [32]. Hence, we determined 
whether TLR stimulation modulated AICL surface expression. AICL was markedly 
up-regulated within 24 h of exposure of monocytes to the TLR ligands LPS, poly 
(I:C), R848, or Pam2Cys SK4 (Figure 2.29a and data not shown). In accord with the 
lack of TLR9 expression by human monocytes stimulation with the TLR9 ligand CpG 
DNA did not affect AICL surface expression. 
 
 
 
Figure 2.29. AICL is up-regulated by TLR stimulation and stimulates TNF release. (a) 
Freshly purified monocytes stimulated for 24 h with indicated TLR ligands were stained with 
AICL-specific antibody 7F12 (black fill) or IgG1 isotype control (dotted line). Stainings of mock-
treated monocytes with 7F12 (gray line) or IgG1 isotype control (black line) are shown. (b) TNF 
in supernatants of freshly isolated monocytes cultivated for 24 h with indicated plate-bound 
antibodies was measured by ELISA. (c) TNF in supernatants of freshly isolated monocytes 
stimulated for 24 h with indicated plate-bound antibodies in the presence (open bars) or absence 
of LPS (black bars) was measured by ELISA. In (b) and (c) means of triplicates are shown, error 
bars represent s.d. All results are representative of at least 3 independent experiments. 
 
Next, we determined whether AICL ligation could stimulate monocytes. Like 
stimulation with LPS or with TREM-1-specific antibodies, AICL cross-linking 
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enhanced monocyte TNF production (Figure 2.29b). In addition, LPS exerted a 
strong additive effect on AICL-stimulated TNF release (Figure 2.29c). 
 
NKp80 promotes lysis of AICL+ target cells 
 
 
Figure 2.30. NKp80-AICL interaction promotes NK cell-mediated cytolysis of myeloid cells. 
(a-c) Cytotoxic activity of freshly purified NK cells was measured during a 4 h 51chromium-
release assay (a,b) Lysis of U937 cells in presence of indicated antibodies. Results are 
representative of four (a) and two (b) independent experiments. (c) Lysis of LPS-activated, 
CD14+ monocytes in the presence of indicated antibodies. Results are representative of two 
independent experiments with cells from different donors. F(ab’)2 fragments were used in all 
experiments. NK cells in (a-c) were from different donors with data depicted as means of 
quadruplicate (a,b) or triplicate (c) samples. Errors bars represent s.d. 
 
Previous studies demonstrated that NKp80 stimulates NK cytotoxicity in redirected 
lysis assays when cross-linked by NKp80-specific antibodies [16,23,24]. However, 
due to the unknown nature of NKp80-L, the importance of NKp80-dependent 
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cytotoxicity in a biologically relevant setting could not be assessed. Here, we 
addressed the impact of NKp80 on NK cell cytotoxicity towards myeloid cells 
expressing AICL. U937 cells express high amounts of AICL, but also of ligands for 
the activating NK receptor DNAM-1 [33]. 
 
Accordingly, freshly isolated NK cells strongly lyzed U937. U937 lysis was partially 
blocked by anti-NKp80 10E4, suggesting that NKp80 markedly contributes to NK 
cell-mediated cytolysis of U937 cells (Figure 2.30a). Furthermore, addition of either 
7F12 or soluble NKp80 also reduced NK cytotoxicity against U937 cells (Figure 
2.30b). In contrast to U937 cells, non-malignant myeloid cells like monocytes express 
low amounts of AICL and DNAM-1 ligands and are largely resistant to NK cell-
mediated cytolysis (data not shown). However, after 24 h of LPS treatment, in two 
out of four donors, we observed moderate NK cell-mediated cytolysis of autologous 
monocytes, which was inhibited by treatment with NKp80- and AICL-specific 
antibodies (Figure 2.30c and data not shown). These data indicate that TLR-
mediated activation may render monocytes susceptible to NKp80-dependent NK cell-
mediated cytolysis. 
 
NKp80-dependent NK-monocyte cross-talk 
A recent report [12] described a bi-directional activation pathway between NK cells 
and monocytes that results in secretion of IFNγ and TNF by NK cells and monocytes, 
respectively. It was suggested that this mutual activation may occur at sites of 
inflammation, particularly during chronic inflammatory autoimmune diseases when 
activated CD56bright NK cells and monocytes are prominent [12]. Co-culture of NK 
cells and monocytes in the presence of monokines results in increased secretion of 
pro-inflammatory cytokines by NK cells and monocytes, and this increase is partially 
dependent on cell contact [12]. However, the receptors involved in this cell contact-
dependent NK cell-monocyte cross-talk remain unidentified. 
Here we here adopted this same experimental system to confirm that co-culture of 
freshly isolated autologous NK cells and monocytes results in increased frequencies 
of IFNγ-secreting NK cells and TNF-secreting monocytes, respectively, as compared 
to cultures of either NK cells or monocytes alone (Figure 2.31). In accordance with 
previous studies, CD56bright NK cells were more prone to produce IFNγ than CD56dim 
NK cells [25] (Figure 2.31b, and Table 2.3). Importantly, addition of IL-15 and IL-
18 monokines was essential to induce cytokine secretion.  
Results and Discussion  163
 
 
 
Figure 2.31. NKp80-dependent stimulation of cytokine release. (a-c) Frequency of IFN-γ-
producing NK cells after 12 h culture with autologous CD14dimCD16+ monocytes. (a) 
Representative analysis of NK cells cultured with monocytes (Mono) or monokines (IL) in the 
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presence of indicated antibodies. Stimulation with PMA and ionomycin served as a positive 
control (right panel). Percentages of IFN-γ+ cells of all CD56+NK cells (upper right quadrant) are 
indicated. (b) Frequency of IFN-γ+CD56dim NK cells (black bars) or IFNγ+CD56bright NK cells 
(open bars) after culture with monocytes, monokines or both. (c) Change in frequency of IFN-γ+ 
NK cells after co-culture with monocytes in the presence of monokines and indicated antibodies. 
(d-f) Frequency of TNF+CD14dimCD16+ monocytes after 12 h culture with autologous NK cells. 
(d) Representative analysis of monocytes cultured with NK cells in the presence of monokines 
and indicated antibodies. Stimulation with LPS served as a positive control (right panel). 
Percentages of TNF+ cells of all HLA-DR+ monocytes (upper right quadrant) are indicated. (e) 
Frequency of TNF+ monocytes after culture with NK cells, monokines or both. (f) Change in 
frequency of TNF+ monocytes after culture with NK cells in the presence of monokines and 
indicated antibodies. In (c) and (f) the frequency of cytokine-producing cells after culture with 
isotype control IgG1 is set as 100% (for details see Methods). All data are means of triplicate (a, 
donor 6) or quadruplicate (b-f, donor 3) samples, and errors bars represent s.d. P-values were 
calculated using the two-tailed Student’s t test and * indicates a significant difference (P < 0.001) 
to the IgG1 isotype control. 
 
To investigate whether NKp80-AICL interactions may contribute to this cell contact-
dependent NK cell-monocyte cross-talk, we added F(ab’)2 fragments of the NKp80-
specific antibody 5D12 and/or the AICL-specific antibody 7F12 to NK cell-monocyte 
co-cultures. Blockade of NKp80-AICL interactions strongly reduced the monocyte-
dependent increase in NK cell IFNγ secretion, demonstrating that NKp80-AICL 
interactions are crucially involved in the activating NK-monocyte crosstalk (Figure 
2.31a,c). Although the frequencies of IFNγ-secreting CD56bright NK cells varied 
widely between various donors (range 3.8% to 40.2%), NKp80 blockade always 
resulted in a strong reduction of responsive cells (Table 2.3). Similarly, frequencies of 
IFNγ-secreting CD56dim NK cells (range 1.7% to 25.2 %) were markedly reduced in 
four out of five donors analyzed. In contrast, 7F12 did not significantly affect IFNγ-
secretion by NK cells, presumably due to its inefficient blocking capability. 
Conversely, enhanced TNF secretion by monocytes co-cultured with NK cells ranged 
between 5% and 62%. In four out of five donors TNF secretion was notably reduced 
when NKp80 was blocked (Figure 2.31d,f and Table 2.3). These results indicate that 
NKp80 engagement also influences cell contact-dependent TNF secretion by 
monocytes. Finally, a contribution of NKp80 to monocyte-induced IFNγ secretion by 
NK cells was also observed in a setting where experimental addition of monokines 
was substituted with LPS treatment of monocytes (Figure 2.32). 
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Figure 2.32. Frequencies of IFNγ-producing NK cells after 12 h co-culture with autologous 
CD14dimCD16+ monocytes in the presence of LPS. (a) Top, representative analysis of NK cells 
cultured with monocytes and 0.1 μg/ml LPS in the presence (right panels) or absence (left 
panels) of neutralizing anti-IL-12 (α-IL12) and in the presence of anti-NKp80 5D12 or an 
isotype control IgG1. Bottom, various controls. Percentages of IFN-γ+ CD56bright NK cells (upper 
right quadrant) are given. 5D12 and corresponding IgG1 control were F(ab’)2 –fragments and all 
antibodies were used at 20 μg/ml. (b) Frequencies of IFN-γ+ CD56bright NK cells after co-culture 
with monocytes in presence of LPS as described in (a). All data are means of pentaplicates, errors 
bars represent s. d. P-values were calculated using the Mann-Whitney Rank Sum test and * 
indicates a significant difference. The experiment in (b) is representative of 2 independent 
experiments. 
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2.2.2.5 Discussion 
 
NK cell activity is governed by the complex interplay of multiple activating, inhibitory 
and co-stimulatory receptors [3]. Hence, a thorough understanding of NK cell 
biology requires the functional definition of these various receptors and their ligands. 
Identification of MHC class I-related ligands and characterization of their stress-
inducible regulation was key to understanding NKG2D function [14] and its role in 
immunosurveillance of viral infections and malignancies as well as in the 
pathogenesis of autoimmune diseases [3,19]. Like NKG2D, NKp80 is a 
homodimeric NKC-encoded activating NK receptor without a known inhibitory 
counterreceptor [16,17]. In contrast to NKG2D, NKp80 is predominantly expressed 
on NK cells and is absent in rodents. Hence, characterization of NKp80 ligands 
would likely aid the attempt to further decipher human NK cell biology. 
We here identify AICL as a ligand of NKp80 and provide the first characterization of 
AICL as a myeloid-specific, activating receptor. AICL shares several features with 
TREM-1 including myeloid-specific expression, up-regulation in response to TLR 
stimulation and down-regulation during differentiation from monocytes to immature 
DCs [32]. In fact, AICL transcripts are among the most prominently down-regulated 
transcripts during in vitro generation of DCs from monocytes [34]. Like TREM-1, 
cross-linking of AICL triggered TNF release by monocytes, which was further 
enhanced by LPS stimulation [32]. However, unlike AICL, TREM-1 is a member of 
the immunoglobulin superfamily with yet unidentified ligands, is not expressed on 
CD14dimCD16+ monocytes and contains a positively charged amino acid in the 
transmembrane domain that allows pairing with the ITAM-bearing adaptor protein 
DAP12 [32]. The cytoplasmic domain of AICL is rather short (7 amino acids) and the 
transmembrane domain lacks charged residues, suggesting that AICL does not 
associate with DAP10, DAP12 or FcεRIγ adaptor proteins. 
Recently, association of the distant AICL relative CD69 with sphingosine-1-
phosphate receptor 1 has been reported [35]. In ongoing studies we will attempt to 
identify AICL-associated proteins and to assess a potential association between AICL 
and human sphingosine-1-phosphate receptors. Similarly, the signal transducing 
elements associated with NKp80 have not yet been defined. Moretta and colleagues 
originally reported that tyrosine phosphorylation of NKp80 was detected upon 
treatment of NK cells with pervanadate, but immunoprecipitation experiments failed 
to identify NKp80-associated signaling molecules [16]. 
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Certainly, it will be important to determine whether NKp80-AICL interactions 
influence NK cell reactivity and immune responses in vivo. Since both receptors have 
no corresponding sequence homologues in rodents, addressing this issue in vivo 
remains difficult. Here we provide in vitro data that can be conceptualized in two non-
exclusive ways. First, we show that expression of AICL, which engages NKp80, 
increased susceptibility of myeloid cells to NK cell-mediated cytolysis. However, 
whereas malignant U937 cells were strongly lyzed by NK cells, NK cell-mediated 
cytolysis of autologous LPS-activated monocytes was considerably lower or even 
absent depending on the donor. NK cell-mediated killing of infected monocytes and 
macrophages has been reported [36], and in these situations TLR-induced AICL 
expression may aid in the elimination of macrophages and other myeloid cells 
exposed to or infected by pathogens. Second, we demonstrated that secretion of pro-
inflammatory cytokines in co-cultures of NK cells and monocytes in the presence of 
monokines was strongly augmented by NKp80 engagement, and that NKp80-AICL 
interactions account, at least in part, for the previously described cell contact-
dependency of the activating cellular cross-talk [12]. Since this reciprocal activation 
involves multiple cytokines and possibly several receptor-ligand interactions, it is not 
unexpected that it was not completely blocked by anti-NKp80 treatment. Of the two 
AICL-specific antibodies generated, 7G4 does not block NKp80 binding, and 7F12 
only partially inhibits NKp80 binding as judged from binding assays with 
recombinant proteins. This may account for the inefficient inhibition of cytokine 
production in NK-monocyte co-cultures by 7F12. However, our data do not exclude 
the possibility that a second unidentified NKp80-L on monocytes may also contribute 
to this cross-talk. 
Our data establish the affinity of the NKp80-AICL interaction in the range of 2-5 μM. 
Affinities of other NKC-encoded homodimeric C-type lectin-like receptor-ligand pairs 
are not available for comparison. Reported affinities for NKC-encoded NK receptors 
interacting with MHC class I molecules or MHC class I-related molecules vary 
between 10 nM and 100 μM [17] (e.g. kinetic data of NKG2D-MICA interactions are 
similar to those of NKp80-AICL interactions [37]). 
Yokoyama and colleagues were the first to describe the genetic linkage of certain 
receptor-ligand pairs within the NKC [27]. This observation aided the recent 
characterization of LLT1 as ligand of human CD161 [28,29], as well as the 
identification of AICL as ligand of NKp80 presented here. In light of these findings, it 
is tempting to speculate that other adjacent genes (e.g. those encoding DCAL1 and 
CD69) located within this NKC subregion may encode receptor-ligand pairs. 
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Whereas the NKC of mice contains genes encoding several inhibitory and activating 
Nkrp1 receptors, the single human Nkrp1 homologue NKRP1A is an inhibitory 
receptor [17]. Since Nkrp1 receptors and their Clr ligands in mice are clustered in a 
subregion of the NKC orthologous to the human NKC subregion encoding NKRP1A, 
LLT1, NKp80, and AICL, NKp80 may be a human equivalent of an activating mouse 
Nkrp1 receptor. Interestingly, transcripts for Clr-b and Clr-g, ligands of the inhibitory 
Nkrp1d and the activating Nkrp1f receptors, respectively, were reported to be 
expressed by myeloid cells [27]. However, lack of specific antibodies impeded 
detailed characterization of Clr protein expression. It has been proposed that the tight 
genetic linkage of Nkpr1-Clr receptor-ligand pairs reflects genetic strategies of 
ancient histocompatibility systems [27]. At least for humans, our analyses of AICL 
expression as well as our studies of LLT1 expression (J. Pfeiffer and A.S., 
unpublished observations) show that these ligands are specifically expressed by 
distinct subsets of hematopoietic cells, suggesting that these NKC-encoded receptor-
ligand pairs may have evolved to orchestrate immune interactions between various 
leukocyte subpopulations. 
In contrast to the activating receptor NKG2D, which is thought to alert NK cells 
towards ‘dangerous’ (e.g. infected or malignant) cells by detecting stress-induced 
self-ligands [3,19], NKp80 may mediate cell contact-dependent communication 
between NK cells and myeloid cells during early phases of infection or during chronic 
inflammatory reactions. Recent studies indicate that NK cells are activated by 
mycobacteria-infected monocytes and respond to Plasmodium-infected erythrocytes 
in concert with monocytes and macrophages [11,38,39]. Hence, addressing an 
involvement of the NKp80-AICL interaction in the immune control of these 
pathogens is of immediate interest. 
In summary, here we identify the orphan AICL as a ligand of the human activating 
NK receptor NKp80 and characterize AICL as a myeloid-specific activating receptor 
(Figure 2.33). We provide evidence that NKp80 engagement by AICL not only 
promotes cytolysis of myeloid cells, but is also critically involved in the mutual 
activation of NK cells and monocytes. 
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Figure 2.33. Activating cellular cross-talk between NK cells and monocytes is partially 
dependent on the NKp80-AICL interaction. AICL is a physiological ligand of the NK receptor 
NKp80. AICL is specifically expressed only on cells of the myeloid linage and is markedly induced 
by TLR ligands (e.g. LPS-containing pathogens). Cross-linking of AICL stimulated TNFα-
release by monocytes and the NKp80-AICL interaction promoted lysis of AICL-expressing cells 
by NK cells. Finally resulted NKp80 blocking in a reduced sectretion of pro-inflammatory 
cytokines, i.e IFNγ from NK cells and TNFα from monocytes. Therefore the activating cellular 
cross-talk between NK cells and monocytes is partially dependent on the NKp80-AICL 
interaction. 
 
To our knowledge, this is the first report describing a cellular cross-talk between 
human NK cells and monocytes mediated by cell-type specific receptors. Therefore 
these findings may provide insight into communication within the innate immune 
system in acute and chronic inflammatory situations, and may aid in the elucidation 
of processes of innate immune defense against human pathogens. 
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3 Summary 
NK cell activity is governed by the complex interplay of multiple activating, inhibitory 
and co-stimulatory receptors. Therefore, a thorough understanding of NK cell 
biology requires the functional definition of these various receptors and their ligands. 
The NKC-encoded, homodimeric C-type lectin-like molecule NKp80 has been 
described as an activating orphan receptor, which is almost exclusively expressed by 
NK cells and stimulates NK cytolysis. 
This thesis identifies the adjacently encoded C-type lectin-like molecule AICL as a 
physiological ligand of NKp80. It also defines AICL as a myeloid-specific, activating 
receptor expressed on monocytes, macrophages and granulocytes. AICL is up-
regulated in response to TLR stimulation and down-regulated during differentiation 
of monocytes to immature DCs. Cross-linking of AICL stimulated TNFα-release by 
monocytes, which was further enhanced by LPS stimulation. Additionally, it was 
shown that the NKp80-AICL interaction promotes lysis of AICL-expressing cells by 
NK cells. Malignant U937 cells were strongly lyzed by NK cells, whereas cytolysis of 
autologous LPS-activated monocytes was considerably lower or even absent 
depending on the donor. In other studies NK cell-mediated killing of infected 
monocytes and macrophages has been reported, and in these situations TLR-induced 
AICL expression may aid in the elimination of cells exposed to or infected by 
pathogens. 
Further, this work shows that secretion of pro-inflammatory cytokines, i.e. IFNγ from 
NK cells and TNFα from monocytes, in co-cultures of NK cells and monocytes was 
strongly augmented by NKp80 engagement, and that the NKp80-AICL interaction 
accounts, at least in part, for the previously described cell contact-dependency of the 
activating cellular cross-talk between monocytes and NK cells. This thesis is the first 
report describing cell-type specific receptors mediating an activating cellular cross-
talk between human NK cells and monocytes, which is thought to play a role in acute 
and chronic inflammatory situations. Therefore these findings provide novel insights 
into the communication within the innate immune system and may have important 
implications for the immune defence of certain pathogens and the pathogenesis of 
autoimmune disorders. 
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Zusammenfassung 
Die NK-vermittelte Zelllyse wird durch ein komplexes Zusammenspiel von 
inhibierenden, aktivierenden und costimulierenden Rezeptoren gesteuert. Für ein 
umfassendes Verständnis der NK-Zellbiologie ist eine funktionelle Charakterisierung 
dieser verschiedenen Rezeptoren und deren Liganden notwendig. Der NKC-kodierte 
C-Typ lektin-ähnliche aktivierende NK-Rezeptor NKp80 wird als Homodimer fast 
ausschließlich auf NK-Zellen exprimiert und ist in der Lage NK Cytotoxizität zu 
vermitteln. 
Diese Arbeit identifiziert AICL als physiologischen Liganden von NKp80 und 
etabliert AICL als myeloidspezifischen, aktivierenden Rezeptor, der auf Monozyten, 
Makrophagen und Granulozyten exprimiert wird. AICL wird nach TLR-Stimulation 
hochreguliert, während AICL bei der Differenzierung von Monozyten zu unreifen 
DCs herunterreguliert wird. Die AICL-Aktivierung führt zur TNFα-Freisetzung 
durch Monozyten, was durch die Stimulation mit LPS noch verstärkt wird. Im 
Rahmen dieser Arbeit konnte gezeigt werden, dass AICL-exprimierende Zellen 
NKp80-vermittelt lysiert werden. Maligne U937-Zellen werden durch NK-Zellen in 
hohem Maße lysiert, autologe LPS-stimulierte Monozyten dagegen spenderabhängig 
kaum oder gar nicht. Es ist bekannt, dass infizierte Monozyten und Makrophagen 
NK-vermittelt lysiert werden. In diesem Fall könnte die TLR-induzierte AICL-
Expression zur Eliminierung von infizierten Zellen führen. 
Es konnte weiterhin gezeigt werden, dass bei der Kokultur von Monozyten und NK-
Zellen NKp80-vermittelt entzündungsfördernde Cytokine freigesetzt werden, d.h 
TNFα durch Monozyten und IFNγ durch NK-Zellen. Die NKp80/AICL-Interaktion 
ist zumindest teilweise für die beschriebene Zell-Zell-Kontaktabhängigkeit dieser 
reziproken Aktivierung verantwortlich. Diese Arbeit liefert die erste Beschreibung 
von zelltypspezifischen Rezeptoren, die an dieser reziproken Aktivierung zwischen 
NK Zellen und Monozyten beteiligt sind, für die eine Rolle bei akuten oder 
chronischen Entzündungen postuliert wird. Diese hier beschriebene NKp80-AICL-
Interaktion liefert neue Einblicke in die Kommunikation innerhalb des angeborenen 
Immunsystems und könnte bei der Immunantwort gegen bestimmte Pathogene oder 
bei der Pathogenese von Autoimmunerkrankungen bedeutend sein.
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4 Abbreviations 
α anti 
α-MEM α-minimum essential medium 
aa amino acids 
Ab antibody 
ADCC antibody-dependent cell-mediated cytotoxicity 
APCs antigen presenting cells 
APC allophycocyanin 
bp base pairs 
BSA bovine serum albumin 
CD cluster of differentiation 
cDNA complementary deoxyribonucleic acid 
CML chronic myeloid leukemia 
CTL cytotoxic T lymphocyte 
DC dendritic cell 
DMEM Dulbecco's Modified Eagle's Medium 
DMSO dimethyl sulfoxide 
dNTP deoxynucleoside triphosphate 
DTT dithiothreitol 
EDTA ethylenediaminetetraacetic acid 
EGFP enhanced green fluorecent protein 
ELISA enzyme-linked immunosorbent assay 
Endo H endoglycosidase H 
ER endoplasmatic reticulum 
Fc constant fragment 
FCS fetal calf serum 
G418 neomycin 
GlcNac N-acetyl-D-glycosamine 
GM-CSF granulocyte-macrophage colony stimulating factor 
GPI glycosylphosphatidyl inositol 
GvHD graft-versus-host disease 
GvT graft-versus-tumor 
HBSS Hank’s Balanced Salt Solution 
HLA human leukocyte antigen 
HPLC high performance liquid chromatography 
HRP horse radish peroxidase 
IFN interferon 
Ig immunoglobulin 
IL interleukin 
IMDM Iscove’s modified Dulbeccos’s medium 
kb kilo bases 
kDa kilo dalton 
KLH keyhole limpet hemocyanin 
mAb monoclonal antibody 
MAP-kinase mitogen-activated kinase 
MBP mannose binding protein 
M-CSF macrophage colony stimulating factor 
MHC major histocompatibility complex 
MIC MHC class I chain–related molecule 
MW molecular weight 
NCR natural cytotoxicity receptor 
NK cell natural killer cell 
NKG2D = KLRK1, killer cell lectin-like receptor subfamily K, member 1 
NKG2D-L NKG2D-ligands 
NKp80-L NKp80-ligands 
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NKT cell natural killer T cell 
NTP nucleoside triphosphate 
ORF open reading frame 
p.i post infection 
PBL peripheral blood leukocytes 
PBMC peripheral blood mononuclear cells 
PBS Dulbecco’s phoshate buffered saline 
PCR polymerase chain reaction 
PDI proteindisulfidisomerase 
PE phycoerythrin 
PI3K phosphatidylinositol-3-kinase 
PMA phorbol 12-myristate 13-acetate 
qPCR quantitative real-time PCR 
RNAsin RNAse-Inhibitor 
ROS reactive oxygen species 
RPMI Roswell Park Memorial lnstitute 
rRNA ribosomal ribonucleic acid 
RT room temperature 
RT-PCR reverse transcriptase PCR 
s soluble 
SDS sodium dodecyl sulfate 
SN supernatant 
ss/dsRNA single stranded/double stranded ribonucleic acid 
SV40 simian virus 40 
TBS Tris-buffered saline 
TCR T cell receptor 
TERT telomerase reverse transcriptase 
TH1, TH2 cell T helper 1 cell, T helper 2 cell 
TIL tumor infiltrating lymphocyte 
TLR toll-like receptor 
TNF tumor necrosis factor 
TNP trinitrophenol 
TReg cell regulatory T cell 
ULBP UL16-binding proteins 
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